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Abstract
Dengue virus presents a growing threat to public health in a number of tropical and 
subtropical countries. Over half of the world’s population lives in areas at risk of infection. In 
its most serious forms, dengue haemorrhagic fever (DHF) and dengue shock syndrome 
(DSS), it is also a major cause of morbidity and mortality, particularly in Southeast Asia 
where it is the principle reason for paediatric admission to hospital during the rainy season. 
There is no vaccine available and the pathogenesis and viral factors that underlie clinical 
disease and protective immunity remain poorly understood. Epidemiological and clinical 
observations have shown that both host and viral factors determine the severity of the disease.
A study of genetic susceptibility to DHF/DSS was carried out to investigate the association of 
HLA alleles and DHF/DSS in Vietnamese children with secondary DENV-2 infection. This 
study has found that HLA Class I and II polymorphism significantly influences genetic 
susceptibility to DSS, in particular, secondary DENV-2 infected children with HLA-B*44 
were likely to have DSS, whereas secondary DENV-2 infected children with HLA-Cw*12 
and HLA-DQB1*03 were at increase risk of DHF when compared with the controls. HLA-A 
and HLA-DRB1 polymorphisms were not associated to DSS. This implies that HLA Class I- 
and II-restricted immune responses may play an important role in DHF disease.
T-cell responses to dengue viruses may be important in both protective immunity and 
pathogenesis. The study of 51 Vietnamese adults with secondary dengue virus infections 
defined the breadth and magnitude of peripheral T-cell responses to 260 overlapping peptide 
antigens derived from a dengue virus serotype 2 (DV2) isolate. There are forty-seven 
different peptides evoked significant IFN-y ELISPOT responses in 39 patients, and of these, 
34 peptides contained potentially novel T cell epitopes. NS3, and particularly NS200-324, were 
important T cell targets. The breadth and magnitude of ELISPOT responses to DENV-2 
peptides was independent of the infecting dengue serotype. Acute ELISPOT responses were 
weakly correlated with the extent of haemoconcentration in individual patients, but not with 
the nadir of thrombocytopaenia or the overall clinical disease grade. NS3556-564 and Env4 i4_422 
were identified as novel HLA-A*24 and B*07-restricted CD8+ T cell epitopes, respectively. 
Acute T cell responses to natural variants of Env4 14.422 and NS3556-564 were largely cross­
reactive and peaked during disease convalescence.
By phenotyping CD8+ T cells (CD387HLA-DR+, CD38+/Ki-67+ or HLA-DR+/Ki-67+) in 
serial blood samples from children with dengue, we found, no evidence of increased CD8+ T 
cell activation prior to the commencement of resolution of viraemia or haemoconcentration. 
Investigations with MHC class I tetramers to detect NS3i33-i42- specific CD8+ T cells in two 
independent cohorts of children suggested the commencement of haemoconcentration and 
thrombocytopaenia in DHF patients generally begins before the appearance of measurable 
frequencies of NS3i33-i42-specific CD8+T cells.
The results highlight the importance of NS3 and cross-reactive T cells during acute secondary 
infection but suggest the overall breadth and magnitude of the T cell response is not 
significantly related to clinical parameters. The temporal mismatch between the appearance 
of surface activated and DENV-specific CD8+ T cells suggests other mechanisms are 
responsible for triggering capillary leakage in children with DHF.
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Chapter 1: Introduction -  Dengue virus infection
1.1 Dengue infection-the global health problem
Dengue is currently the most important arboviral disease of human. Dengue is caused by any 
one of four serotypes of dengue virus (DENV). During the last few decades the global 
prevalence of dengue has grown dramatically. In a new estimate of burden of dengue from 
PDVI, the disease is now endemic in 124 tropical countries of the world, threatening more 
than 3.6 billion people (WHO/TDR 2009). This new estimation shows that there may be 70 
million to 500 million cases of DENV infections worldwide every year, which result in 36 
million cases of dengue fever and 2.1 million cases of dengue haemorrhagic fever/ dengue 
shock syndrome and 21,000 deaths each year. Dengue haemorrhagic fever (DHF) and dengues 
shock syndrome (DSS), the most serious consequences of DENV infection, is also a major 
cause of morbidity and mortality. Particularly in.Southeast Asia, dengue is a principle reason « 
for pediatric admission to hospital during the rainy season.
Although classical dengue fever has been recorded for many centuries, DHF appears to be a 
more recent phenomenon. Epidemics of DHF have become more frequent since the 1950s in 
Southeast Asia. Before 1970, only nine countries had known epidemics of dengue 
haemorrhagic fever, but this number has increased up to 70 countries in 2005 (Kroeger and 
Nathan 2006). Dengue is now endemic in countries of Africa, the Americas, and the Eastern 
Mediterranean. Countries in Southeast Asia and the Western Pacific are seriously affected by 
the illness.
2
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1.2 Emergence of Dengue/Dengue Haemorrhagic Fever
The earliest clinical and epidemiologic description of the potential dengue-like illness is 
recorded in a Chinese medical encyclopaedia in 992 (Gubler 2006). After World War II, the 
subsequent growth of cities in Southeast Asia and movement of people led to an increased 
co-circulation of multiple DENV serotypes and epidemic activity. The first major epidemics 
of the severe and fatal form of disease, dengue haemorrhagic fever (DHF), occurred in 
Manila, Philippines, from 1953 to 1954 as a direct result of this changing ecology (Mairuhu, 
Wagenaar et al. 2004). Within 20 years the disease in epidemic form had spread throughout 
Southeast Asia; by the mid-1970s, DHF had become a leading cause of hospitalization and 
death among children in the region (Gubler 1998). Since then, epidemics of DF/DHF have . 
appeared in many new countries. In Asia, epidemic DHF has expanded geographically from?. 
Southeast Asian countries west to India, Sri Lanka, the Maldives, and Pakistan and east to 
China (Gubler 1997). Several island countries of the South and Central Pacific (Niue, Palau, 
Yap, Cook Islands, Tahiti, New Caledonia, and Vanuatu) have experienced major or minor r 
DHF epidemics (Gubler 1998). In the Americas, dengue outbreaks have mainly occurred in; 
the central and southern regions, with the first major DHF epidemic in Cuba in 1981 followed 
by outbreaks in Venezuela and Colombia (Kyle and Harris 2008) (Usme-Ciro, Mendez et al.
2008). Several dengue serotype 2 virus epidemics were documented, but no DHF cases were 
described in Africa (Diallo, Sail et al. 2005).
1.3 Dengue virus
1.3.1. Dengue virus structure
Dengue virus (DENV) is a positive single-sense RNA virus belonging to the Flaviviridae 
family, Flavivirus genus. This family comprises more than 70 RNA viruses, many of which 
are causes of important human diseases, such as yellow fever virus, Japanese encephalitis
Chapter 1: Introduction -  Dengue virus infection
virus, and tick-borne encephalitis virus (van Der Most, Murali-Krishna et al. 2000). There are 
four serotypes (DENV 1-4), classified according to their antigenic features. The single­
stranded RNA genome is encapsulated by an icosahedral nucleocapsid and covered by a lipid 
bilayer containing protein envelope and (pr) membrane. The mature virion is 40-50 nm in 
diameter and contains an 11-kb plus-sensed RNA genome consisting o f a single open reading 
frame directing the synthesis o f a polypeptide, which is proteolytically cleaved by host-cell 
and virus-specified proteases into ten viral proteins. O f these, three are structural proteins: 
core (C), envelope (E) and membrane (M, synthesized in precursor form prM); the remaining 
seven are nonstructural (NS) proteins. The order o f proteins encoded is 5'-C-prM( M)-E- 
NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3' (Rothman 2004) (Rigau-Perez, Clark et al. 
1998) (Kuhn, Zhang et al. 2002) (Henchal and Putnak 1990) (Figure 1.1).
Figure 1.1 Schematic diagram of DENV genome and polyprotein processing
Structureal genes Nonstructural genes
5’ f
C prM knv NSI NS2A NS2B NS3 NS4A NS4B NS5
FP Opep N S3B D  SB II MT RP
FP: fusion peptide
Opep: octapeptide o f  NS1/N S2A
NS3BD: NS3 binding domain
SB: substrate-binding pocket o f  viral protease
H: lielicase
M T : methyltransferase
RP: RNA dependent-RNA polymerase
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1.3.2. Dengue virus protein function
Flavivirus RNA replication involves cyclization of the viral genome. DENV and other 
mosquito borne flaviviruses RNA have two pairs of complementary sequences at the 5’ and 
3’ un-translated regions (UTRs) that play crucial roles in the initiation and regulation of 
translation, RNA synthesis, and viral assembly. The 5’ UTR of DENV genome contains two 
defined elements essential for viral replication; a large stem-loop structure and 5’ upstream 
AUG region (Lodeiro, Filomatori et al. 2009). Alvarez et al. demonstrated that deletion of 
individual domains of the 3’ UTR of DENV affected RNA synthesis, RNA amplification and 
viral replication (Alvarez, De Leila Ezcurra et al. 2005).
The three structural proteins are associated with virus assembly, fusion activity, and virus-cell 
interactions. The envelope protein, which is exposed on the surface of the virus particle, is 
responsible for the main biological functions of the virion, including virus attachment and 
virus-Specific membrane fusion in acidic pH endosomes. It binds to receptors on host cells, 
allowing the virus to be transported into the cell. In addition, the envelope protein is 
associated with haemagglutination of erythrocytes, induction of neutralizing antibodies, and 
protective immune responses (Guzman and Kouri 1996).
The non-structural proteins (NS1-NS5), expressed as both membrane-associated and secreted 
forms, are primarily involved in the replication of viral RNA as a part of the replication 
complex (Chambers T.J. and Rice 1990). The glycoprotein NS1 is not a part of the virion but 
is expressed on the surface of infected cells. Although no precise function has yet been 
ascribed to NS1, preliminary evidence suggests its involvement in viral RNA replication and 
serves an important role in the pathogenesis of severe dengue infections (Young, Hilditch et 
al. 2000). NS2B, NS4A, and NS4B proteins are assumed to be membrane-associated proteins 
as they exhibit conserved hydrophobicity profiles among flaviviruses (Chambers T.J. and
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Rice 1990) (Appanna, Huat et al. 2007). NS3 protein exhibits protease, nucleoside 
triphosphatase (NTPase), helicase, and RNA triphosphatase activities (Falgout, Pethel et al. 
1991). NS2B protein is an ER resident integral membrane protein of about 14 kDa and has 
been extensively studied as an essential cofactor for the activity of the NS3 serine protease 
(Niyomrattanakit et al., 2004). Flavivirus NS5 proteins have been shown to possess RNA- 
dependent RNA polymerase activity (Malet, Masse et al. 2008).
1.3.3. DENV replication in vivo
Dengue infection is initiated by the bite of a mosquito on the skin, where the virus is 
introduced into the host. The host cells of DENV can be dendritic cells, monocytes, 
macrophages or B cells. Skin dendritic cells are believed to be ten times more permissive to 
dengue infection than monocytes or macrophages (Wu, Grouard-Vogel et al. 2000). These 
host cells express dendritic cell specific ICA3M-grabbing non-integrin receptor (DC-SIGN), 
a mannose-specific, C-type lectin that serves as binding-receptors for all four serotypes 
(Navarro-Sanchez, Altmeyer et al. 2003) (Tassaneetrithep, Burgess et al. 2003). The virus 
binds to and enters a permissive host cell via these receptors and then endocytosed through 
engagement with an as yet unidentified factor (or co-receptor) (Lozach, Burleigh et al. 2005). 
Alternatively, Fc receptors or mannose receptors may be other kind of receptors for dengue 
virus-penetration. Dengue binds to antibody against a dengue serotype from a previous 
infection (enhancing antibody) and is then endocytosed by Fc receptor bearing cells.
During infection, DENV is internalized into the endosomal compartment where there is a 
conformational change in the envelope structure, which is triggered by an acidic pH, 
permitting fusion of the virus envelope to the endosomal membrane and release of the viral 
genome into the cytoplasm (Kuhn, Zhang et al. 2002) (Lozach, Burleigh et al. 2005)
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(Mukhopadhyay, Kuhn et al. 2005) (van der Schaar, Rust et al. 2007). The first step of 
DENV assembly takes place in association with the membranes of the ER (Chambers T.J. 
and Rice 1990). The DENV RNA genome is translated into a polyprotein in the ER where a 
viral replication complex is assembled facilitating repeated replication of the: genome 
(Lindenbach, 2001).
Immature virus particles are transported to the plasma membrane in vesicles for subsequent 
release by exocytosis. The surface glycoprotein prM then is proteolytically processed by a 
host protease, known as fiirin, in the exocytotic pathway of the trans-Golgi network, leaving 
the short polypeptide M protein on the surface of the virion and allowing the E protein to fold 
into its mature, homodimeric form (Yu, Zhang et al. 2008) (Zybert, van der Ende-Metselaar 
et al. 2008) (Duarte dos Santos, Frenkiel et al. 2000).
1.4 Vertebrate host-vector
All four serotypes of DENV have a similar natural history, including humans as the primary 
vertebrate host and Aedes mosquitoes of the subgenus Stegomyia (especially Ae. aegypti, Ae. 
albopictus and Ae. polynesiensis) as the primary mosquito vectors (Senanayake 2006). Ae. 
aegyti is highly anthropophilic, thriving in crowded cities and biting primarily during the day 
while Ae. albopictus is less anthropophilic and inhabits rural areas. In Africa, and perhaps 
parts of Asia, dengue viruses also exist in enzootic forest cycles with nonhuman primates as 
the vertebrate host (Rico-Hesse 1990) (de Silva, Dittus et al. 1999). The adult mosquito 
usually rest in dark indoor sites. The species is day-active, with most biting activity occurring 
in the early morning or late afternoon. Significant increases in mosquito larval populations 
are seen during the rainy season. This is an obvious reason why epidemics of dengue tend to 
coincide with the rainy season (Thavara, Tawatsin et al. 2001).
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1.5 Transmission
For transmission to occur, the female Aedes mosquitoes must bite an infected human during 
the viraemic phase of the illness which can last up to 7 days (Gubler 1997). Each mosquito 
may be infected by several virus subtypes without affecting the virus yield. The feeding 
behaviour of the mosquito is characterized by easily interrupted feeding and repeated probing 
of one or several hosts (Stephenson 2005).
After biting an infected human, there is an obligatory extrinsic incubation period for the 
mosquito itself before it becomes infectious. This period is about 8 to 12 days. The virus first 
replicates in the midgut, reaches the haemocoel, and then infects the salivary gland. The virus 
is finally secreted in the saliva, causing infection during probing. Several studies suggested 
the genital tract is also infected and the virus may enter the fully developed egg at the time of 
oviposition (Joshi, Mourya et al. 2002)'
1.6 Clinical manifestation
1.6.1 DF and DHF
All four serotypes of DENV are human pathogens. A person infected by one of the four 
DENV serotypes is believed to be immune to that serotype (homologus immunity), but only 
transiently (~6 months) immune to the three other serotypes (heterologus immunity). The 
clinical outcomes of DENV infection can vary from asymptomatic infection to dengue fever 
to severe and life-threatening dengue haemorrhagic fever (DHF), of which the rates of 
morbidity and mortality are high in areas with little clinical experience in managing the 
disease (Gubler 1998) (Guzman and Kouri 2003) (WHO. 1997).
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After an incubation period of 3 to 7 days, people with symptomatic illness usually develop at 
least one of the following’symptoms; high fever, headache, rash, abdominal pain, myalgia 
and arthralgia for 2 to 7 days. In earlier data on the epidemiology of inapparent dengue 
disease and dengue severity, Burke et al. found that the majority of dengue virus infection, 87 
percent, were either asymptomatic or minimally symptomatic (Burke, Nisalak et al. 1988). 
Later, Endy et al. showed an equal incidence of occurred inapparent and symptomatic 
secondary dengue infection (Endy, Chunsuttiwat et al. 2002). Conversely, the disease can be 
complicated with symptoms such thrombocytopenia, plasma leakage, bleeding, and 
hypovolemic shock; this is commonly referred to as dengue hemorrhagic fever (DHF). In a 
prospective population-based cohort of Thai school-age children, Anderson et al. shown that - 
sixteen percent of symptomatic confirmed dengue infections were classified as dengue 
haemorrhagic fever (Anderson, Chunsuttiwat et al. 2007).
1.6.2 Other severe dengue syndromes
There are. some unusual manifestations of dengue. These include severe haemorrhage, hepatic; 
damage, cardiomyopathy, and encephalopathy (Rigau-Perez, 1998 #43) (WHO. 1997) 
(Solomon, Dung et al. 2000) (Lawn, Tilley et al. 2003). Neurological manifestations such as 
altered consciousness, convulsions, and coma have been ascribed to an encephalopathy 
secondary to prolonged DHF/DSS (Solomon, Dung et al. 2000). Other unusual presentations 
of dengue infection include ocular manifestations (Haritoglou, Scholz et al. 2000) 
(Haritoglou, Dotse et al. 2002).
1.7 Clinical management
There are no specific therapies or licensed vaccines for dengue. However, careful case 
management, centered on the maintenance of circulating body fluids, saves many lives. 
Without treatment, the mortality rate associated with DHF can exceed 20% (Stephenson
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2005). With proper care, including fluid or blood transfusion, fluid resuscitation (in DSS 
cases) and supportive care the mortality rate can be reduced to < 1% (Stephenson 2005).
1.8 Clinical and laboratory diagnosis
1.8.1 Clinical diagnosis
The World Health Organization (WHO) has published guidelines for the diagnosis and 
management of dengue infections (WHO. 1997). There are variable clinical manifestations 
associated with dengue infection. DF cases are characterized by an acute febrile illness with 
two or more manifestations (headache, retro-orbital pain, myalgia, arthalgia, rash, 
haemorrhagic manifestations, or leucopenia). DHF cases are characterized by three major 
clinical manifestations: haemorrhagic tendencies, thrombocytopenia and haemoconcentration 
(WHO. 1997). All three features must be present for a DHF classification. The most common 
haemorrhagic phenomenon is a positive tourniquet test and easy bruising and/or bleeding at 
venupuncture sites. The other common findings of DF/DHF are leukopenia,.' 
hypoproteinaemia, hyponatraemia, and elevated levels of serum aspartate aminotransferase.
In practice, there are difficulties in following the WHO criteria for DF/DHF classification. In 
many studies, application of strict WHO criteria for DHF has been problematic (Phuong, 
Nhan et al. 2004) (Balmaseda, Hammond et al. 2005). This has led to the suggestion that the 
existing WHO classification scheme needs to be refined (Balmaseda, Hammond et al. 2005) 
(Bandyopadhyay, Lum et al. 2006) (Deen, Harris et al. 2006). A new WHO Dengue case 
classification has been published to resolve this problem (WHO-TDR, 2009). This new 
scheme classify dengue cases into 2 main groups - severe dengue and mild dengue, which in 
turn is subdivided into 2 groups -  dengue with and without warning signs (WHO-TDR,
2009).
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1.8.2 Laboratory diagnosis
Laboratory diagnosis of DENY infection can be made by the isolation of virus, detection of 
viral antigen, genomic sequence, and/or virus-reactive antibodies (Guzman, Pelegrino et al. 
2003) (Guzman and Kouri 1996) (Gubler 1998) (WHO. 1997). Currently, the most 
commonly used approaches are detection of the genomic sequence by a nucleic acid 
amplification technology or detection of DENV specific antibodies and DENV antigen. After 
the onset of illness, the virus is found in serum or plasma, circulating blood cells, and 
selected tissues, especially those of the immune system, for approximately 2 to 7 days, 
roughly corresponding to the period of fever (WHO. 1997). Recent studies suggest that 
assays for NS1 antigen detection could be a potential means for the early diagnosis of DENV 
infection (Alcon, Talarmin et al. 2002) (Koraka, Burghoom-Maas et al. 2003) (Young, 
Hilditch et al. 2000) (Kumarasamy, Wahab et al. 2007) (Hang, Nguyet et al. 2009).
1.8.2.1 Antibody detection
Several methods have been described for the serological detection of DENV-specific 
antibodies, including the hemagglutination inhibition (HI) test (16), the neutralization test 
(77), the indirect immunofluorescent- antibody test (90), ELISA (6), complement fixation 
(30), dot blotting (10), Western blotting (51), and the rapid immunochromatography test (for 
which several commercial kits are available). Among these, capture IgM and/or IgG ELISAs 
and the HI test are the most commonly used techniques for the routine diagnosis of DENV 
infections. The use of IgM antibody-capture ELISA (MAC-ELISA) serves as a valuable tool 
for the presumptive diagnosis of acute flaviviral infections since IgM antibody titers are 
detectable early, peaking at about 2 weeks postinfection, and subsequently decline to lower 
levels over the next few months. IgM antibodies are generally less cross-reactive than IgG in
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primary infections, and the serotype having the highest IgM titer is often the one responsible 
for current infection (WHO. 1997). Differentiation between primary and secondary infections 
has been suggested by determining the ratio of IgM to IgG in acute-phase sera (15, 29). In 
this context, the term “secondary infection” is used to describe the nature of the serological 
response and does not imply this was necessarily the second DENV infection experienced by 
the patient, since it Could also be third or fourth DENV infection (Gibbons, Kalanarooj et al. 
2007). Several commercial MAC-ELISA assays had been validated as both sensitive and 
specific methods for DENV antibodies diagnosis (Porter, Widjaja et al. 1999) (Vaughn, 
Nisalak et al. 1999) (Wu, Grouard-Vogel et al. 2000); The IgG ELISA is also reported as a 
diagnostic tool of high sensitivity and specificity (Hapugoda, Batra et al. 2007).
1.8.2.2 Antigen detection
Recent studies suggest that assays for NS1 antigen detection could be a potential means for 
the early diagnosis of DENV infection (Alcon, Talarmin et al. 2002) (Koraka, Burghoom- 
Maas et al. 2003) (Young, Hilditch et al. 2000) (Kumarasamy, Wahab et al. 2007) (Hang, 
Nguyet et al. 2009) (Alcon-LePoder, Drouet et al. 2005). NS1 antigens in the form of an 
immune complex could be detected in the acute-phase sera of both patients with primary and 
secondary DENV infection up to 9 days after the onset of illness (Alcon, Talarmin et al. 
2002) (Koraka, Burghoom-Maas et al. 2003) (Young, Hilditch et al. 2000) (Kumarasamy, 
Wahab et al. 2007) (Alcon-LePoder, Drouet et al. 2005). Hang et al. recently reported the 
sensitivity and specificity of two commercial NS1 assays for diagnosing dengue, the Platelia 
ELISA and a lateral flow rapid test (Hang, Nguyet et al. 2009). Their results indicate these 
tests are most sensitive when used during the first 3 days of illness and are most likely to be 
positive if the patient has primary dengue. Hand et al. also showed the relationship between 
the sensitivity of both and the level of viraemia in patients.
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1.8.2.3 Viral isolation
During the febrile phase, dengue viruses can be isolated from serum, plasma, or leucocytes. It 
can also be isolated from postmortem tissues such as liver, lung, spleen, lymph nodes, 
thymus, cerebrospinal fluid, or pleural/ascitic fluid (WHO. 1997).
Virus isolation by cell culture or in mosquitoes is a gold standard diagnostic method, 
although it is less sensitive and requires a longer time for a result when compared to other 
methods (Yamada, Takasaki et al. 2002) (Teles, Prazeres et al. 2005). The isolation of viruses 
from clinical samples can be carried out with cultured mosquito cells C6/36 (Yamada, 
Takasaki et al. 2002) or mammalian cells, such as Vero, BHK21 (Guzman and Kouri 1996).
1.8.2.4 Molecular diagnosis
DENV nucleic acid may also be detected in tissue or serum samples from human or in 
mosquitoes by RT-PCR techniques which were developed from the early 1990s (Lanciotti, 
Calisher et al. 1992) (Harris, Roberts et al. 1998) (Wang, Lee et.al. 2000) (Sudiro, Zivny et 
al. 2001) (Raengsakulrach, Nisalak et al. 2002) (De Paula, de Melo Lima et al, 2004) 
(Pinheiro, Tadei et al. 2005). Among these, the two-step nested RT-PCR protocol originally 
reported by Lanciotti et al. is well known (Lanciotti, Calisher et al. 1992) (Harris, Roberts et 
al. 1998). More recently, the real-time RT-PCR assay has gradually replaced conventional 
PCR or RT-PCR methods for the rapid diagnosis of DENV infection as it provides 
quantitative measurements, a lower contamination rate, a higher sensitivity, a higher 
specificity, and easy standardization (Chen, Yeh et al. 2001) (Drosten, Gottig et al. 2002) 
(Houng, Chung-Ming Chen et al. 2001) (Shu, Chang et al. 2003) (Wang, Sung et al. 2002) 
(Chutinimitkul, Payungpom et al. 2005). DENV-specific primers and probes are usually 
designed for targeting conserved sequences among four dengue serotypes within the E, NS3,
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NS5 region or recently the 3’ non-coding region (Lanciotti, Calisher et al. 1992) (Houng, 
Chung-Ming Chen et al. 2001) (Chien, Liao et al. 2006) (Seah, Chow et al. 1995).
1.9 Immunopathogenesis to dengue infection
1.9.1 Innate immune responses against dengue virus infection
Before the proliferation of B and T cells, the initial host response to DENV infection is likely 
to be by the innate immune system, Mononuclear phagocyte lineages such as dendritic cells, 
macrophages, monocytes are considered to be the prime target cells for DENV infection (Wu, 
Grouard-Vogel et al. 2000) (Marovich, Grouard-Vogel et al. 2001) (Kyle, Beatty et al. 2007). 
Activated DCs also seCrete cytokines such as TNF-a and IFN-a in response to DENV 
infection (Libraty, Pichyangkul et al. 2001) (Ho, Wang et al. 2001).
Cytolysis by natural killer (NK) cells may be also important in limiting DENV replication 
(Shresta, Kyle et al. 2004). Ex vivo phenotyping data imply a potential role for activated NK 
cells during early DENV infection (Green, Pichyangkul et al. 1999). A significant increase in 
circulating NK cell frequencies was found in patients during acute dengue disease (Azeredo, 
De Oliveira-Pinto et al. 2006).
In vitro infection of human cells and cell lines with DENV, or exposure to dengue antigens, 
results in the production of various anti-viral cytokines. For instance, neutrophils may 
produce TNF-a that can act directly against viral infections (Navarro-Sanchez, 2005). IFN-a 
might play an important role in the mechanisms of host cell defense against DENV. The 
release of IFN-a appeared to be critical for early immune response and resistance to DENV 
infection in a mouse model (Shresta, Kyle et al. 2004). A strong IFN-a inhibitory effect on
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DENV replication was observed when different cell types were treated with cytokine prior to 
exposure to virus (Diamond, Roberts et al. 2000).
The role of complement in dengue is not well understood. Complement activation occurs 
during the acute and early convalescent phase of the disease, and the degree of activation 
appears to be correlated with disease severity. Levels of C3a, C4a, and C5a in patients with 
DHF were increased when compared to those with DF (Wang, Chen et al. 2006) 
(Nascimento, Silva et al. 2009). The complement cascade is activated by DENV antibody 
complex or by different cytokines to release C3a and C5a that may also have an effect on 
vascular permeability (Avirutnan, Punyadee et al. 2006).
1.9.2 Antibodies responses against dengue virus infection
1.9.2.1 Dengue virus-specific antibodies after primary and secondary infection
After a primary DENV infection, anti-DENV IgM becomes detectable in most patents by the 
time of defervescence. Levels of IgM peak at two weeks after infection, and decay over a 
period of 2-3 months after infection. Low titres of anti-DENV IgG are detected during the 
early convalescent phase (Churdboonchart, Bhamarapravati et al. 1991).
During secondary infections, IgG levels increase quickly during the acute phase, but IgM 
levels are low or even undetectable. IgG specific for E, NS3 and NS5 DENV proteins can 
usually be detected during the acute phase of infection, while IgG specific for other proteins 
such as C and NS1 DENV proteins can be detected during the convalescent phase 
(Churdboonchart, Bhamarapravati et al. 1991). These antibodies tend to be highly cross­
reactive with other serotypes of the virus. Therefore, it is usually not possible to identify the 
infecting serotypes of DENV from the antibody response profile during acute secondary 
dengue.
15
Chapter 1: Introduction -  Dengue virus infection
After a primary DENV infection, individuals develop neutralizing antibody and probably, 
lifelong immunity to the homologous serotype. Subsequent secondary infection by one or 
more of the three heterologous serotypes is generally accepted as a major risk factor for DHF 
and/or dengue shock syndrome due to antibody dependent enhancement (ADE) (Guzman, 
Kouri et al. 1990) (Halstead 1988).
1.9.2.2 Role of DENV-specific antibodies in protective immunity
Antibodies to DENV have been reported to mediate three biologic functions in vitro which 
may contribute to prevention of or recovery from DENV infection: neutralization, 
complement-mediated cytolysis, and antibody-dependent cell-mediated cytotoxicity 
(Laoprasopwattana, Libraty et al. 2007) (Lin, Lei et al. 2001). However, antibodies might 
also augment DENV infection through the phenomenon called antibody-dependent 
enhancement. Passive protection studies in mice have shown that DENV-specific monoclonal 
antibodies are capable of conferring some degree of protection against further challenges 
(Calvert, Huang et al. 2006).
Antibody-dependent cellular cytotoxicity (ADCC) is a mechanism in which virus-specific 
antibodies bind to the surface of heterologous DENV-infected cells and mediate lysis by NK 
cells. A higher level of ADCC activity measured before secondary DENV-3 infection was 
associated with lower subsequent viremia levels, which suggests a protective role of 
antibodies mediating ADCC (Laoprasopwattana, Libraty et al. 2007).
1.9.3 Cellular immune responses in dengue infection
i.9.3.1 T-cell regcognition of DENV proteins
Most studies of DENV-specific T cell responses have occurred in the context of T-cell clones 
generated from live attenuated DENV vaccines, or less frequently, from dengue patients 
(Dharakul, 1994) (Gagnon, 1996) (Green, 1993), (Kurane, 1991) (Kurane, 1995) (Mathew,
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1996). CD4+ and CD8+ T cell response to DENV is directed against multiple viral proteins, 
although the NS3 protein appears to be an immunodominant protein, with multiple epitopes 
throughout the protein. Serotype specific and cross-reactive T cells vary in their ability to 
recognize different DENV serotypes, depending upon the degree of conservation in the 
amino acid sequences of the epitopes and the TCR (Kurane, Zeng et al. 1998) (Zivny, Kurane 
etal. 1995).
1.9.3.2 DENV-specific T cell responses in subjects who received live attenuated DENV 
vaccines
PBMG from individuals who received live attenuated DENV vaccination showed 
proliferative responses to multiple dengue and other non-dengue flaviviruses with the highest 
response to homologous DENV serotype (Dharakul, 1994) (Mathew, 1996). CD8+ T cells 
were predominant cytotoxic cells identified in short term generated T-cell lines. Gagnon etal. 
isolated CD4+ cytotoxic T cells against core protein and found that these T cells could 
cognate target cell as well as bystander target cells (Gagnon, 1999). Most of the CD4+ and 
CD8+ T-cell lines generated from these donor responded to virus, viral antigen, or peptide 
stimulation by secreting Thl cytokines including IFN-y , TNF-a, TNF-P, MIP-ip, and IL-2 
(Gagnon, 1999) (Kurane, 1994) (Kurane, 1989).
Serotype specificity and cross-reactivity T cells vary in their ability to recognize different 
DENV serotypes, depending upon the degree of conservation in the amino acid sequence of 
the epitopes and the TCR (Kurane, Zeng et al. 1998) (Zivny, Kurane et al. 1995). Dominance 
of cross-reactive T cells was observed among DENV specific memory T cells during 
secondary infection (Mathew, Kurane et al. 1998).
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1.9.3.3 DENV-specific T cell responses in patients with natural DENV infections
There have been some studies of naturally immune people (Mathew, Kurane et al. 1998) 
(Gagnon, Mori et al. 2002) (Zivna, Green et al. 2002) (Mongkolsapaya, Dejnirattisai et al. 
2003) (Simmons, Dong et al. 2005). Cytotoxic T-cell clones and bulk lines generated from 
patients following natural secondary infections were broadly serotype-cross-reactive and 
directed against the non-structural proteins (Mathew, 1998). Zivna et al. showed the 
frequency of HLA-B*07-restricted epitope specific T cells measured by ELISPOT assay was 
higher in patients with DHF compared with DF (Zivna, 2002). It is possible to detect DENV- 
specific CD4+ and CD8+ memory cytotoxic T lymphocytes (CTLs) up to a year after a 
natural secondary infection (Mathew, Kurane et al. 1998). A detailed analysis of a CTL 
response during acute dengue showed that there was an association between the magnitude of 
the T-cell response and disease severity (Mongkolsapaya, Dejnirattisai et al. 2003). More 
recently, our results showed that the T-cell response to DENV-2 peptides was independent of 
the infecting DENV serotype, suggesting that cross-reactive T cells dominate the acute 
response during secondary infection (Simmons, Dong et al. 2005).
Activated T lymphocytes and their byproducts have been detected in patients with dengue 
(REF). Circulating level of soluble CD4, sCD8, sIL-2R, and sTNFR are elevated in the serum 
or plasma of patients with servere disease (Bethel DB, 1998) (Green, 1999) (Hober, 1996) 
(Kurane, 1991). There were significant increases in the expression of CD69 on CD8+ T cells 
and NK cells in children with DHF compared with DF during the febrile period of illness 
(Green, 1999).
1.9.4 Cytokine responses in dengue infection
DENV infected monocytes, B-lymphocytes, and mast cells produce different cytokines. At 
the present there is disagreement about the predominant cytokines produced during dengue
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fever and DHF. DENV-infected human peripheral blood leukocytes produce Thl and Th2 
cytokines such as TNF-a, IFN-y , IL-2, IL-4, IL-5, IL-6, and IL-10 (Chaturvedi, Elbishbishi 
et al. 1999) (Chen and Wang 2002) (Mangada and Rothman 2005). Some studies have 
suggested that Thl type cytokine (IL-2, IFN-y) responses are seen in early days of illness and 
Th2 type cytokine (IL-5, IL-4) responses occur later. According to Chaturvedi et al., serum 
concentrations of TNF-a, IL-2, IL-6, and IFN-y are highest in the first three days of illness 
whereas IL-10, IL-5, and IL-4 tend to appear later (Chaturvedi, Elbishbishi et al. 1999). 
Contrarily, some reports suggest that predominant Th2 responses occur in DHF/DSS, where 
Thl responses seem to protect against severe infections. Increased levels of IL-13 and IL-18 
have also been reported during severe dengue infections, with highest levels seen in patients 
with grade IV DHF. Serum IL-12 levels are highest in patients with dengue fever, but 
undetectable in patients with grade III and IV DHF. Levels of TGF-jl (an inhibitor of Thl and 
enhancer of Th2 type cytokines) correlate with severity of disease and show an inverse 
relationship with IL- 12 levels (Mustafa, Elbishbishi et al. 2001). DHF patients have higher 
levels of TNF-a, IL-6, IL-13, IL-18, and cytotoxic factor compared with DF patients. These 
cytokines have been implicated in causing increased vascular permeability and shock during 
dengue infections (Mustafa, Elbishbishi et al. 2001) (King, Marshall et al. 2000).
1.10 Risk factors for the development of DHF
Several risk factors have been proposed for development of DHF. These include: serotype 
and virulence of the infecting DENV; age, sex, immune status; and genetic background of the 
host.
19
Chapter 1: Introduction -  Dengue virus infection
1.10.1 Virulent factors
Viral factors are hypothesized to contribute to the progression of DHF. The risk for DHF is 
higher where two or more virus serotypes are circulating simultaneously (Halstead, 1997). 
Particular structural differences in several viral proteins and the 5’ and 3’ untranslated 
regions between DENV genotypes have been found to correlate with disease severity 
(Leitmeyer, Vaughn et al. 1999) (Mangada and Igarashi 1998).
All four DENV serotypes can cause DHF/DSS but DENV-2 is more frequently associated 
with DHF/DSS (Balmaseda, Hammond et al. 2006). DENV-4 usually caused mild clinical 
symptoms but sometimes it can cause severe dengue (Nisalak, Endy etal. 2003). American 
genotype DENV-2 viruses isolated in the Pacific islands and Venezuela are associated with 
DHF and DSS, and the absence of DHF and DSS in a Peruvian outbreak could be attributed 
to antibodies from a previous outbreak caused by DENV-1 (Stephenson 2005).
1.10.2 Host immune
Evidence shows that at the defervescent stage, Viral load falls abruptly as the fever abates, 
associated with severe symptoms such as vascular leakage, hemorrhage, and shock (Vaughn, 
Green et al. 2000) (Wang, Chao et al. 2003). This observation suggested that it may be the 
host immune response to the virus, rather than the virus itself, that causes the pathology.
1.10.2.1 Antibody-dependent enhancement
Antibody-dependent enhancement (ADE) is hypothesized to contribute to the pathogenesis of 
severe dengue illness, as seroepidemiological studies have identified secondary infection as a 
risk factor for DHF and have shown that the presence of pre-existing anti-DV antibodies 
correlates with DHF (Bruke, 1988; Halstead, 1970). Halstead proposed that during secondary 
DENV infection, the pre-existing DENV antibodies at sub-neutralizing or non-neutralizing 
levels to infecting serotype may result in ADE of infection (Halstead, Lan et al. 2002).
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The mechanism of action of ADE is thought to involve formation of complexes of DENV 
and pre-existing, non-neutralising antibody against a different DENV serotype; these 
complexes then bind to FcyRI and FcyRII bearing cells via the Fc portion of the antibody 
(Littaua, Kurane et al. 1990). This allows for the infection of greater numbers of cells which 
can lead to a greater viral load, particularly early in infection. High viral load during DENV 
infection have been shown to correlate with progression to DHF at defervescence (Vaughn, 
Green et al. 2000) (Libraty, Young et al. 2002).
The occurrences of DHF during primary DENV infection in the first year of life in children 
born to mothers with immunity to DENV, who therefore acquired antibody against DENV 
transplacentally, also support the idea of an in vivo role for ADE (Kliks, Nimmariitya et al. 
1988) (Witayathawomwong 2001) (Pancharoen and Thisyakom 2001) (Chau, Quyen et al.,
2008). However, high viremia titers in older children and adults with primary DENV 
infections and in clinically mild secondary DENV infections indicate that other factors are 
involved (Sudiro, Zivny et al. 2001) (Vaughn, Green et al. 1997).
1.10.2.2 T-cell activation
Excessive immune activation during secondary infection has also been hypothesized to act in 
concert with other risk factors and promote the development of severe vascular leak. In 
particular, the rapid mobilisation of serotype cross-reactive memory T cells that release 
vasodilatory inflammatory molecules has been suggested to explain some aspects of the 
clinical syndrome (Kurane, Rothman et al. 1994). Accordingly, relatively higher frequencies 
of activated, cross-reactive CD8+ T cell (Mongkolsapaya, Dejnirattisai et al. 2003) (Zivna, 
Green et al. 2002), and a range of direct and indirect markers of cellular immune activation 
have been associated with severe disease during secondary infection (Gagnon, Mori et al.
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2002) (Green, Pichyangkul et al. 1999) (Green, Vaughn et al. 1999) (Kurane, Innis et al. 
1991).
There is strong evidence of T-cell activation in vivo during DENV infection, and such 
activation of CD4+ and CD8+ T cells is greater in patients with DHF than those with the 
milder dengue fever (Rothman 2003). Studies of the extent of T-cell activation in children 
from Thailand with DHF/DSS indicated that severe disease is associated with high levels of 
T-cell activation accompanied by massive apoptosis (Mongkolsapaya, Dejnirattisai et al.
2003).
1.10.3 Host genetic
Observations on dengue epidemiology in the Americas and in Africa suggest the host genetic 
make-up may be risk factors for DHF/DSS. In Haiti, despite hyperendemic transmission of 
dengue fever, DHF is not reported (Halstead, Streit et al. 2001). In Africa, where all four 
dengue viral serotypes circulate and epidemics of dengue fever occur, few cases of DHF are 
seen (Nimmannitya, 2002). Human genetic factors have been little studied in DHF. A few 
studies have looked at the effect of polymorphisms at the major histocompatibility complex 
locus on susceptibility to DHF. Loke et al. found that polymorphism at the HLA class I loci 
was significantly associated with DHF disease susceptibility (Loke, Bethell et al. 2001). 
Another study suggested HLA-A*0203 to be associated with less severe, dengue, regardless 
of the secondary infecting virus serotype. Furthermore, HLA-A*0207 was associated with 
DHF in patients having secondary DENV-1 or DENV-2 infections only. This study also 
suggested HLA-B*51 to be associated with development of DHF in patients with secondary 
infections, and HLA-B*52 to be associated with dengue fever in patients with secondary 
DEN-1 and DEN-2 infections. Moreover, after secondary dengue infections HLA-B44, B62, 
B76, and B77 appeared to protect against development of disease (Stephens, Klaythong et al.
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2002). Five polymorphic non-HLA host genetic (IL-4, IL-IRA, MBL, VDR, FcyRII) might 
influence susceptibily to DHF. The less frequent t-allele of a variant at position 352 of the 
vitamin D receptor (VDR) gene was associated with resistance to severe dengue. 
Homozygotes for the arginine variant at position 131 of the FcyRIIA gene, who have less 
capacity to opsonize IgG2 antibodies, may also be protected from DHF (Loke, Bethell et al. 
2002).
1.11 Dengue in Vietnam
DHF first occurred in the rainy season of 1963 in South Vietnam and at the time was a 
leading cause of hospitalization and death in Vietnamese children (Halstead, Voulgaropoulos 
et al, 1965). The number of DF/DHF cases and case fatality mortality rate in South Vietnam 
from 1994 to 2007 is shown in Figure 1.2. In 1998, there was a widespread DHF epidemic 
that affected 19 provinces in southern Vietnam. In this outbreak, 123,997 cases were reported 
to the Dengue Control Program in South Vietnam at Pasteur Institute in Ho Chi Minh City. 
This epidemic comprised 119,429 cases of DHF and 342 deaths (Ha, Tien et al. 2000) 
(Pasteur 2007). The case fatality rate has been decreasing from 0.3% in 1998 to 0.09% in 
2007 (Pasteur 2007).
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Figure 1.2 The number of DF/DHF cases and dengue mortality rate in South Vietnam 
from 1994 to 2007 (Data was obtained from Pasteur Institute, HCMC, 2007)
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Figure 1.3 Correlation between death rate and age in DF/DHF cases in southern 
Vietnam (Data was obtained from Pasteur Institute, HCMC, 2007)
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From 1987 to 2007, the circulation o f DENV serotypes has changed depending on the period 
of time. DENV-2 was responsible for the 1987 epidemic. DENV-1 was predominant from 
1990 to 1995 but was almost absent by 1999 (Ha, Tien et al. 2000). DENV-1 has recently re- 
emerged as the dominant serotype in 2006. DENV-3 was first detected in 1987 only in Ho 
Chi Minh City, and by 1991 it was also identified in Tien Giang Provine (Ha, Tien et al. 
2000), (Pasteur 2007). In the largest DHF epidemic in Vietnam in 1998, DENV-3 became a 
dominant serotype in hospitalizaed dengue cases. From 2002 to 2006, DENV-2 was the 
major serotype isolated in hospitalized patients. DENV-4 was dominant from 2001-2002 
(Figure 1.4).
Figure 1.4 Dengue cases and prevalence of DENV serotypes in patients in South of 
Vietnam. (Data was obtained from Pasteur Institute, HCMC, 2007)
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2.1 Serological confirmation
2.1.1 Dengue IgM/IgG capture ELISA for the detection of secondary Dengue infection
Dengue cases were confirmed via serological testing of acute and early convalescent phase 
plasma with a commercial capture-immunoglobulin M IgM) and IgG enzyme-linked 
immunosorbent assay (ELISA) (Panbio, Brisbane, Australia). The ELISA was performed and 
results were interpreted according to the manufacturer’s instructions. Results were 
determined by comparison with IgM and IgG reference sera provided (cut-off calibrators). A 
positive sample was defined as having a calibrator absorbance ratio greater than 1.0 and a 
negative sample with a ratio less than 1.0. Dengue infection was confirmed by the elevation 
of either IgM or IgG.
2.1.2 Dengue serological tests (MAC ELISA)
A Japanese encephalitis virus (JEV)/Dengue IgM and IgG ELISA (Venture Technologies, 
Sarawak, Malaysia), employing inactivated viral antigen from DENV 1-4 and JEV, was used 
to discriminate between DENV- or JEV-specific IgM and IgG responses. The procedures 
were performed as described previously (Cardosa, Wang et al. 2002). Briefly, ELISA plate 
(Maxisorp, Nunc) was coated with 100 pi per well of anti-human IgM (A 0425, 
DakoCytomation) or IgG (I 2136, Sigma) with a dilution ratio of 1:2000 and incubated 
overnight at 4 °C. Plates were then blocked with 200 pi blocking solution (3% BSA-PBS) 
per well and incubated for 2 hours at room temperature (RT). After washing the plates 3 
times with phosphate buffered saline with 0.05% Tween 20 (PBS-0.05%), 100 pi of diluted 
plasma specimens (1:100), positive control (1:100), and negative control (1:100) were added 
and incubated for 2 hours at RT. Specimens were added in triplicate for each sample, three 
sets of triplicate positive control and at least five sets of triplicate for negative control. After
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washing the plates 5 times with PBS-0.05% Tween 20, 100 pi of each antigen (DENV, JEV, 
and control) was added to each well and incubated overnight at 4 °C. After washing, the plate 
was incubated with 100 pi of mouse monoclonal antibodies to DENV and JEV for 1 hour at 
room temperature and then detected by 100 pi of anti-mouse Ig Horseradish Peroxidase 
(HRP) (DakoCytomation) at a dilution ratio of 1:2000. After washing, the plate was 
developed by o-phenylenediamine dihydrochloride (OPD) (Sigma) and stopped by 10% 
hydrogen peroxide. The optical absorbance of the samples at a wavelength of 490 nm was 
then measured. The IgM and IgG positive control sample was a pool of acute plasma from 
dengue patients. The negative control sample was a mixture of plasma collected from healthy 
Vietnamese donors. Wells with PBS in place of DENV antigen were used to define 
absorbance background value. The cut-off value was defined as being 5 times higher than the 
mean OD of negative control samples after the subtraction of background OD.
A diagnosis of confirmed dengue was made if there was evidence of rising IgM titres to 
DENV antigen in paired plasma specimens and the response to DENV antigen was greater 
than to JEV antigen. A determination of primary dengue in patients was made if IgM levels 
exceeded IgG levels at the time of discharge from the hospital. Conversely, a determination 
of secondary dengue was made if there was detectable IgG response in patients at the time of 
both hospital admission and discharge.
2.2 RNA extraction and dengue viral PCR
2.2.1 RNA isolation
DENV RNA was isolated from plasma by the Boom method (Boom, Sol et al. 1990). 
Reagents for Boom extraction were repaired as following and stored in dark.
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• L6 lysis buffer was made by adding 120 g of guanidinium isothiocyanate to 100 mL 
of 0.1 M Tris/HCl (pH of 6.4) and 22 mL of 0.2 M EDTA pH 8.0, and 2.6 g of Triton 
X I00, and then stirred overnight in the dark to dissolve.
• L2 buffer was made by adding 120 g of guanidinium isothiocyanate to 100 mL of 0.1 
M Tris/HCl pH 6.4 and then stirred overnight in the dark to dissolve.
• Size-fractionated silica particles were made by adding 60 g of silicon dioxide to 500
i ■
mL of distilled water in a measuring cylinder and allowed to equilibrate for 24 hours 
at room temperature. A 430 mL of supernatant was discarded and solids were re­
suspended in 500 mL of distilled water and allowed to equilibrate again at RT for 5 
hours. A 440 mL of supernatant was discarded and then added 600 ul of concentrated 
HC1 (pH of 2.0) and aliquoted into 1.5 mL volumes.
In each sample, a standard amount of Equine Arteritis Virus (EAV) was used as an internal
control on extraction and the PCR process. Briefly, for RNA extraction Using the Boom
method, 50 to 200 pi of plasma was added to a tube containing 1 mL of L6 lysis buffer and
20 pi of a suspension of size-fractionated silica particles; the mixture is then briefly vortexed.
After incubation for 10 minutes (min) at RT, the tube was vortexed for 5 seconds and
centrifuged for 1 min at 13,000 x G. The supemanant was then discarded and 1 mL of
washing buffer L2 was added to the silica-nucleic acid complex, vortexed at 5 sec followed
by two washes with buffer L2 (1 min at 13,000 jc G), two washes with 70% (vol/vol) ethanol,
and finally one wash with 1 mL of acetone (Merck). After disposal of the acetone, the tube
was dried at 56 °C with open lid in a heating block for 10 min. The pellet was re-suspended
in 100 pi of 1 x TE buffer, vortexed for 5 seconds, and left at 56 °C for 10 min to elute the
nucleic acids. After incubation, it was vortexed again and centrifuged for 2 min at 13,000 x
G. Only 70 pi of the supernatant containing viral RNA were gently pipetted to a new 0.5 mL
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eppendorf to avoid disturbing the pellet. In most cases, RNA was immediately used for 
synthesis of complementary DNA (cDNA); otherwise, the RNA was stored at negative 80 C 
Until used.
2.2.2 cDNA synthesis
cDNA was generated from viral RNA by using Random hexamers (Roche, Lews, UK) and 
Superscript III reverse transcriptase (Invitrogen). A mixture of 8 pi of RNA, 1 pi of 100 
ng/pl random hexamers, 0.4 mM dNTPs (Roche, Lews, UK), and sterile distilled H2O 
adjusted up to 13 pi was incubated at 65 °C for 5 min and immediately chilled on ice for at 
least 1 min. A mixture of 4 pi of 5x First-strand buffer (Invitrogene), 2.5 mM dithiothreitol 
(DTT) (Invitrogene), 16 units of Rnase Inhibitor (Invitrogene) and 40 units of Superscript III 
RT (Invitrogene) adjusted with sterile distilled H2O to make up a reverse transcription 
reaction volume of 20 pi. The content was mixed by gentle pipetting up and down then 
incubated at 25°C for 10 min followed at 48 °C for 30 min, then 95°C for 5 min. The resulting 
cDNA was used as template in the subsequent PCR reaction.
2.2.3 SYBR Green RT-PCR dengue screening
Dengue virus genomic material was detected by RT-PCR using a range of approaches. In 
some experiments, a dengue virus complex-specific assay was used. Briefly, 4 ul of cDNA 
were used as template in a fluorogenic PCR in 20 pi of a reaction mixture containing 1.25x 
HotstarTaq buffer (pH 8.7), 1.2mM MgCL, 0.4mM dNTP, 0.625x SYBR Green, 0.02 pM 
FC, one unit HotstarTaq (Qiagen) and 0.8 pM of each forward and reverse primer. Dengue 
group primers were as described by Shu et al. with minor modification (inosines instead of 
degenerate positions) (Shu, Chang et al. 2003). Sequences of forward and reverse primers 
were:
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5’-CAATATGCTGAAACGCGiGAGAAA-3’: forward primer (nucleotide position 
135-158)
5’-CCCCATCTiiYCAiiATYCCTGCTGT-3’: reverse primer (nucleotide position 
282-305)
After pre-treatment at 95 °C for 15 min, reaction mixtures were subjected to 45 cycles of 
denaturation at 95 °C for 20 seconds (s), annealing at 55 °C for 30 s and extension at 72 °C 
for 30 s, and product melt at 83 °C for 10 s. The PCR product was 176 bp in length. 
Following amplification, a melting curve analysis was performed to verify the correct product 
by the specific melting temperature (Tm = 83°C). Melting curve analysis was comprised of a 
denaturation at 95 °C for 1 min, lowered to 60 °C for 10 min, and followed by 70 cycles of 
incubation in which the set point temperature was increased to 95 °C at a rate of 0.5 °C /10 
s/cycle with continuous reading of fluorescence.
2.2.4 Dengue serotyping by TaqMan real time RT-PCR
We used a serotype-specific, fluorogenic real-time RT-PCR assay to measure dengue 
viraemia levels in plasma. The dengue-specific primers and probes were adapted from 
previously published sequences and are summarized in Table 2.1 and Table 2.2 (Laue, 
Emmerich et al. 1999). Hotstar Taq polymerase was used in all assays (Qiagen, USA). PCR 
conditions were 95 °C for 14 mins then 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s for 
45 cycles. Linearised plasmids in which the target amplicon had been cloned were used to 
generate a standard curve against which Ct values derived from test samples were compared. 
Results were expressed as cDNA equivalents per milliliter of plasma. For DENV1, DENV2 
and DENV3, the detection limit was 1 copy per reaction. For DENV4, the detection limit was 
10 copies per reaction. All reactions were performed in duplicate and sample measurements 
were only valid when positive and negative control samples were valid.
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Table 2.1 DENV and EAV specific primer sequence
Forward primer sequence (5’-3’) Position Reverse primer sequence (5’-3’) Position
D1 ATCCATGCCCACCAYCAATG 9960-9980 CAGGGATCCACACCAYTGATC 10100-10121
D2
ACAAGTCGAACAACCTGGTCC 
AT
9938-9941 GCCGCACCATTGGTCTTCTC 10095-10115
D3 TTTCTGCTCCCACCACTTTCAT 9719-9741 TGGCGTTGGATGCYAGTCT 9915.9934
D4 GYGTGGTGAAGCCYCTRGAT 9587-9607 AGT G ARCGGCC AT CCTTC AT 9744-9764
EAV CATCTCTTGCTTTGCTCCTTAG 1847-1869 AGCCGCACCTTCACATTG 1962-1980
Table 2.2 DENV and EAV specific probe sequence
Sequence Position
D1
5’(FamiIusi, Moore et al.)- TCAGTGTGGAATAGGGTTTGGATAGAGGAA- 
3'(TAMRA)
10002-10032
D2 5'(Familusi, Moore et al.)- GTTTTGTCTTCCATCCA (BHQ.-1)- 3' 10038-10055
D3
5'(Familusi, Moore et al.)- AAGAAAGTTGGTAGTTCCCTGCAGACCCCA- 
3'(TAMRA)
9761-9791
D4
5'(Familusi, Moore et al.)- ACTTCCCTCCTCTTYTTGAACGACATGGGA- 
3'(TAMRA)
9612-9642
EAV
S'(CyS)- CGCGCTCGCTGTCAGAACAACATTATTGCCCACAGCGCG 
(BHQ3)- 3'
1888-1927
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2.3 DNA extraction for human leukocyte antigen -  sequence specific primers (HLA- 
SSP) PCR
DNA extraction from blood samples was performed using a commercial DNA extraction kit 
(Nucleon, Amersham Biosciences, UK) according to manufacturers’ instructions. Briefly, the 
blood pellet was re-suspended in red cell lysis buffer, reagent A (10 mM Tris-HCl, 320 mM 
surose, 5 mM MgCb, 1% Triton-XlOO, pH of 8.0), with a ratio of 1:4. The nucleated cells 
were pelleted after a 10-minute centrifugation at 1300 x G. The cell pellet was re-suspended 
and lysed in 350 pi of reagent B (40 mM Tris-HCL, 60 mM EDTA, 150 mM NaCl, 1% SDS, 
pH of 8.0), and incubated for 10 min at 37°C. Then the cell lysate was mixed with 100 pi 
sodium perchlorate followed by 600 pi of chloroform. The tube was mixed by hand and 
inverted at least seven times. Without remixing the phase, 150 pi of nucleon resin was added 
to the tube and centrifuged at 350 x G for one minute. Without disturbing the nucleon resin 
layer, the upper phase was transferred to a new tube. Next, two volumes of cold absolute 
ethanol was added and mixed by inversion until the precipitate appeared. The tube was 
centrifuged at top speed for five minutes to pellet the DNA, and the supernatant was 
discarded. The pellet was washed with 1 mL of cold 70% ethanol, re-centrifuged, and the 
supernatant was discarded. The pellet was dried for 10 minutes before dissolving in an 
appropriate volume of water or TE buffer.
2.4 DNA measurement by PicoGreen assays
In this study, all genomic DNA concentrations were quantified using PicoGreen. PicoGreen 
is an ultra-sensitive fluorescent nucleic acid stain for quantifying double-stranded DNA 
(dsDNA). DNA concentration determinations were performed according the manufacturer’s 
instructions in Micro Amp Optical 96-well plates (Costar, Coming Incoporated, USA) and 
using a fluorescent microplate reader at 485/535 nm (GENios or SPECTRAFluor Plus,
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TECAN, United States). Each plate contained a duplicate set of lambda DNA standards 
ranging from 0 to 800 ng/ml. Each sample was assayed in duplicate. The level of 
fluorescence in each well was measured and the concentration of each sample was then 
calculated based on the standard curve on a Microsoft Excel spread sheet or was 
automatically calculated by the reader software. If the standard curve was not linear, the 
process was repeated (Figure 2.1).
PG Standard Curve (0 - lOOOng/ml)10000
e0
1
1
‘S 1000
100
0.01 0.1
Concentration [ug/ml]
1
st1. curve 030304: lg(y)= 0.90034 *lg(x)44.0639 d = 145.5 r = 0.99889
Figure 2.1 The standard curve for estimation of DNA concentration. Red tine indicates 
the DNA standard curve. Y-axis corresponds to logarithm of fluorescent intensity. X- 
axis corresponds to DNA concentration.
Chapter 2: Materials and Methods
2.5 PCR using Sequence-Specific Primers (PCR-SSP) for HLA typing
Typing of HLA class I and class II alleles was performed using the amplification refractory 
mutation system PCR (ARMS-PCR) with sequence specific primers as described previously 
(Bunce, O'Neill et al. 1995). One hundred and ninety two PCR reactions were performed to 
genotype HLA-A, B, Cw, DRB1 and DQB1 alleles was performed using 96-well 
polycarbonate plates (Thermo-Fast 96, Low profile, ABgene, UK) and a Peltier thermal 
cycler machine (DNA Engine Tetrad 2, BIO-RAD). Each well of a 96-well PCR plate 
contained a unique set of allele-specific PCR-primers and a set of internal control primers 
(amplifying a conserved region from the third intron of the HLA-DRB1 locus): PCR cycling 
conditions are listed in Table 2.3.
Table 2.3 PCR cycling conditions for PCR-SSP
Stage Cycling condition No. of cycles
1 96 °C - 1 minute 1
2 96°C - 20 s, 70°C - 45 s, 72°C - 25 s 5
3 96 °C - 25 s, 65 °C - 50 s, 72 °C - 30 s 21
4 96 °C - 30 s, 55 °C - 60 s, 72 °C - 90 s 4
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Each PCR reaction was carried out in 13 pi volume containing primers (1-4 pM for allele- 
specific primers and 0.1 pM for DRB1 control primers), PCR buffer (6 mM MgCh, 1.63x 
buffer, 0.3 mM dNTP, 0.45M Betaine). BIOTAQ™ polymerase (Bioline) was used for these 
PCR reactions.
PCR products were visualized using 2% Ethidium Bromide (EtBr) stained agarose/TBE gel 
(Tris/borate/EDTA buffer: 89 mM Tris base, 89 mM boric acid, 2 mM EDTA). The presence 
of an allele is defined as when the allele-specific PCR product is present and negative when 
only the internal control product is present. 192 PCR reaction was performed to genotype 
HLA-A, B, Cw, DRB1 and DQB1 alleles. Primer pairs and the HLA class I and class II 
alleles they detected are listed in Appendix 1.
The frequency (J) of HLA class I and II antigens was determined by the formula /  = n/N, 
where n is the number of individuals that are positive for a particular HLA (either 
heterozygotes or homozygotes) and N  the number of individuals tested.
2.6 Separation of peripheral blood mononuclear cells from peripheral blood
2.6.1 The Ficoll method
Peripheral blood mononuclear cells (PBMCs) were separated using Lymphoprep (Axis- 
Shield Poc AS, Oslo, Norway). Initially, Lymphoprep™ was placed in a 50 mL Falcon tube. 
Then whole blood was added to the Lymphoprep™ at a 1:1 ratio and centrifuged at 3000 
revolutions per minutes (rpm) for 20 to 25 minutes at room temperature with no brake. After 
centrifugation, the translucent interface layer (the PBMCs layer) was transferred into other 
another 50 mL tube. PBMCs were washed twice with RPMI or PBS+3% heat-inactivated 
FCS. PBMCs were re-suspended in cRPMI (RPMI 1640 medium containing 10% HI-FCS, 2 
mM L-glutamine, 100 pg/ml Streptomycin, 100 U Penicillin) for direct use in enzyme-linked
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immunospot (ELISPOT) assay. PBMCs were also cryopreserved in HI-FCS containing 10% 
dimethyl sulfoxide (DMSO) and placed in liquid nitrogen container for future use.
2.6.2 CPT Vacutainer method
Peripheral blood was collected into CPT Vacutainer tubes (Becton Dickinson) containing 
sodium heparin. The tubes were centrifuged in a swing-out centrifuge at 3000 rpm for 20 
minutes at room temperature with no brake. PBMCs and plasma remained above the gel. The 
PBMCs were transferred into a Falcon tube then washed once with RPMI containing 1% FCS 
and used directly or cryopreserved as described above.
2.7 Counting PBMCs for Elispot Assay and Cryopreservation
PBMCs were separated from peripheral blood and counted before cryopreservation or use in 
Elispot assays. Trypan blue (final concentration 0.36%) was used to discriminate dead from 
viable cells. An aliquot of diluted PBMC in Trypan blue were enumerated on KOVA® glastic 
slides with standard grids (Hycor Biomedical, UK).
2.8 Cryopreservation of PBMCs
PBMC were cryopreserved at a cell concentration of 5 x 106 to 10 x 106 viable cells per 
milliliter in freezing medium (HI-FCS + 10% DMSO) and aliquoted to cryovials (Coming 
Incorporated, CORNING, Mexico). The cryovials were immediately placed in a slow-freeze 
container (NALGENE™ Cryo 1°C Freezing Container, USA) which was then placed in a -70 
°C freezer for 4 to 24 hours. After 4 to 24 hours, the cryovials were transferred into a liquid 
nitrogen-rated box and placed into the vapor phase of liquid nitrogen (-135°C) containers for 
long-term storage.
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2.9 Thawing of cryopreserved PBMCs
Cryovials containing frozen PBMCs were removed from liquid nitrogen storage and placed in 
a 37 °C water bath until the majority of the suspension had thawed. The suspension was then 
transferred to a 15 mL centrifuge tube containing 5 mL of chilled cRPMI medium. The 
thawed cells then were washed and counted as described in section 2.7.
2.10 Peptides for IFNy ELISPOT assay
We designed 260 peptides spanning the structural antigens (capsid, preM/M, and Env) and 
nonstructiiral viral antigens (NS3 and NS4a) from a dengue virus serotype 2 sequence (strain 
16681). Peptides were synthesized by standard, solid-phase 9-fluorenylmethoxy carbonyl 
chemistry. Purity ranged from 30 to 90% as determined by high-performance liquid 
chromatography. Peptides consisted of 220 15mers and 40 20mers peptide. All peptides 
overlapped by 10 amino acids. The sequences of peptides are shown in Appendix 3.
2.11 IFNy ELISPOT assay
The IFNy ELISPOT assay was performed according to the manufacturer’s instructions 
(Mabtech AB, Stockholm, Sweden). The 96-well polyvinylidene difluoride (PVDF)-backed 
plates (MAIP, Millipore, USA) were coated with coating antibody 1-D1K (50 ul at 15 ul/ml), 
incubated at room temperature for 2 hours or overnight at 4 °C. The wells were then washed 
twice with 200 ul of sterile PBS followed by blocking with 100 pi of cRPMI for at least one 
hour at room temperature. PBMC samples (1 x 10s to 3 x 105 cells/well) were stimulated with 
individual peptides or peptide pools. Individual peptides were used at a final concentration of 
2 pg/mL. Peptide pools were used at a final concentration of 5 pg/mL for each peptide. Two 
hundred and sixty peptides were arranged into a matrix of 32 peptide pools containing 16
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individual peptides. Each peptide was present in two different pools. A peptide was identified 
as evoking a response in the IFNy ELISPOT assay as it drove a response in two different 
pools. In every positive ease, peptides identified as being antigenic in this manner were 
retested as individual peptides. Thus, each positive response was confirmed twice: first in the 
matrix pools then in confirmatory individual assays. PBMCs were incubated overnight with 
peptides at 37 °C in a humidified incubator containing 5% CO2 in air.
After overnight incubation, wells were washed twice with PBS containing 0.05% Tween 20 
(Sigma) to remove cells and media. Next, detection monoclonal antibody, 7-B6-1-biotin (50 
ul at 1 pg/ml Mabtech, Sweden) was added to each well for 2 hours at 37 °C. The wells were 
washed again twice with PBS containing 0.05% Tween 20 before incubating with 50 pi of 
streptavidin-alkaline phosphate (1 pg/ml Mabtech, Sweden) for one hour at 37 °C. After 
washing again twice with PBS-0.05%, streptavidine-alkaline phosphate conjugate (Mabtech) 
was added at a dilution of 1:1000 in PBS to visualize the spot-forming cells. The number of 
spot-forming units (SFU) in each well was counted with the aid of a dissecting microscope 
and the background (no antigen stimulation) was subtracted. For each assay, the 
phytohemagglutinin (Sigma, Poole, UK) was used as the positive control.
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Figure 2.2 Elispot assay to quantify secretion of cytokines by T lymphocytes
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2.12 CD4+ and CD8+ T cell depletions
CD4+ and CD8+ T cells were depleted from PBMCs using anti-CD4 or anti-CD8 antibody- 
coated immunomagnetic beads (Dynal, Oslo, Norway). The PBMCs were incubated with the 
appropriate immunomagnetic beads in 0.5 mL of cRPMI, at a ratio of five beads per cell, at 4 
°C for 30 minutes with gentle mixing. Cells attached to immunomagnetic beads were 
removed using magnetic particle concentrator (Dynal), and the remaining cells were collected 
for further analysis. Flow cytometry analysis indicated this approach routinely achieved over 
95% depletion of the target cells.
2.13 Cytotoxicity assay
T-cell lines were generated by pulsing 2 x 106 PBMCs with 100 pM of Env4 j4-422 peptide for 
one hour. Cells were cultured in cRPMI supplemented with 25 ng of IL-7/mL for 3 days. 
Thereafter, 100 U of IL-2/niL was added every 3 to 4 days. After 14 days, cells were 
harvested and used as effectors in a 51-chromium (Gr)-labeled release assay. Target cells in. 
the chromium release assay consisted of a 51-Cr-labeled B-cell line (BCL) that was HLA 
matched with effectors only at the B*07 locus. The BCL was pulsed for 1 hour with the 
Env414-^22 peptide, washed, and aliquoted in microtiter plates (5,000cells/well). Then effector 
cells were added in a range of effector-to-target ratios.
Un-pulsed cells were used as negative controls. The 51-Cr release was calculated from the 
following equation:
C =  ,C r e x p '< > s p o n  1 Q O o/o
Cr ■ Crmax spon
([experimental release spontaneous release]/[maximum release spontaneous release]) x 
100%.
Nonspecific killing of un-pulsed target cells was subtracted from that of pulsed target cells.
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2.14 Reagents and monoclonal antibodies for CD8+ T cell phenotype
Cell phenotype for T cell activation was determined by cell surface and intracellular staining. 
Cell surface staining was routinely performed on 100 jiL of fresh whole blood. The mouse 
anti-human surface monoclonal antibodies (mAbs) used in this study included: APC- 
conjugated anti-CD3, PE-conjugated anti-CD8, PE-Cy7-conjugated anti-CD38, and PerCP- 
conjugated anti-HLA-DR. Intracellular staining marker used FITC-conjugate anti-Ki-67. All 
antibodies were purchased from Becton Dickinson, CA, USA. Data acquisition was 
performed on a BD FACS Canto II flow cytometer (Becton Dickinson, San Diego, CA, 
USA). The data analysis was using FlowJo software (Tree Star, Inc., OR, USA).
2.15 MHC tetramers and FACS analysis
Tetramer were prepare as described previously (Altman, Moss et al. 1996). Briefly, the 
recombinant HLA-A* 1101 heavy chain contains the BirA-recognition site, which has been 
incorporated into the carboxyl terminus of the MHC molecule. The monomer adopts an 
appropriate conformation following the addition of 0 2  microglobulin (P2m) and synthetic 
peptide (NS3 133-142 peptide). Then the enzyme BirA is used to attach a biotin molecule to 
the specific BirA-recognition sequence. Four MHC-biotin complexes are link to a single 
streptavidin molecule, using the specific biotin-avidin interaction, to form a tetramer. The 
streptavidin molecule here is tagged with phycoerythrin fluorochrome.
HLA*A-1101 MHC class I tetramers containing the NS3133-142 epitope from all four DENV 
serotypes were synthesized as previously described (Mongkolsapaya, Dejnirattisai et al.
2003). The four tetramers (DVlNS3i33-i42 GTSGSPIVNR, DV2.1NS3i33.,42 GTSGSPIIDK, 
DV2.2NS3,33.i42 GTSGSPIVDK, DV3-4NS3133_i42 GTSGSPIINR) were pooled at equal 
concentrations and used to stain fresh whole blood. Briefly, whole blood was stained with
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pooled PE-labeled NS3i33_i42 tetramers at 37°C for 30 min in the dark and then for surface 
makers at 37 °C for 15 min by addition of APC-conjugated anti-CD8 Ab. Stained blood were 
then lysed, washed, fixed, and analyzed by flow cytometry.
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Chapter 3: Genetic susceptibility to DHF/DSS -  HLA class I and II alleles
3.1 Genetic susceptibility to infectious disease
The interaction between the microbe, the host and the environment is a major selective force 
in evolution. Interest in the role that host genetic variation plays in susceptibility to infection 
has occurred from both the individual severity of disease and its progression, as well as 
infection rate at a population level. Genetic associations might therefore provide answers to 
fundamental questions about the pathogenesis of an organism and the host response. The best 
known example of such genetically determined factors is found in malaria and 
haemoglobinopathy (Hill, Bennett et al. 1992). For example, heterozygosity for sickle cell 
haemoglobin is strongly associated with protection against death and severe disease.
The outcome of infection with several diseases such as tuberculosis and human 
immunodeficiency virus (HIV) was subsequently correlated with polymorphisms in some 
host genes (Hill 1996). Additional evidence of the selective genetic pressure of infectious 
agents can be demonstrated by the higher level of polymorphisms seen in the human 
leukocyte antigen (HLA) region when compared with other regions in the human genome. 
Positive and negative genetic associations between particular HLA variants and a variety of 
major infectious diseases, such as HIV/AIDS, hepatitis, leprosy, tuberculosis, malaria, 
leishmaniasis, and schistosomiasis have been reported to include (reviewed in Blackwell,
2009).
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3.2 Case and control studies for studying genetic susceptibility to infectious disease
There are two main approaches to determine the contribution of genes to disease 
susceptibility, involving either linkage or association studies, or both. While linkage studies 
can only use familial data, association studies can be family or case-control based. The 
collection of case-control series is often easier than multi-case families. Case-control studies 
need to be well-matched in terms of ethnicity (genetic background) and environment. 
Matching for age and sex is less important as allele frequencies seldom differ between sexes 
nor change with age. A further advantage of the case-control study is that the completion time 
for the study is relatively short, and multi-risk factor can be compared in the same study 
population. However, large sample sizes are usually required for these studies so that 
sufficient power is obtained to detect effects in the order of two-fold change in risk. 
Moreover, the results do not provide direct information about the mechanism of disease risk; 
it only provides an estimate of relative risk.
To determine if a gene is a contributing risk factor to the disease phenotype, its 
polymorphisms are examined for association in case-control studies. Significant differences 
between genotype frequencies in the cases aiid controls might suggest a role for genetic 
factors in disease outcome. In the simplest form, the association between a particular risk 
factor and the disease outcome can be assessed using a 2x2 contingency table (%2 test of 
association). The Odds Ratio (OR) is the ratio of odds of disease among people with the risk 
factor to the odds of disease among people without the risk factor.
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3.3 Studies of Genetic influences on Dengue virus infections
Central in the pathogenesis of DHF and DSS is the loss of endothelial integrity that is
believed to be the result of an “abnormal” immune response and a disturbance in immune
regulation. There are several possible reasons why some infected individuals might produce a
greater inflammatory response than others. Retrospective analysis of the Cuban epidemic of
dengue hemorrhagic fever in 1981 suggested that those of African descent were hospitalized
v
less frequently with DHF and DSS than those of European descent (Kouri, Guzman et al. 
1989). In addition, despite the hyperendemic transmission of multiple DENV serotypes in the 
Haitian population, neither DHF/DSS outbreaks nor sporadic cases has been reported 
(Halstead, Streit et al. 2001). The results of these studies suggest that human genetic factors 
may influence susceptibility to DHF. Several studies have confirmed that some genetic 
polymorphisms may protect or predispose an individual to DHF or DSS.
3.4 HLA and dengue
One of the functions of the human leukocyte antigens (HLAs), encoded by the major 
histocompatibility complex (MHC) and whose genes are On chromosome 6, is to display 
antigenic peptides to receptors on host T-lymphocytes in order to activate cellular host 
immune responses. HLA genes show great variability and specific polymorphisms seen in 
human HLA gene regions influence peptide epitope binding (Cooke and Hill 2001). Several 
studies have looked at the variation in the HLA genes and found some of them to be 
associated with the severity of dengue virus infection (Table 3.1).
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Table 3.1 Summary of associations between human leukocyte antigen class I and II 
alleles and DF/DHF
Class Allele Population Type of 
association3
Reference
Class I Al Cubans (Paradoa Perez, Trujillo et al. 1987)
A l Thai -  ■ (Stephens, Klaythong et al. 2002)
A*0203 Thai ' + (Stephens, Klaythong et al. 2002)
A*0207 Thai - (Stephens, Klaythong et al. 2002)
A24 Vietnamese - (Loke, Bethell et al. 2001)
Vietnamese - (Nguyen, Kikuchi et al. 2008)
A29 Cubans + (Paradoa Perez, Trujillo et al. 1987)
A3 3 Vietnamese + (Loke, Bethell et al. 2001)
B blank Thai (Chiewsilp, Scott et al. 1981)
Cubans (Paradoa Perez, Trujillo et al. 1987)
B13 Thai + (Chiewsilp, Scott et al. 1981)
B14 Cubans + (Paradoa Perez, Trujillo et alT 1987)
B15 Cubans ■ - (Sierra, Alegre et al. 2007)
B31 Cubans - (Sierra, Alegre et al. 2007)
B44 Thai ■ + (Stephens, Klaythong et al. 2002)
B46 Thai - (Stephens, Klaythong et al. 2002)
B51 Thai - (Stephens, Klaythong et al. 2002)
B52 Thai + (Stephens, Klaythong et al. 2002)
B62 Thai + (Stephens, Klaythong et al. 2002)
B76 Thai + (Stephens, Klaythong et al. 2002)
B77 Thai + (Stephens, Klaythong et al. 2002)
Class II DRB1*04 Cubans + (Sierra, Alegre et al. 2007)
Mexicans + (LaFleur, Granados et al. 2002)
DRB1*07 Cubans ■+ (Sierra, Alegre et al. 2007)
DRB 1*0901 Vietnamese + (Nguyen, Kikuchi et al. 2008)
DQ1 Brazil - (Polizel, Bueno et al. 2004)
DR1? Brazil - (Polizel, Bueno et al. 2004)
a +, protection against DF/DHF; susceptibility to DF/DHF
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3.4.1 HLA class I and dengue
The HLA class I region can be divided into eight exons encoding the different domains, and 
three individual loci, HLA-A, -B, -C, -E, -F, -G (Figure 3.1). HLA-B is the most 
polymorphic, followed by HLA-A, and HLA-C (Steven G.E. Marsh 2000). Each individual 
expresses up to two alleles for each locus. Alleles at each of these loci are related 
phylogenetically and can be separated into families. HLA class I products have wide 
distribution and are present on the surface of all nucleated cells and on platelets. Antigens 
associated with HLA class I products will interact with CD8+ T cells during an immune 
response.
< —  class II region — ► class III region —► < class I region — — . >
B C E A G F
II I I II
I - ■ . I I l    I
0 1 2 3 4
■4— centromere relative position (megabases) telormere —►
Figure 4.1 Simplified map of the HLA complex (Steven G.E. Marsh 2000)
JXX
DP DM DQ DR complement
I I j  ■  ■  'C4BfC2'II I  I  III
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Chiewlip et al. was the first to report an association between HLA class I and the severity of 
dengue virus infection (Chiewsilp, Scott et al. 1981). The frequency of the HLA types in 
unrelated Thai children who had clinical DHF/DSS deviated from those of controls, with p  < 
0.05, for six antigens: HLA-A 1, . HLA-A2, HLA-A9, HLA-B13, HLA-B17, and HLA-B. 
Later, a study in Cuban patients who had been hospitalized with DHF/DSS also showed a 
significant difference in the frequency of HLA antigens when compared with a control group 
(Paradoa Perez, Trujillo et al. 1987). This Cuban study reported that HLA-A29 was 
associated with protection against DHF, whereas HLA-A 1 and HLA-Cwl were associated 
with susceptibility to DHF.
Subsequently, a larger case control study in Vietnamese demonstrated that polymorphisms in 
the HLA class I region, particularly of the HLA-A gene, were significantly associated with 
susceptibility to DHF (Loke, Bethell et al. 2001). Of the 26 alleles of HLA class I and II 
studied, two particular alleles were relevant: patients with HLA-A33 were less likely to 
develop DHF (P = 0.01; odds ratio, 0.56; 95% confidence interval, 0.34-0.93), whereas those 
with HLA-A24 allele were at an increased risk to develop DHF (p = 0.02; odds ratio, 1.54; 
95% confidence interval, 1.05-2.25). HLA-B alleles were not associated with DHF disease 
susceptibility.
Another case-control study, in Thai children, suggested that the HLA-A2 locus serotype was 
associated with disease susceptibility (Stephens, Klaythong et al. 2002). HLA-A*0203 was 
increased in all DF patients with secondary infections when compared with either the control 
or DHF with secondary infections. In this study, HLA-A*0207 was associated with 
susceptibility to the more severe DHF in patients with secondary DENV1 and DENV2 
infections only. In the same study, they also observed dengue virus-specific associations 
within the HLA-B5 group of related alleles, whereby molecularly determined HLA-B*51
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alleles were associated with DHF after secondary dengue virus infections. By contrast, HLA- 
B*52 showed a strong association with less severe DF secondary DENV-2 infections. 
Moreover, the reduced frequency of the HLA-B 15-related alleles (B62, B76, and B77) was 
observed in the patients with secondary dengue virus infections, suggesting that they may be 
protected against developing clinical disease in immunologically primed individuals. By 
contrast, HLA-B46 was increased in the DHF patients with seconday infections. Since HLA- 
B46 is in strong linkage disequilibrium HLA-A*0207, it is believed that the effect of B46 
was likely to be an adjunct to that of A*0207. Finally, HLA-B44 appeared to be protective 
against the development of severe disease in patients with secondary dengue virus infections. 
Recently, a hospital-based case-control study in two provinces in Southern Vietnam showed 
an increase of frequency of HLA-A*24 in both DHF and DSS patients (Nguyen, Kikuchi et 
al. 2008). The frequency of HLA-A*24 with histidine at codon 70, based on main anchor 
binding site specificity analysis in DSS and DHF patients, was significantly higher than that 
in the population background groups.
3.4.2 HLA class II and dengue
The organization of class II genes is similar to class I genes, where each of the exons encode 
a different domain. HLA class II products consist of HLA-DO, -DR, -DP, and -DQ (Figure 
3.1). The HLA class II products have more limited distribution on B-cell, macrophages, 
dendritic cells, Langerhans cells and activated T cells. HLA class II molecules are involved in 
the presentation of exogenous antigens to CD4+T helper cells.
A study of HLA-DR antigen frequencies in Mexican patients with dengue found that the 
frequency of HLA-DRB1 *04 was lower in DHF patients than in DF patients and that this 
allele was negatively associated with DHF risk (LaFleur, Granados et al. 2002). These 
findings are in contrast to the finding of Loke et al., who studied polymorphisms in the HLA-
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DRB1 gene in Vietnamese DHF patients but did not find an association (Loke, Bethell et al.
2001).
Recently, a significantly increased frequency of HLA-A*31 and HLA-B* 15 has been 
demonstrated in Cuban individuals with a history of symptomatic dengue virus infection 
compared with controls (Sierra, Alegre et al. 2007). HLA-DBR1*07 and HLA-DRB 1*04, on 
the other hand, showed an evaluated frequency in control subject compared with dengue case 
patients suggesting these alleles are associated with protection (Sierra, Alegre et al. 2007). In 
a study of HLA alleles and severe dengue in Southern Vietnam, the frequency of HLA- 
DRB 1*0901 in particular was significantly decreased in DSS when compared with DHF in 
DENV-2 infection (Nguyen, Kikuchi et al. 2008).
Notwithstanding the previous studies of HLA and dengue, the interpretation of previous case- 
control studies is potentially confounded by a number of factors including heterogeneity in 
the case classification, serological and virological features of the patients being investigated 
leading to small subgroup analysis and limited power.
3.5 Study design
Human leukocyte antigens expressed on the cell surface function as antigen presenting 
molecules and that polymorphism can shape an individuals’ adaptive immune response.
In this study, I first aimed to investigate the HLA class I and II polymorphisms present in a 
population of Vietnamese children with DSS resulting from secondary infections with 
DENV-2, compared to a group of population controls (cord bloods). Then we aimed to 
confirm the correlation appearing in the second independent case-control study in wider 
range of clinical presentation.
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3.6 Patient recruitment
There are two prospective studies described. In the first study, pediatric patients with dengue 
shock syndrome (<15 yrs of age) were recruited into a prospective study at the Pediatric 
Intensive Care Unit of the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, 
between 1999-2002. All patients were of Vietnamese Kinh ethnicity and had a clinical 
diagnosis of DHF/DSS Grade III or IV. Blood samples were collected at study entry (day 1) 
and then on day 2 and day 4 for research and hematological, investigations.
The second study was a prospective study of children with mild dengue at Ward Pediatric A 
of the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, between 2002 and 2006. 
Any Vietnamese Kinh child between 2-15 years of age hospitalized with clinically suspected 
dengue and fever for < 72 hours was eligible for study entry. Any child who developed Shock 
(DSS) was transferred to the Pediatric Intensive Care Unit. All patients had daily haematocrit 
and platelet count. Blood samples were collected at study entry and then on the 6th day of 
illness for research purposes.
For both studies, DNA was extracted from the blood pellets using a commercial DNA 
extraction kit (Nucleon, Amersham Biosciences, UK) according to the manufacturer’s 
instructions. Clinical symptoms were recorded in standardized case record forms and 
laboratory investigations (see Figure 3.2) were used to confirm the diagnosis.
Written informed consent was obtained from a parent or guardian of each study participant. 
The study protocol was approved by the Scientific and Ethical committees at the Hospital for 
Tropical Diseases and the Oxford University Tropical Research Ethical committee.
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Figure 3.2 Dengue diagnostic algorithm
ves
yes yes
PCR positive Viral culture positive DEN IgM or IgG 
seroconversion 
from SI to S2
Clinical syndrome that could be dengue
Confirmed acute dengue
Paired plasma >3 days apart and Is sample collected within 7 days of illness onset
3.7 Control samples
Umbilical cord blood samples were used as the control samples for this study. Cord blood 
samples were collected from the umbilical cord of healthy neonates at the time of delivery to 
mothers of Vietnamese Kinh ethnicity at Hung Vuong Obstetric Hospital, HCMC. After 
centrifugation of cord blood, the cells and the plasma were separated and stored at -20°C. 
Written informed consents were obtained from mothers. The study protocol was approved by 
the Scientific and Ethical committees at Hung Vuong Hospital and the Hospital for Tropical 
Diseases and the Oxford University Tropical Research Ethical committee.
3.8 Statistical analysis
HLA class I and II typing was performed to establish the frequencies of the major HLA 
alleles. The frequency of HLA class I and II antigens was determined by the formula n/N,
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where n equals the number of individuals that are positive for a particular HLA (either 
heterozygotes or homozygotes) and N  equals the number of individuals tested. 2x2 ^2 test 
and P values derived from StatCalc (Epilnfo) software were used for comparing allele 
frequencies. P values of less than 0.05 were considered significant. The odds ratio (OR) and 
95% confidence interval were used to assess the risk of disease associated with a specific 
class I and II phenotype.
3.9 Results
3.9.1 Characteristic of patient population
As the first purpose of this study was to investigate the association of HLA alleles and 
dengue shock syndrome in Vietnamese children with secondary DENV-2 infections, we 
selected DNA samples from a subset of patients enrolled in a prospective study of DSS at the 
Pediatric Intensive Care Unit of the Hospital for Tropical Diseases, Ho Chi Minh City, 
Vietnam. Between 1999 and 2002, there were 120 patients who were experiencing a 
secondary DENV2- infection. After applying the former WHO case classification criteria 
(WHO. 1997) to each dengue case, there were 113 DHF grade III patients and 7 DHF grade 
IV patients. The characteristics of the patient population are described in Table 3.2.
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Table 3.2 Characteristics of the patient population selected for HLA typing
Variable
DHF grade in  
N=113
’ DHF grade IV
. N= 7
Male sex, no. (%) ' . . ■ ' 62 (54%) 3 (42%)
Age (years) 10(3-14) 11(5-13)
Day of illness 5 (3-10) 4(3-5)
Petechiae 95/95(100%) 5/7(71%)
Skin bleeding 59/112(52%) 4/7 (57%) .
Other bleeding* 25/109 (22%) 1/7 (14%)
Effusion 40/107 (37%) 1/7(14%)
Ascites 32/107 (29%) 1/7(14%)
Hepatomegaly (mean) 1.8 ±0.1 2.1 ±0.3
Platelet nadir, cells/pL 22,000 (8,310-90,000) 20,000 (12,000-50,000)
Maximum hemoconcentration, % 38.9(21.5-66.7) 50 (32.4-53.4)
* Other bleeding including Gum bleeding, Epistaxis, Purpura, GI bleeding, PV bleeding
3.9.2 HLA class I and II genotyping by PCR sequence-specific primers
All DSS patients (n=120) and cord blood control samples (n=120) were typed for HLA class 
I and II using amplification refractory mutation system PCR (ARMS-PCR) with sequence 
specific primers (SSP) (Brunce et al., 1995). One hundred and ninety two PCR reactions 
were performed to simultaneously detect HLA-A, B, Cw, DRB1 and DQB1 alleles. At the 
time this study was conducted, this approach was recognized as a high resolution technique 
and better at distinguishing HLA alleles subtypes compared to serological methods. Indeed 
HLA typing by PCR-SSP has proven to confer significantly greater sensitivity, accurate, and 
resolving power than serology typing methods (Petersdrorf EW, 1999).
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The results from this integrated class I and II method can be visualized on a single 
photographic or electronic image and hence is described a “Phototyping”. A phototype is 
determined successful when the control amplifications are positive and at least one allele or 
group of alleles is present in each locus. Amplification of control primers gives a product of 
796 base pairs fragment from the third intron of HLA-DRB 1 locus. An example of HLA 
phototype of dengue patient DF398 is shown in Figure 3.3.
Figure 3.3 HLA PCR SSP phototyping of patient DF389. The sample type was A*24, 
A*33, B*15, B*35, Bw6, Cw*04, DRB1*04, DRB3, DRB5, DQB1*04, DQB1*06
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3.9.3 Phenotype frequencies of HLA class I and II alleles
We identified 14 HLA-A alleles, 21 HLA-B alleles, 10 HLA-Cw alleles, 13 HLA-DRB 1 
alleles and 5 HLA-DQB1 alleles in the study subjects. Major alleles (phenotype frequencies 
having more than 5% in either the patient or control groups) are shown in Table 3.3-3.7, 
accounted for about 80-90% of the total phenotypes.
The most common HLA-A, -B, -Cw, -DRB1 and DQB1 alleles were A*02, A *ll, A*24 and 
A*33; B*15 and B*46; Cw*01 and Cw*07; DRB1*12 and DRB1*15; DQB1*03 and 
DQB1*05, respectively. Alleles of HLA- A*74 (2.5%), -B*48 (0.8%), -B*52 (1.7%), -B*54 
(0.8%, -Cw^l6 (0.8%), -DRB 1*01(2.5%) were observed in DSS patients but not in control 
subjects.
Table 3.3 Frequency of HLA-A alleles in DSS patients with secondary DENV-2 
infection and control subjects
HLA-A
antigen
Case patient 
(A=120)a
Control subject 
(W=120)a
Odds ratio (95% Cl) x2 P
*01 8(6.7) 6(5) 1.36(0.41-4.58) 0.30 0.581
*02 57 (47.5) 62 (51.7) 0.85(0.49-1.45) 0.42 0.518
*11 55 (45.8) 60 (50) 0.85(0.49-1.45) 0.42 0.518
*24 40(33.3) 38(31.7) 1.08(0.61-1.92) 0.08 0.783
*33 27(22.5) 34 (28.3) 0.73(0.39-1.37) 1.08 0.299
%2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen).
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Table 3.4 Frequency of HLA-B alleles in DSS patients with secondary DENV-2 infection
and control subjects
HLA-B
antigen
Case patient 
(AT=120)a
Control subject 
(JV=120)a
Odds ratio (95% Cl) x2 P
*07 4(3.3) . 9(7.5) 0.43(0.11-1.57) 2.03 0.153
*13 13 (10.8) 8(6.7) 1.7(0.63-4.7) 1.3 0.253
*15 60 (50) 65 (54.2) 0.85(0.49-1.45) 0.42 0.518
*27 11 (9.2) 5 (4.2) 2.32(0.71-7.95) 2.41 0.120
*35 8(6.7) 7(5.8) 1.15(0.36-3.68) 0.07 0.789
*38 11(9.2) 9(1,5) 1.24(0.46-3.42) 0.22 0.640
*40 11(9.2) 11 (9.2) 1(0.38-2.6) 0.00 1.000
*44 4(3.3) 14(11.7) 0.26(0.07-0.89) 6.01 0.014b
*46 21 (17.5) 27(22.5) 0.73(0.37-1.45) 0.94 0.333
*51 5 (4.2) 7 (5.8) 0,7(0.19-2.56) 0.35 0.553
*56 11(9.2) 13(10.8) 0.83(0.33-2.08) 0.19 0.666
*57 7(5.8) 6(5) 1.18(0.34-4.1) 0.08 0.775
*58 12(10) 15(12.5) 0.78(0.32-1.86) 0.38 0.539
X2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen). 
b Statistically significant.
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Table 3.5 Frequency of HLA-Cw alleles in DSS patients with secondary DENV-2
infection and control subjects
HLA-Cw
antigen
Case patient 
(A^120)a
Control subject 
(7V=120)a
Odds ratio (95% Cl) y P
*01 34 (28.3) . 43 (35.8) 0.71(0.4-1.27) 1.55 0.21
*03 27 (22.5) 17(14.2) 1.76(0.86-3.62) 2.78 0.095
*04 21 (17.5) 26(21.7) 0.77(0.38-1.52) 0.66 0.416
*06 9(7.5) 6 (5) 1.54(0.48-5.06) 0.64 0 : 4 2 3
*07 46 (38.3) 49(40.8) 0.9(0.52-1.56) . 0.16 0.692
*08 23 (19.2) 14(11.7) 1.8(0.83-3.92) 2.59 0.107 '
*12 12(10) 4(3.3) 3.22(0.93-12.25) 4.29 0.038b
*15 22(18.3) 17(14.2) 1.36(0.65-2.87) 0.77 0.381
X2 test and P values derived from Statcalc (Epilnfo) sofware.
a Data are no. positive for antigen (frequency of antigen).
b Statistically significant.
Table 3.6 Frequency of HLA-DRB1 alleles in DSS patients with secondary DENV-2
infection and control subjects
HLA-DRB1 Case patient 
antigen (7V=120)a
Control subject 
(V=120)a
Odds ratio (95% Cl) x2 P
*03 8 (6.7) 6 (5) 1.36(0.41-4.58) 0.30 0.581
*04 23(19.2) 29 (24.2) 0.74(0.38-1.44) 0.88 0.347
*07 15(12.5) 25(20.8) 0.54(0.25-1.15) 3.00 0.083
*08 16(13.3) 14(11.7) 1.16(0.51-2.68) 0.15 0.696
*09 25 (20.8) 35 (29.2) 0.64(0.34-1.2) 2.22 0.136
*10 18(15) 12(10) 1.59(0.69-3.71) 1.37 0.241
*12 59 (49.2) 57 (47.5) 1.07(0.62-1.83) 0.07 0.796
*13. 4(3.3) 8(6.7) 0.48(0.12-1.83) 1.40 0.236
*14 14(11.7) 9 (7.5) 1.63(0.63-4.28) 1.20 0.272
*15 29 (24.2) 23 (19.2) 1.34(0.69-2.61) 0.88 0.347
X2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen).
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Table 3.7 Frequency of HLA-DQB1 alleles in DSS patients with secondary DENV-2 
infection and control subjects
HLA-DQB1 
antigen
Case patient 
(V=120)a
Control subject 
(V=120)a
Odds ratio (95% Cl) x2 P
*02 19(15.8) 27 (22.5) 0.65(0.32-1.3) 1:72 0.189
*03 79 (65.8) 52 (43.3) 2.43(1.4-4.23) 11.35 0.0007c
*04 15(12.5) 9 (7.5) 1.76(0.69-4.58) 1.67 0.196
*05 52 (43.3) 52 (43.3) 1(0.58-1.72) 0.00 1.000
*06 40 (33.3) 48 (40) 0.75(0.43-1.31) 1.15 0.283
X2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen). 
b Statistically significant.
3.9.4 Association of HLA-B, HLA-Cw, and HLA-DQB1 alleles and DSS
We analyzed only these major alleles for the evaluation of the risk of disease severity because 
rare alleles might have little impact on population risk. Studying fewer alleles, would also 
mitigate the problem of multiple comparisons.
A summary of the statistical comparisons is shown in Table 3.3-3.7. There was an increase in 
the frequency of the antigen HLA-DQB1*03 in the DSS patient group (65.8% vs 43.3%, P = 
0.0007), with an OR of 2.43 (95%CI = 1.4-4;23), indicating that individuals carrying HLA- 
DQB1*03 have a higher chance of developing DSS than individuals not expressing this 
antigen. The antigen frequency of HLA-Cw* 12 was also moderately increased in DSS 
patients when compared with the control (10% vs 3.3%, P = 0.038, OR = 3.22, 95%CI = 
0.93-12.25). Conversely, HLA-B*44 decreased in frequency in the DSS patient group when 
compared with the control (3.3% vs 11.7%, P  = 0.014, OR = 0.26, 95%CI = 0.07-0.89).
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There were no other statistically significant associations between the typed HLA alleles and 
DSS.
3.9.5 Association of HLA-DQB1*03 alleles and dengue
To explore more fully the correlationship between the HLA-DQB1*03 and DSS in 
Vietnamese children with secondary DENV-2 infections, we selected DNA samples from a 
independent subset of patients and cord blood controls. Patients who were experiencing 
secondary DENV-2 infections enrolled in two prospective studies on either the Pediatric 
Ward A (uncomplicated patients) and the Pediatric intensive Care Unit (DSS patients) of the 
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam represented the case population. 
The controls were cord blood samples collected at the same time as the previously described 
cord blood samples but from different newborns. The characteristics of the dengue patient 
populations are described in Table 3.8.
Table 3.8 Characteristics of the DENV-2 infected patient population selected for HLA- 
DQB 1*03 typing
Variable DSS (n=98)
uncomplicated dengue 
(n=147)
Male sex, no. (%) 48 90
Age (years) 10(3-14) 12 (5-16)
Day of illness 4.5 (3-7) 3(2-5)
DF 37
DHF
Grade I 39
Grade II 71
Grade III 85
Grade IV 13
Platelet nadir, cells/pL 24,400 (6,000-80,000) 49,900 (10,800-290,000)
Maximum hemoconcentration, % 37.8(20.0-71.5) 19(0-55.7)
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A summary of the statistical comparisons between the two patient groups and cord blood 
controls, which are independent of the above control group, are shown in Table 3 .9-3 .11. 
The HLA-DQB1 *03 allele was significantly increased in frequency in DSS patients (P = 
0.0001, OR = 10.54, 95%CI = 2.25-6.82) and DF/DHF patients (P = 0.0007, OR = 4.39, 
95%CI = 1.64-12.15) when compared to the controls. There was no different in frequency of 
HLA-DQB1*03 alleles between two patient groups (DSS patients versus DF/DHF patients).
Table 3.9 Frequency of HLA-DQB1 alleles in DSS patients with secondary DENV-2 
infection and control subjects
HLA-DQB1
antigen
DSS patients
(N=98)a
Control subject 
CN=100f
Odds ratio (95% Cl) x2 P
*02 19(19.4%) 17(17) 1.17(0.54-2.57) 0.19 0.663
*03 96 (98%) 82 (82) 10.54(2.25-67.82) 13.88 0.0001b
*04 8 (8.2) 6(6) 1.39(0.42-4.74) 0.35 0.552
*05 44 (44.9) 43 (43) 1.08(0.59-1.97) 0.07 0.787
*06 14 (14.3) 25 (25) 0.50(0.23-1.09) 3.59 0.058
X2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen). 
b Statistically significant.
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Table 3.10 Frequency of HLA-DQB1 alleles in uncomplicated dengue patients with
secondary DENV-2 infection and control subjects
HLA-DQB1
antigen
uncomplicated 
dengue patients 
(N=147)a
Controls
(V=100)a
Odds ratio (95% Cl) X2 P
*02 22(15) 17(17) 0,86(0.41-1.81) 0.19 0.666
*03 140 (95.2) 82 (82) 4.39(1.64-12.15) 11.46 0.0007b
*04 4(2.7) 6(6) 0.44(0.10-1.81) 1.65 0.199
*05 63(42.9) 43 (43) 0.99(0.58-1.72) 0.00 0.982
*06 30(20.4)- 25 (25) 0.77(0.40-1.47) 0.72 0.394
%2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen). 
b Statistically significant.
Table 3.11 Frequency of HLA-DQB1 alleles in DSS and uncomplicated dengue patients 
with secondary DENV-2 infection
HLA-DQB1
antigen
DSS patients
(N=98)°
uncomplicated 
. dengue patients 
(N=147)
Odds ratio (95% Cl) x2 P
*02 19(19.4) 22(15) 1.37(0.66-2.83) 0.83 0.363
*03 96 (98) 140 (95.2) 2.4(0.44-17.11) 1.23 0.267
*04 8 (8.2) 4(2.7) 3.18 (0.84-12.97) 3.74 0.053
*05 44 (44.9) 63 (42.9) 1.09(0.63-1.88) 0.10 0.752
*06 14(14.3) 30 (20.4) 0.65 (0.31-1.37) 1.50 0.221
%2 test and P values derived from Statcalc (Epilnfo) sofware. 
a Data are no. positive for antigen (frequency of antigen).
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Collectively, this study has found that HLA Class I and II polymorphism significantly influences 
genetic susceptibility to DSS, in particular, secondary DENV-2 infected children with HLA- 
B*44 were likely to have DSS, whereas secondary DENV-2 infected children with HLA-Cw* 12 
and HLA-DQB1*03 were at increase risk of DHF when compared with the controls. HLA-A and 
HLA-DRB1 polymorphisms were not associated to DSS.
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3.10 Discussion
There is still much to be learnt about the possible influence of host genotype in resistance or 
susceptibility to DSS. For most HLA/DENV studies performed to date, the HLA allele 
frequencies in DF, DHF and sometimes DSS patients were compared to frequencies observed 
in control age-matched healthy individuals of the same ethnicity. Allelic frequencies that 
significantly deviate from frequencies observed in the control population suggest a negative 
or positive association between the HLA genotype and DENV disease status. Previous 
studies have focused on polymorphisms of HLA class I and II (Table 3.1). Nonetheless, none 
of the reported associations has been replicated in different populations. The inconsistency of 
these HLA associations may be the result of differences in ethnicity, differences in the 
predominant virus serotype during the study periods and HLA typing technique (Chaturvedi, 
Nagar et al. 2006). In our study, we tested the hypothesis that some HLA class I and II alleles 
may be associated with the occurrence of a particular clinical disease form resulting from 
DENV-2 infection. Our data demonstrated a higher frequency of the antigen HLA-B*44 in 
controls compared with DSS patients. Conversely, HLA-Cw* 12 was associated with the 
development of DSS in patients with secondary DENV-2 infection. Our finding was similar 
to the findings of Stephens et al. (Stephens, Klaythong et al. 2002) who showed the antigen 
frequency of HLA-B44 were reduced in all DHF patients with secondary infections compared 
with the controls, although the frequency of HLA-B*44 and HLA-Cw* 12 in our results are 
smaller than 5% in case patients and controls, respectively. The association here is more 
difficult to characterize in HLA and disease association studies due to the small frequencies 
of the HLA antigens in study population. A second independent study with a larger patient 
sample may resolve this issue.
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These Vietnamese data on HLA class I association with DHF support the relevance of MHC 
class I variation suggested by some previous studies (Table 3.1), even though the allelic 
associations in each study differ, perhaps as a result of viral, clinical outcome and other non- 
MHC host genetic variation polymorphism. A recent case-control study of HLA associations 
in Vietnamese DHF patients revealed evidence for HLA-A*24 and HLA-A*33 in 
susceptibility and resistance respectively DHF (Loke, Bethell et al. 2001). We did not 
confirm these associations in our current study. A possible reason why we did not confirm an 
association between HLA-A*24 or HLA-A*33 and DSS is that in the study by Loke et al, 
DENV infections were confirmed serologically in only a small proportion of DHF patients 
(Loke, Bethell et al. 2001), and there was no information on the infecting serotype. In 
contrast, our DSS patient set comprised only laboratory confirmed secondary DENV-2 
infection. In addition, DENV-2 was the prevalent serotypes in South of Vietnam from 1999 
to 2006 while DENV-1 was predominant from 1990 to 1995 when Loke et al. collected their 
samples (Ha, Tien et al. 2000) (Pasteur 2007). The study performed by Nguyen et al is also 
found association between DHF/DSS patients and HLA-A*24 but not HLA-A*33 (Nguyen, 
Kikuchi et al. 2008). Infact, there were inconsistent association results between their three 
patient groups as they devided patient into primary/secondary. There was also no information 
on the infecting DENV serotype in Nguyen et al study.
HLA-DQB1*03, which was the most frequent class II allele in our study population and 
appeared to be associated with increased susceptibility to DSS, with OR 2.43 and P value of 
0.0007 (Table 3.7). This association was confirmed in another independent population of 
cases with either DSS or DF/DHF grade I and II. We hypothesize that the HLA-DQB1*03 
association observed might be explained by its higher efficacy in presenting DENV-2 
epitopes to CD4+ T cells. In this model, HLA-DQB 1*03 might facilitate a greater level and
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breadth of the immune response to virus peptides and this may contribute to the pathogenesis 
of dengue (King, 2003). Although HLA class I restricted cytolytic CD8 T lymphocytes are 
also likely to be most important for clearing virus infected cells, dengue specific HLA class II 
restricted CD4+ T cell clones with cytolytic activity have been raised from individuals 
infected or vaccinated with dengue virus (Kurane, Okamoto et al. 1995) (Livingston, Kurane 
et al. 1994) (Green, Kurane et al. 1993) (Luhn, Simmons et al. 2007). Such DENV-specific 
CD4+ T lymphocytes may contribute to immunopathology by lysing virus-infected MHC 
class II expressing cells, e.g. macrophages, and secreting pro-inflammatory cytokines that 
might lead to capillary leakage (Kurane, Innis et al. 1990). For example, CD4+ T cell clones 
are capable of secreting a range of cytokines including IFNy, TNFa, and IL-2 upon re­
stimulation and it is conceivable that these molecules have an impact on normal vascular 
endothelium function.
HLA-DQB 1*03 could also be just a marker for variants of other genes linked to the HLA or 
other HLA linked gene that has the potential to influence the diseases outcome. The 
DRB 1 *0401-DQA1*03-DQB 1*0302 haplotype is reportedly more common in type I 
diabetes patients (Volpini, Testa et al. 2001) and DRB 1*0402-DQA1*03-DQB 1*0302 in 
Insulin-dependent diabetes mellitus patients (Saruhan, 2000). Thus to determine whether the 
association identified above are because of the marker being part of one specific halotype has 
to be address in further studies.
Due to the complexity of the immune system, genetic susceptibility to infectious diseases is 
most likely to be the combined effects of many genes. With the candidate gene approach, we 
are looking for an effect at one of the many genes. There are some strength of the study 
design, (i) Our DSS patient set comprised only laboratory confirmed scondary DENV-2 
infection. At the time samples were collected, DENV-2 was the most prevalent serotypes in
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South of Vietnam (1999 to 2006). (ii) All our patients and control were intensively typed for 
HLA class I and II alleles.
There are obvious weaknesses with this study design. If the effect of the individual genes is 
small or the alleles of a polymorphism are rare, extremely large studies would be needed to 
see an effect. It is only possible to study genes and polymorphisms that have been mapped 
and sequenced and this will become easier with the Human Genome Project. Improvements 
in technology that permit high-throughput genotyping of genetic polymorphisms have 
allowed a genome-wide approach to investigating host genetic susceptibility. Essential to this 
approach are large sample sizes in order to make statistical correction of the number of 
comparisons being made. Replication of the genetic association in a second population is now 
considered an essential validation step.
Another methological issue is that of selection of study population and sampling strategy. 
Most candidate gene studies use a case-control approach, and unrecognized ethnic differences 
between the groups are likely to be reflected in fake genetic associations that are unrelated to 
the disease of interest. This issue of “population stratification” can be minimized if cases and 
controls are carefully matched and its presence can also be quantified from the genetic data 
themselves. The majority of Vietnamese people (85%) belong to the Kinh ethnic, whereas the 
remaining (15%) represent 60 minorities (Vu-Trieu, Djoulah et al. 1997). In fact, there was a 
first GWAS to look at host susceptibility to dengue shock Syndrome (Long et al, unpublished 
data) demonstrated for the first time that Vietnamese Kinh is distinct from other Asian 
populations such as the Chinese and Japanese. This genotyping data of SNPs in all the 
Vietnamese Kinh cases and control were compared with those of SNPs in Caucasian (CEU), 
African (YRI) and Asian populations (HCB and JPT) indicated that the case and the control
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samples are homogeneous. To these evidences, we are confident that our Vietnamese Kinh 
cases and controls are ideal population for case-control genetic association studies. 
Collectively, these genetic data underscore the potential importance of HLA class Il-alleles in 
DHF/DSS, however, it is not possible to conclude from this evidence the actual role of HLA 
class II-restricted responses in pathogenesis. Association between HLA, DENV serotype, and 
DENV infection outcome are complex and require further explanation and research. 
Association-based observations require confirmation with functional studies that validate 
interaction between HLA-associated genotypes and dengue. The only way to understand the 
role of HLA restricted responses in dengue infections and DHF pathogenesis is to initiate 
studies in naturally immune individuals.
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Chapter 4: Spectrum and kinetic of T cell responses to epitopes in dengue viruses
4.1 Background
Epidemiological studies suggest that individuals who experience a secondary infection with a 
heterologous dengue serotype are at significantly greater risk of developing DHF (Burke, 
1988) (Graham, Jufffie et al. 1999) (Thein, Aung et al. 1997). In endemic countries, children 
carry most of the symptomatic disease burden but young adults are also significantly affected. 
Several hypotheses have been proposed for the risk factors of severe dengue. Viral, host 
genetic, age and nutritional factors have been associated with susceptibility to DHF (Gamble, 
Bethell et al. 2000) (Leitmeyer, 1999) (Loke, 2001) (Loke, 2002) (Stephens, 2002) 
(Thisyakom) (Stephenson, 2005). Viral risk factors include infection with a more virulent 
dengue virus and the size of the viral load. Antibody-dependent enhancement (ADE) is also 
hypothesized to contribute to the pathogenesis of severe dengue illness. Halstead proposed 
that during secondary DENV infection, the preexisting DENV antibodies at sub-neutralizing 
or non-neutralizing levels to infecting serotype may result in ADE of infection (Halstead,
2002).
Profound immune activation during secondary infection contributes to other risk factors and 
promotes the development of severe plasma leakage. There are evidences of CD4+ and CD8+ 
T cell activation in vivo during dengue infection. Accordingly, frequencies of CD8+ T cells 
are higher in patients with DHF than in those with mild dengue fever (Rothman, 2003) 
(Green, 1999) (Mongkolsapaya, 2003) (Zivna, 2002). Following the viral replication and 
presenting antigen to T cells, activation of CD4+ and CD8+ memory T cells in secondary 
infection leads to proliferation and release of proinflammatory cytokines (Mangada, Endy et 
al. 2002). Several plasma cytokines of cellular immune activation, including tumor necrosis
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factor-alpha, gamma interferon, interleukin-2 receptors, interleukin-6, interleukin-13 and 
interleukin-18, are elevated in DHF compared to DF (Rothman, 2003) (Kurane, 1991) 
(Juffrie, 2001) (Mustafa, 2001). These cytokine can act directly upon vascular endothelial 
cells to elicit increased vascular permeability. Together, these studies suggest a vital role of 
immune response in immunopathogenesis of viral infection. However, the mechanism of how 
T cells contribute to DHF pathogenesis is less clear since only a few studies have directly 
examined the responses of T cell during acute disease (Green, 1999) (Mongkolsapaya, 2003). 
Thus there exists a need to study the cellular immune responses of T cells and serotype cross­
reactivity in a patient population with a mixed HLA background to determine the relationship 
between T cell response and disease severity. Therefore, the aim of the current work is to 
identify novel T cell epitopes in dengue viruses that are restricted through HLA alleles 
common in Vietnamese population. Furthermore, we seek to determine the kinetics and 
cross-reactivity of the responses to novel epitopes.
4.2 Study design
During primary infection, inflammatory cytokines are released from infected cells, including 
dendritic cells, B cells, monocytes, and hepatocytes that can attract adaptive immune cells 
including T cells, NK cells, and B cells. Naive T cells specific for the infecting serotype are 
preferentially expanded. In the secondary infection, the level of T lymphocyte activation is 
markedly increased, reflecting the increased antigen presentation, the increased frequency of 
DENV-specific and cross-reactive T lymphocytes in secondary, and the more rapid activation 
and proliferation of memory T lymphocytes. Infected cells present 8-llmers or 15-20mer 
peptides, dependent on the class of HLA molecules bound to the peptides, to specific T 
lymphocytes. Hence, identification of antigenic peptides recognized by dengue virus-specific 
T lymphocytes may suggest new way to suppress viral replication and prevent prolonged
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infection. Recently, studies of dengue patients have successfully identified several peptides 
that are specific for CD8+ and CD4+ T lymphocytes (Table 4.1). In this study, we sought to 
identify the novel epitopes and measured ex vivo responses to a spectrum of dengue virus 
antigens by studying T cell responses to peptide antigens spanning the DENV-2 genome.
Due to several limitations, we were unable to collect enough blood from patients to study the 
T cell responses to peptide antigens spanning the entire genome. Therefore, we focused our 
investigations on structural antigens (capsid, preM/M, and Env) and nonstructural viral 
antigens previously nominated as being T cell imunogens (NS3 and NS4a). A total of 260 
peptides (including two hundred and twenty 15mers and forty 20mers) span the capsid, preM, 
M, Env, NS3, and NS4a sequences from a DENV serotype 2 isolate (strain 16681) (Appendix 
3). PBMC were tested in EFN-y ELISPOT assay against the total of 260 peptides arranged 
into a matrix of 32 peptide pools, with 16 peptides in each pool and each peptide present in 
two different pools. The exceptions were pool 16 with 20 peptides and pools 29, 30, 31, and 
32 with 18 peptides (Appendix 4). A peptide is identified as being antigenic if it drives a 
response in two different pools in IFN-y ELISPOT assay. In every case, identified peptides 
were retested as individual peptides.
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Table 4.1 Epitopes on dengue viral proteins recognized by virus-specific human T cells
Protein Amino acids Sequence Subset HLA Reference
C 47-55 VLAFITFLR CD4 DPw4 (Gagnon, Zeng et al. 1996)
83-92 GFRKEIGRML CD4 DR1, DPw4 (Gagnon, Zeng et al. 1996)
N S3 . 71-79 SVKKDLISY CD8 B62 (Zivny, DeFronzo et al. 1999)
130-144 GTSGSPIIDKK CD8 A l 101 (Mongkolsapaya, 2003)
146-154 VIGLYGNGV CD4 DR15 (Kurane, 1995)
202-211 RKYLPAIVRE CD4 DR15 (Kurane, 1995)
222-230 APTRW AAE CD8 B7 (Mathew, 1998)
224-234 TRWAAEMEEA CD4 DR15 (Kurane, 1998)
235-243 AMKGLPIRY CD8 B62 (Zivny, 1995)
241-249 IRYQTTATK CD4 DR15 (Kurane, 1995)
255-264 EIVDLMCHAT CD4 DPW2 (Okamoto, Kurane et al. 1998)
352-362 WITDFV GKT VW CD4 DR15 (Zeng, 1996)
500-508 TPEGIIPTL CD8 B35 (Livingston, 1995)
4.3 Patient recruitment
Adult patients with a clinical suspicion of dengue virus infection were recruited from the 
intensive care unit of the Hospital for Tropical Disease, Ho Chi Minh City, Vietnam. Venous 
blood samples were collected from patients on the first day after admission (Study Day 1), on 
Study Day 3 and on Study Day 5 unless the patient was discharged earlier. Convalescent 
samples were obtained at 2 weeks and 1 month post-admission. WHO classification criteria 
(World Health Organization, 1997) were applied to each case after review of the study notes.
Platelet counts and haematocrit values were recorded regularly during hospitalization. The 
extent of hemoconcentation during symptomatic illness was determined by comparing the 
maximum haematocrit recorded during hospitalization with the value recorded at 
convalescence.
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Written informed consent was obtained from the patients. The study protocol was approved 
by the Scientific and Ethical Committee at The Hospital for Tropical Diseases and; by the 
Oxford Tropical Research Ethical Committee.
4.4 Results
4.4.1 Characteristics of patient population
This study was carried out at The Hospital for Tropical Diseases, Ho Chi Minh City, 
Vietnam. Between June of 2002 and April of 2003, we recruited 51 patients suspected of 
having a dengue virus infection from the adult intensive care unit into a prospective study of 
cellular immune responses. After applying WHO criteria (World Health Organization, 1997) 
to each case, all patients were classified as DHF cases, including DHF Grade I (n=13), DHF 
Grade II (n=17), and DHF Grade III (n=20); only 1 patient was diagnosed with DHF Grade 
IV. Two subjects had clinical manifestation of plasma leakage (e.g., pleural effusion) and 
mucosal bleeding, but platelet counts were between 100,000 and 120,000. We classified these 
cases as DHF grade II. The patients’ mean age was 19 years (SD, 3 years; range, 15 to 27 
years). The mean duration of illness was 5 days (SD,1 day; range, 1 to 10 days). Serology of 
paired plasma samples indicated that all patients were experiencing a secondary dengue virus 
infection. For the period of hospital admission, the average maximum haematocrit recorded 
was 49% (SD, 4.7%, range, 41 to 60%) and the mean nadir of the platelet count was 47,700 x
103/ml (SD, 33,900>< 103/ml, range, 13,900 * 103/ml to 115,000 * 103/ml). Amongst the 51
investigated patients, 39 patients (76%) had a response to at least one peptide in the IFN-y 
ELISPOT assay. The characteristics of the patients with positive SFU in response to at least 
one peptide are shown in Table 4.2.
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Table 4.2 The characteristic of the patients respond to DENV-2 peptides
Patient
Age
(years) Sexa
Day of 
illness Serology Diagnosis'3
Dengue
serotype0
A
HLA class I type
B Cw
BC309 24. F . 5 Secondary II 1 24/34 15/46 03/03
BC310 17 F . 3 Secondary III 1 11/24 35/51 04/14
BG311 19 M 4 Secondary m 4 24/26 38/15 07/08
BC313 19 M 5 Secondary hi 0 24/26 38/15 07/03
BC314 18 M 4 Secondary m 2 02/11 46/15 01/08
BC315 19 F 10 Secondary ii 2 29/33 58/81 03/15
BC316 22 . M 5 Secondary hi 0 29/30 07/13 06/07
BC317 22 M 6 Secondary. iu 1 11/26 38/15 07/08
BC318 15 F 6 Secondary n 2 24/33 44/15 04/07
BC320 18 F 5 Secondary in 0 02/33 46/58 01/03
BC322 26 M 3 Secondary hi 2 . 11/30 07/54 01/15
BC323 31 M 4 Secondary m 0 11/24 46/51 . 01/14
BC324 20 F 5 Secondary IV 2 29/68 07/51 15/-
BC325 17 M Secondary ii o 02/11 56/15 01/-
BC327 20 M 4 Secondary r 1,4 02/31 51/39 07/-
BC331 17 M 5 Secondary n 1 11/24 . 40/35 03/03
BC332 16 M .5  '. Secondary hi 0 02/11 38/37 07/06
BC333 22 M 5 Secondary ii 0 11/26 38/15 07/08
BC334 31 M 5 Secondary n 0 02/11 07/57 06/07
BC336 . 21 F 4 Secondary n 2. • . 02/31 46/51 01/14
BC337 16 M 4 Secondary in 1 11/24. 15/46 01/08
BC338 22 F 3 . Secondary n 2 11/33 13/46 01/03
BC343 22 M 5 Secondary ii 1 24/29 07/15
BC347 20 M . 5 • Secondary hi 2 • 02/11 15/46 01/03
BC348 16 M 3 Secondary hi 0 24/33 15/58 03/08
BC349 17 F 4. Secondary hi 2.
BC350 17 F 5 Secondary n 2 24/34. 15/46 01/03
BC352 . 15 F 5 . Secondary n 2 24/29 07/48 08/15
BC353 15 F 6 Secondary m 2 11/- 39/56 01/07
BC354 17 F 4 Secondary ii 1 11/- 15/- 08/-
BC500 26 M 2 Secondary i 4 01/11 15/57 06/08
BC501 20 M 5 Secondary i 4 02/11 51/54 01/-
BC502 16 M 5 Secondary i o 02/29 07/13 .03/15 .
BC503 23 M 4 Secondary i 1 11/- 07/46 01/15
BC504 27 M 4 Secondary i 4 11/29 07/46 01/15
BC507 26 M 5 Secondary i 4 02/24 15/15 04/07
BC508 15 M 5 Secondary H 4 02/03 46/15 01/08
BC509 20 M 5 . Secondary I 0 02/03 38/35 .07/12
BC510 15 M 5 Secondary I 1 33/- 18/44 07/07
a F, female; M, male.
b WHO classification: I-DHF grade I; II-DHF grade II; III-DHF grade III; IV-DHF grade IV. 
c DENV serotype: 1-DENV1; 2-DENV2; 3-DENV3; DENV4
77
Chapter 4: Spectrum and kinetic o f  T  cell responses to epitopes in dengue viruses
4.4.2 IFN-y ELISPOT responses against a panel of peptides spanning the capsid, 
preM, M, Env, NS3 and NS4a viral antigens
To measure the breadth and magnitude of T cell responses to multiple dengue virus antigens, 
PBMC samples from dengue virus-immune Vietnamese adults were tested in IFN-y 
ELISPOT assays against overlapping peptides spanning the capsid, preM, M, Env, NS3, and 
NS4a viral antigens from a DENV-2 isolate. Amongst the 51 DHF patients, we have defined 
the IFN-y ELISPOT response to dengue peptides in PBMC samples from 39 patients. In these 
39 patients, one or more individual peptides that reproducibly evoked an IFN-y response in 
the ELISPOT assay exceeded 25 spot forming units (SFU) per million PBMC. In total, T 
cells from the 39 patients recognized 47 different peptides. In terms of the percentage of 
peptides recognized of the total number tested for each viral antigen, the peptides from the 
capsid and M protein were most frequently recognized in ELISPOT assays (Figure 4.1). 
However, in categorical terms, there were more peptides (n=30, 64%) from the NS3 protein 
that evoked T cell responses in IFN-y ELISPOT assay compared to 11% for capsid, 6% for 
prM/M, 17% for Env and 2% for NS4a.
The magnitude of responses to individual peptides ranged from 27 SFU to 500 SFU per 
million of PBMC. The breadth of the response in individual patients ranged from 1 to 10 
peptides. The breadth and magnitude of responses from all patients are shown in Appendix 5. 
A summary of the individual peptides that reproducibly evoked responses in IFN-y ELISPOT 
assays is provided in Table 4.3. In several cases, two adjacent and overlapping peptides 
evoked a response in the same patient, suggesting that they contain a shared epitope, or 
alternatively, the presence of overlapping epitopes. Thirteen of the 47 peptides (28%) 
recognized by PBMC contain sequences that have previously been characterized as dengue- 
or flavivirus-specific CD4+ or CD8+ T cell epitopes (Table 4.3).
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Figure 4.1 T cell responses by viral antigen. Shown are the numbers o f peptide antigens 
from different viral antigens that evoked T cell responses in convalescent dengue patients 
(Study days 5-14).
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Table 4.3 Summary of antigenic peptides recognized by T cells from secondary dengue
patients
Sequence3 Location Nb
ELISPOT
frequency'
Sub-
setd
Minimum epitope, HLA 
restrictione
PFNMLKRERNRVSTVQQLTK Capsid 12-31 1 100
RVSTVQQLTKRFSLGMLQGR Capsid22-ti 1 70
TAGILKRWGT1KKSKAINVL Capsidi2-Ri 3 97(60-130) CD4
IKKSKAINVLRGFRKEIGRM Capsid 72-9i 5 58(30-120) CD4 Capsids3-92 (GFRKEIGRML)/DPw4
RGFRKEIGRMLNILNRRRRS Capsids2.ini 5 58(40-80) CD4 Capsidsj-92 (GFRKEIGRML)/DPw4
LGELCEDTITYKCPLLRQNE preMu-w 3 203(28-500) CD4
MSSEGAWKHVQRJETWILRH M20-39 2 95(60-130)
QRIETWILRHPGFTMMAAI M30-49 1 120
FVEGVSGGSWVDIVL Env, us 1 500
SGGSWVPIVLEHGSC Env 16.30 2 230(60-400)
LRK Y CIE AKLTNTTT Env56-7o 2 115(80-150)
. VTMECSPRTGLDFNE EnV|8|-195 1 120
MENKAWLVHRQWFLD Env2oi-2i5 1 80
tlvtfknphakkqdv EnV236-2S0 1 66
KKQDVWLGSQEGAM EnV746-260 2 96(75-117)
RMAILGDTAWDFGSL' En\'4| M25 8 142(60-300) CD8
TFHTMWHVTRGAVLM NS345-59 •5 151(55-390) CD4
IEPSWADVKKDLISY NS365-79 3 151(100-194) CD8 NS37i.;9 (SVKKDLISY)/B*62
ADVKKDLIS Y GGG WK NS3 70-84 1 97 NS37i-79 (SVKKDL1SY)/B*62
AVSLDFSPGTSGSP1 NS3125-139 1 140
FSPGTSGSPIIDKKG NS3,30-144 5 167(53-240) CD8 NS3,33-142 (GTSGSPIIK)/A* 11
KWGLYGNGWTRSG NS3145-159 3 140(140-140) CD4 • NS3,46-154 (VJGLYGNGV)/HLA-DR 15
TKRYLPAIVREA1KR NS3200-2I4 3 63(40-85) CD4 NS32o:-2i 1 (RKYLPAIVRE)/ HLA-DR15
GLRTLJAPTRVVAA NS32I5-229 3 92(75-100)
ILAPTRWAAEMEEA NS3220-234 7 150(40-350) CD8 NS3221-232 (LAPTRWAAEME)/B*07
EMEE ALRGLPIR Y QT NS3230-244 3 213(120-260) CDS NS3235-243 (AMKGLPIRY)/B*62
LRGLPIRY QTPA1RA NS323 5-249 2 47(45-48)
IRYQTPAIRAEHTGR NS3240-254 4 109(27-210)
EHTGREIVDLMCHAT NS3250-264 1 200 CD4 NS3255-2m(EIVDLMCHAT)/HLA-DPw2
EIVDLMCHATFTMRL NS3255-269 2 150(100-200) CD4 NS3255.264(EIVDLMCHAT)/HLA-DPw2
LSPVRVPNYNLIIMD NS3270-284 3 173(90-230)
VPNYNL1IMDEAHFT NS3275-289 3 213(190-230)
LI1MDEAHFTDPAS1 N S3 280-294 3 172(85-310)
EAHFTDPAS1AARGY NS3 285-299 4 160(80-200) CD8
EMGEAAGIFMTATPP NS3305-3I9 1 70
AGIFMTATPPGSRDP NS33JO-324 3 105(80-153)
KXVIQLSRKTFDSEY NS3380-394 1 118
NDWDFWTTDISEMG NS340<M14 1 100
LDN1NTPEG1IPSMF NS3495-509 2 155(80-230) CD8 NS35oo-508 (TPEG1IPTL)/B*35
TPEGIIPSMFEPERE NS3500-5I4 3 167(70-240) CD8 NS35oo.508 (TPEGIIPTL)/B*35
GDLPVWLAYRVAAEG NS3 540-554 1 60
VAAEGINYADRRWCF' NS3550-564 4 222(100-310) CD8
INYADRRWCFDGVKN NS3s55-569 1 310
EGERKKLKPRWLDAIY NS3s85-599 2 68(38-97)
KLKPRWLDARIYSDP NS359<M»4 1 85
WLDARIY SDPLALKE NS3s95^,09 1 250
LATVTGGIFLFLMSGRGIGK NS4a6i-so 1 58
a sequence is derived from DEN V2 isolate 16681
b ‘N ’ indicates the number o f  patients who responded to each peptide
c shown are the mean (range) number o f  SFU/million PBMC evoked by each peptide
d the T cell subset responding to peptide stimulation was determined by bead depletion o f  CD4+ and
CD8+ T cells
e the peptide sequence and HLA restriction o f  published epitopes that are present in the larger, 
overlapping 15 or 20mer peptide is shown. References link to table 3.1 
f Peptides shown in the boldface were studied further
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4.4.3 Antigen specificity of IFNry ELISPOT responses and their relationship to 
recognized structural motifs
All identified peptides recognized by T cells from dengue patients were evaluated for their 
relationship to recognized conserved structural motif. The spectrum of identified antigenic 
peptides was examined in the context of known biological features in each of the respective 
viral antigens. Several antigenic peptides were identified in the capsid protein, primarily 
located near to the conserved cleavage point of the C-terminal hydrophobic signal sequence 
(Table 4.3 and Fig. 4.2.A). Antigenic peptides were also detected in preM/M (Table 4.3 and 
Fig. 4.2.B), Env (Table 4.3 and Fig. 4.2.C), and NS4a (Table 4.3 and Fig. 4.2.D) proteins. 
These antigenic peptides were riot associated with any recognized conserved structural 
motifs: NS3, a 618 amino acid long serine protease and helicase, contained the highest 
number (n=30) of antigenic peptides (Table 4.3 and Fig. 4.2.E). Fourteen from 30 (47%) of 
these antigenic peptides were clustered within a 124 amino acid long stretch of NS3 (NS3200- 
324) (Fig. 4.2.E). Alignment of consensus amino acid sequences from all four dengue 
serotypes indicated that this region of NS3 is more conserved (78%) than NS3 as a whole 
(68%). NS3 was the most frequently recognized viral antigen, with 56% of all tested patients 
responding to at least one antigenic peptide compared to 27% for Env, 23% for the capsid, 
10% for prem/M and 2% for NS4a.
81
Chapter 4: Spectrum and kinetic o /T  cell responses to epitopes in dengue viruses
( apsid
<\ Ci
I" '
I (HI I U
B
p r \ l  & \ l
J U lL
C-1 C i  03  04 05  04  07  06  Ot«OW^Mn v** v V J *  s *  •> O ' -C* >  *3^ s> NV <*• ^ ^ ^  ^ ^ ^ ^
OVL p«ptH le»
F nvrlnp
D
o
I n  * .
1 2 
1 1
& 0 6  *
£  0 6  
QI 04 
S 0 2
«s JV J  J» J° ^  J* J» s« *  C> •>
OVL popttdvs
E
i ?
"6
1
E
5
4
32 H 1 o
M I 2 I 6 2 I I I  I I  H IM  4 2 1 )
S l » ( 1 4 ’ . | 5 4 l  |  1 1 (1 1 1  «!■»)
I I  ( IN K -2IIM
II IJXO-2N7I II l llll K.t|
ll Jl l U lT f f n t  f f n i r n  i r m f n m r i r n m  i n » W n n m r f f m » » W/  *£■' sty  ____  .___ h ii in irn i tX iiI r
OVL P e p tld o s
jLiLiAt iFJf’ jflUPiv //y av
Figure 4.2 T cell responses by viral antigen. Shown is the frequency with which individual 
antigenic peptides in the (A) capsid, (B) preM/M, (C) Env, (D) NS4A and (E) NS3 viral 
antigens were recognized by PBMC collected on Study Days 5-14 from 51 patients with 
secondary’ dengue. Shown within each viral protein are recognized structural features and in 
parentheses their amino acid location with respect to the start o f the protein.
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4.4.4 Relationship between the serotype of the infecting virus and the breadth and 
magnitude of responses to overlapping DENV2 peptides in IFN-y ELISPOT 
assays
A dengue serotype-specific PCR performed on acute plasma samples collected from all 51 
patients identified the serotype of the infecting virus in 35 individuals (68%). Dengue viral 
RNA was detected in 28 (72%) of the 39 patients who made responses to one or more 
individual peptides. Amongst these 28 patients dengue serotype 1 (DV1) was detected in 9 
(32%), DV2 in 12 (43%) and DV4 in 6 (21%). One patient had a mixed infection comprising 
DV1 and DV4 (4%). Dengue viral RNA was detected in 7 of the 12 patients (58%) who 
failed to respond to any of the peptide antigens. Interestingly, the spectrum of viruses 
detected in these 7 PCR-positive individuals was narrow, with DV2 detected in 6 (86%), and 
DV3 detected in 1 (14%).
We sought to determine whether a relationship existed between the breadth and magnitude of 
the T cell response to individual peptides and the serotype of the infecting virus. We did not 
include the patient with a mixed DENV1/DENV4 infection in this analysis. In cases when 
patients responded to adjacent peptides, we included responses to both in the analysis. 
Amongst the 47 patients analysed, the breadth of the responses was not significantly 
associated with the serotype of the infecting virus. Thus, patients infected with DENV2 
(n=18) did not respond to significantly more peptides (median=2, range 0-10) than patients 
infected with either DENVl (n=9, median; 2, range 1-7), DENV3 (n=l, median; 0), DENV4 
(n=6, median; 2, range 1-4) or patients in whom a dengue virus could not be detected (n= 16, 
median; 1, range 0-5) (Figure 4.3.A). Like the breadth of the response, the mean sum of 
ELISPOT frequencies to individual DENV2 peptides in patients infected with DENV2 did 
not significantly exceed (mean±standard deviation; 62±57 SFU/million PBMC) those in 
patients infected with either DENV1 (189±127 SFU/million PBMC), DENV4 (112±61
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SFU/million PBMC) or patients in whom a dengue virus could not be detected (90±86 
SFU/million PBMC) (Figure 4.3.B).
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Figure 4.3 Relationship between the serotype of the infecting virus and the breadth and 
magnitude of T cell responses to DENV2 peptides. Shown are the breadth o f IFN-y 
ELISPOT responses (A) and the mean o f the sum o f IFN-y ELISPOT responses recorded (B) 
to peptide antigens in dengue patient by infecting DENV serotype.
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One possible explanation for the absence of significantly stronger responses to DENV2 
peptides in patients infected with a serotype 2 virus is that the DENV2-specific response had 
not sufficiently matured at the time of analysis (Study Day 5). To test this hypothesis, 
ELISPOT responses to pools of overlapping DENV2 peptides were measured in serial PBMC 
samples collected from 5 prospectively recruited patients infected with DENV2. Responses 
detected against pooled peptides were verified using individual peptides. In the 4 patients 
who made responses to one or more peptide antigens, the breadth of the response actually 
contracted rather than expanded with time since infection elapsed (Figure 4.4). The 
narrowing of the breadth of responses coincided with a reduction in the magnitude of 
responses to each antigenic peptide. This suggests a significant DENV2-specific response 
does not evolve with increased time since secondary infection. The DENV2-specific response 
had sufficiently matured at convalescence.
Figure 4.4 Breadth of the ELISPOT response to DENV2 peptides in patients infected 
with a dengue serotype 2 virus at different times post-presentation. The number o f  
individual peptide antigens that evoked significant responses (>50 SFU/million PBMC) in 
PBMC samples collected from four patients infected with DENV2 was determined at different
6
1-3 3-6 10-20 30-60
Study day
times post-infection. Shown are the number o f peptides recognized in each patient at different
times post-diagnosis.
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4.4.5 Relationship between clinical parameters and the breadth and magnitude of 
responses to overlapping DENV2 peptides in IFN^y ELISPOT assays
Clinical disease grade had no apparent relationship with the breadth or magnitude of the T 
cell response. With respect to the breadth of responses, patients with DHF grade I (n=13) 
recognized on average 1.9 peptides (range 0-8) in ELISPOT assays, which was virtually 
identical to patients in grade II (n=17, 2.4 peptides (range 0-7)) or III (n=20, 2.1 peptides, 
(range 0-6)). Only one patient with DHF grade IV was recruited to the study, although 
interestingly, PBMC from this individual recognized 10 different peptides. Like the breadth 
of the response, there were no significant differences between the mean sum of ELISPOT 
responses recorded for patients in each of the disease grades (Grade I: mean±standard 
deviation: 103±127, Grade II: 117±87, Grade III: 85±76, Grade IV: 110; see Figure 4.5).
The magnitude of the responses to individual peptides in each patient was also compared to 
the minimum platelet count and maximum relative increase in haemoconcentration recorded 
during hospitalization. The extent of acute haemoconcentration was determined by 
comparing the maximum haematocrit recorded during hospitalization to the haematocrit 
recorded at follow-up in each patient. This data was available for 24 patients, all of whom 
had detectable acute ELISPOT responses. Correlation analysis revealed a significant 
relationship (r=0.41, P=0.04) between the magnitude of IFN-y ELISPOT responses measured 
on Study Day 5 and the extent of haemoconcentration in individual patients (Figure 4.6). 
Conversely, the nadir of thrombocytopaemia did not significantly correlate with the sum of 
responses to peptides in individual patients (r=0.13, .P=0.56).
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Figure 4.5 Relationship between clinical disease grade and the breadth and magnitude 
of T cell responses to DENV2 peptides. Shown are the breadth o f IFN-y ELISPOT 
responses (A) and the mean o f the sum o f IFN-y ELISPOT responses recorded (B) to peptide 
antigens in dengue patient by disease grade.
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Figure 4.6 T cell responses and haemoconcentration. Shown is the correlation between the 
sum of individual peptide-specific T cell responses detected in IFN-y ELISPOT assays and 
the maximum percentage haemoconcentration recorded in each patient (P=0.04, Pearson 
correlation). The maximum percentage haemoconcentration occurring in each patient vim 
deduced by comparison o f haematocrit values obtained during hospitalization to those 
obtained from paired convalescent blood samples collectedfrom 14 to 31 days after hospital 
admission.
4.4.6 The minimum determinant and HLA restriction of T cells responding to Env^j-^s 
For several of the peptide antigens from 47 different peptides that was found to evoke T cell 
responses, we employed IFN-y ELISPOT assays with PBMC depleted of either CD4+ or 
CD8+ T cells to identify the responding T cell subset. These experiments identified several 
peptides (capsid^-si, preM4i-6o, Env4iM25, NS345-59, NS3285-299, NS3550-564) that contain novel 
CD4+ or CD8+ T cell determinants (Table 4.3). Where possible, we attempted to predict the
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HLA restriction of CD8 + T cell responses by Comparing the HLA types of all individuals who 
responded to the peptide in question. In cases with only one HLA antigen in common 
between all the responders, we nominated this allele as the restricting determinant.
The peptide RMAILGDTAWDFGSL (Env4 i 1-425) was amongst the most frequently 
recognized by patient T cells in ELISPOT assays. Cells from 8  of 39 patients recognized 
E n v 4 i  1-425 with a mean response of 153±76 SFU per million PBMC (Fig. 4.7A). In five 
patients, depletion of CD4+ or CD8 + T cells from PBMC prior to ELISPOT assay revealed 
that both CD4+ and CD8 + T cell enriched fractions responded to Env4 i4-422 peptide stimulation 
(Fig. 4.7B). In two patients, truncated synthetic peptides and ELISPOT assays were used to 
determine the minimum epitope within Env4 11.425 that was recognized by CD8 + T cells. 
Peptides with the sequences MILGDTAWDF, ILGDTAWDF, ILGDTAWDFG and 
RMAILGDTAWDF were recognized equally well by PBMC enriched for CD8 + T cells, 
suggesting the sequence ILGDTAWDF (Env4 14-422) may represent the minimum determinant 
for CD8 + T cell responses (Fig. 4.8). HLA typing of patients possessing CD8 + T cells that 
recognized peptide Env4 i4.422 revealed that HLA-B*07 was the only class I HLA antigen 
shared by all responders. We confirmed the HLA restriction of Env4 i4-422 via a CTL killing 
assay. A short term T cell line generated from Env4 i4-422 peptide-stimulated PBMC from 
BC503 was lytic to a peptide-pulsed BCL that shared only B*07 in common with the effector 
cells (25% specific lysis at an effector to target ratio of 1 0 :1  for Env4 14^22 peptide pulsed 
targets versus -2.5% for targets alone) (Fig. 4.9).
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Figure 4.7 T cell responses evoked by RMAILGDTAWDFGSL (Env4iM2s) stimulation.
(A) T cell responses evoked by RMAILGDTAWDFGSL (E11V411-425) stimulation from seven 
adult dengue patients. (B) PBMC from five adult dengue patients who recognized Env 411-425 
were depleted o f CD4 or CD8  T cells via magnetic beads. In each case, depletion removed 
>95% of targets cells. Untouched PBMC and cells remaining after CD4 or CDS T cell 
depletion were co-cultured with Env4i 1-425 in IFN-y ELISPOT assays.
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Figure 4.8 Recognition by CD8+ T cells of truncated peptide variants of 
RMAILGDTAWDFGSL (Env4i 1-425). Shown are the frequencies o f IFN-y SFU elicited by 
truncated Env4j 1.425 peptides in IFN-y ELISPOT assays against PBMC from BC502 and 
BC503 after enrichment for CDS T cells.
30 
25
.<2 2 0  
1  15£ 10 
*  5
0 
-5
Figure 4.9 HLA-B*07 restricted recognition of the Env4]4_422 peptide. A CTL line from 
BC503 was co-cultured in a 4hr 51 Cr release assay with an Env4 i4.422-pulsed B 
lymphoblastoid cell line that matched the effector cells only at the B7 locus. Shown is the 
specific killing attained at a 1 0 : 1  ratio o f effectors to targets.
□  no peptide 
■ ILGDTAWDF pulsed
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4.4.7 Kinetic and cross-reactivity of responses to Env4i4-422
To measure the dynamic and serotype specificity of T cells specific for Env4 14422, we 
prospectively identified six HLA-B*07-positive patients with secondary dengue infections. 
The dengue serotype responsible for the current infection was determined in 4 patients: 
BC385, BC389 and BC395 were infected with DV2 and BC504 was infected with DV4. 
Virus was not detected in BC400 or BC414. Patients BC385, BC389, BC400, BC395 and 
BC504 were classified as DHF grade II whilst BC414 was DHF grade III. Initially, the extent 
of sequence variation present at Env4 i4.422, across all four dengue serotypes was examined. 
The sequence of Env4 i4.422 in DENV1-3 was invariant (ILGDTAWDF) whilst DENV4Env4i4_ 
422 differed by only one amino acid (ILGETAWDF). The dynamic of T cell responses to these 
variant peptides were then measured in 6 prospectively identified HLA-B*07-positive 
patients. All 6 patients responded to the HLA-B*07-restricted epitopes Env4 i4 4 2 2  (Fig. 4.10.A 
and 4.10.B) in ELISPOT assays, with the peak response measured at Study Day 3 or 14. 
ELISPOT responses to each of the epitope variants were generally similar. In samples from 
patient BC414, however, we observed much stronger responses (6-fold) to the DENV1 to 
DENV3 Env414—422 (ILGDTAWDF) epitope variant than to DENV4 Env414-422 
(ILGETAWDF). Stronger responses to DENV1 to DENV3 Env414-422 were also observed 
in patient BC504 (3.5-fold at days 3 and 14) and patient BC395 (2-fold at day 14) but were 
less pronounced.
The generally concordant responses to the Env4 14422 peptide variants were confirmed in 
peptide titration assays using PBMC from BC400. These experiments indicated that the 
frequency of T cells responding to each of the B*07-restricted peptide variants was virtually 
identical across all peptide concentrations, including low peptide concentrations that are more 
likely to reflect in vivo conditions (Fig. 4.10.C).
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Figure 4.10 Kinetic and cross-reactivity of responses to Env4 i4-422- The data depict the 
number o f IFN-y SFU detected in PBMC enriched for CD8 + T cells from 6  HLA-B*07- 
positive patients with secondary dengue infections. PBMC were incubated with peptides 
corresponding to (A) DENV I -3Env414.422 and (B) DENV4Env4j4.422- Patients BC385, BC389, 
BC400, BC395 and BC504 were DHF grade II. BC414 was DHF grade III. Patients BC389, 
BC395 and BC385 were infected with DENV2. BC504 was infected with DENV4. Virus was 
not detected in BC400 or BC414. (C) A peptide titration experiment suggested T cells from 
BC400 were cross-reactive for the variant peptides DENV I-3 Em>4j 4.422 and DENV4Env 414.422 
even at low peptide concentrations.
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4.4.8 The minimum determinant and HLA restriction of T cells responding to NS3s5o-564 
In IFN-y ELISPOT assays, patient BC313 (HLA-A*24, A*26, B38, B15, Cw7, Cw3) 
responded to three non-overlapping NS3 peptides: VAAEGINYADRRWCF (NS3550-564), 
EAHFTDPASIAARGY (NS3285-299) and IEPSWADVKKDLISY (NS365-79). Depletion of 
CD4+ or CD8+ T cells from PBMC prior to ELISPOT assay indicated the responding cells 
were CD8+ T cells (Fig. 4.1 l.A). The peptide spanning NS365-79 contained a previously 
defined HLA-B*15-restricted epitope, NS371-79 (Zivny, DeFronzo et al. 1999). Since patient 
BC313 was also HLA-B* 15-positive, it was not further investigated. Two lines of evidence 
suggested the NS3550-564 peptide contained an HLA-A*24 epitope. Firstly, a peptide 
containing this sequence had previously been shown to evoke T cell responses in HLA-A*24- 
positive Vietnamese dengue patients (Loke, Bethell et al. 2001). Secondly, the sequence 
NYADRRWCF (NS3556-564) conformed to the consensus A*24 sequence, which predicts 
peptides with a tyrosine or phenylalanine at the 2nd position and an uncharged amino acid at 
the C-terminal anchor position. The minimum determinant in NS3550-564 that elicited a 
response from patient BC313, who was HLA-A*24-positive, was identified by using 
truncated peptides spanning the predicted epitope in ELISPOT assays. INYADRRWCF 
(NS3555-564) was the minimum peptide that evoked the strongest response at the lowest 
peptide concentration from BC313 (Fig. 4.1 l.B).
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Figure 4.11 NS3555.564 is a CD8+ T cell epitope. In IFN-y ELISPOT assays, PBMC (study 
day 3) from subject BC313 responded to the DENV2 NS3 peptide VAAEGINYADRRWCF 
(NS3 550-564) in a CD8 dependent fashion (A). The truncated peptide INYADRRWCF (NS3sso- 
s m )  was the minimum peptide that evoked the strongest ELISPOT response at the lowest 
peptide concentration (B).
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4.4.9 Kinetic and cross-reactivity of responses to NS3556-564
Responses of T cells to peptides, corresponding to all known natural variants of the A*24- 
restricted NS3s56-564 epitope, were measured in 16 prospectively recruited, HLA-A*24- 
positive dengue patients during early convalescence (hospital discharge). The sequence of 
NS3556-564 was variant from four serotypes. T cell responses to any one of the NS3s56-564 
variants were detected in 4 of 16 (25%) subjects, suggesting this is not a dominant epitope. 
The dengue serotype responsible for the current infection was determined in 2 patients: 
BC311 (infected with DENV4) and BC398 (infected with DENV2). In all patients, the peak 
response to each of the epitope variants was recorded on Study Day 14 (Fig. 4.12). The 
spectrum of responses detected in each of the four patients varied according to the peptide 
antigen (Fig. 4.12). Thus, some patients made monotypic responses (BC313) whilst others 
had responses against 2 peptide variants (BC311, BC398, BC404). In both patients where 
information on the infecting viral serotype was available (BC311-DENV4 and BC398- 
DENV2), there was an ELISPOT response to the NS3s56-564 epitope matching the serotype of 
virus mediating the current infection, but also a response to a second natural NS3556-564 
epitope sequence (Fig. 4.13). Patients BC311 and BC398 also responded to the second 
NS3556-564 epitope sequence at low peptide concentrations that is reflective of in vivo 
conditions (Fig. 4.13).
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Figure 4.12 Kinetic of T cell responses to NS3555-564. Shown are the kinetic and magnitude 
o f IFN-y ELISPOT responses in 4 patients with secondary dengue infection to each o f the 
recognized peptide variants o f NS3555-564- PBMC from each patient was stimulated with (A) 
DENV INS3555.564 (FQYSDRRWCF), (B) DENV2NS3 555-564 (INYADRRWCF) (C) 
DENV3NS3555-564 (IKYTDRKWCF) and (D) DENV4NS3555-564 (ISYKDREWCF). Subject 
BC311 was infected with DENV4 and subject BC398 with DENV2.
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Figure 4.13 T cell responses to NS3ss5_564 variants during acute secondary dengue 
infection. Shown are (A) peptide titration curves in IFN-y ELISPOT assays for PBMC 
collected acutely (study day 5) from BC31J (infected with DENV4) and stimulated with 
DENV4NS3555.564 (ISYKDREWCF) or DENV2NS3555.5M (INYADRRWCF). Show in (B) are 
peptide titration cwves in IFN-y ELISPOT assays for PBMC collected acutely (study day 5) 
from BC398 (infected with DENV2) and stimulated with DENV2NS3555.564 (INYADRRWCF) 
andDENVJNS3<;55.564 (FQYSDRRWCF).
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4.5 Discussion
T lymphocytes (CTL) play an important role in the elimination of dengue virus-infected cells 
(Kurane, 1994). Identification of antigenic peptides recognized by dengue virus-specific T 
lymphocytes may suggest novel ways to suppress viral replication and prevent persistent 
infection. Multiple peptides from the conserved regions of the dengue virus may be essential 
in the development of a universally immunogenic vaccine (Pervikov 2000). Over the last few 
years, studies of dengue patients have successfully identified several peptides that are specific 
for CD8+ and CD4+ T lymphocytes. The breadth and specificity of the responses of T cell to 
dengue viral antigens in populations of areas where dengue is endemic remain relatively 
poorly characterized. This serological and virological study of Vietnamese adults with 
secondary dengue virus infection measured the breadth and frequency of the responses of T 
cells to 260 overlapping peptides from a DENV2 virus. A strength of the study is the large 
numbers of subjects and peptides included. One of the key findings is that neither the breadth 
nor magnitude of the recorded peptide-specific T cell responses was significantly associated 
with clinical disease grade or the serotype of dengue virus mediating the current infection. 
Another key finding was the identification of 34 different peptide sequences that potentially 
contained many novel T cell epitopes. These assays facilitated the identification of a novel 
HLA-B* 07-restricted epitope in Env and an HLA-A*24-restricted epitope in NS3.
Most studies of dengue virus-specific T cells was conducted using T cell clones generated 
from live attenuated dengue virus vaccines, or less frequently, from dengue 
patients(Dharakul, Kurane et al. 1994) (Gagnon, 2002) (Kurane, 1991) (Kurane, 1995) 
(Mathew, Kurane et al. 1996) (Mathew, 1998). This study is the first attempt to define the 
relative antigenicity of peptides from multiple dengue viral antigens in a large number of 
patients from a hyperendemic country. Peptides from the NS3 region were recognized by
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cells from more than half of all Vietnamese adult patients. In addition, they contained the 
largest number of antigenic peptides to which T cell preferentially appear to respond. These 
results are consistent with previous studies that have emphasized the importance of NS3 as 
the target of T cells (Mathew, Kurane et al. 1996). Fourteen of the 30 NS3 antigenic peptides 
(47%) were clustered within a 124 amino acid long stretch of NS3200-324 that represents 20% 
of the whole protein. NS32oo-324is highly conserved (78%) across all four serotypes of dengue 
virus, containing motifs and charged residues that are essential for helicase activity and viral 
replication (Matusan, 2001) (Matusan, 2001). Given the conserved nature of NS3 (68%), and 
particularly NS3200-324, it seems likely that many of the NS3-derived antigenic peptides 
identified in this study were targets of reactivated, dengue virus cross-reactive T cells that 
were primed by a previous dengue virus infection. In addition, the breadth and magnitude of 
the responses to DENV2 peptides in patients infected with either DENV 1 or DENV4 were 
equivalent to patients infected with DENV2. This observation supports the contention that 
serotype cross-reactive, rather than serotype-specific, T cells dominate the acute response 
during secondary infection. In patients infected with DENV2, there was no evidence that the 
T cell response to DENV2 peptides increased in breadth with time since secondary infection. 
All patients in this study experienced a secondary infection, suggesting that a previously 
mounted immune response against the virus is being boosted, a phenomenon referred to as 
“original antigenic sin” in the antibody response. This suggests the early, cross-reactive T 
cells’ response remains dominant in late convalescence when the memory T cell pool has 
been established. This is supported by a previous study done with Thai schoolchildren in 
which dominance of cross-reactive T cells was observed among DENV-specific memory T 
cell 12 months after secondary DENV infection (Mathew, 1998). It is thought that peptides of 
non-structural proteins recognized by both serotype-specific and serotype cross-reactive
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CD8+ CTL will have important implications for the design of effective subunit vaccines 
(Livingston, 1995).
The purpose of peptide titration (figure 4.13) is to show whether serotype cross-reactive 
exists in parallel with serotype-specific T cells at the acute response during secondary 
infection. The response of DENV infected patients to the second NS3 epitope sequence was 
virtually identified at all peptide concentrations, including low-peptide concentrations that is 
likely reflective of in vivo conditions. Although the figure shows lesser response to infecting 
strains at lower concentration, the difference is not significant. The ELISPOT responses to 
infecting and second epitope peptides are equivalent in breadth and strength.
In this study, several patients also responded to the proteins capsid, preM/M, Env, and NS4a. 
The capsid protein contains a C-terminal hydrophobic domain and is present in infected cells. 
This hydrophobic domain may serve to localize an assembly of nucleocapsid at the 
membrane site and function as a signal sequence for prM (Bulich and Aaskov 1992). The E 
protein is thought to contain peptides that predominantly induce virus-neutralizing antibody 
responses. This protein is responsible for virus attachment to susceptible . cells and 
consequently virus growth. This antigen also mediates virus-specific membrane fusion, which 
presumably allows the newly infecting virus to escape the endocytic vesicle and initiate its 
intracellular replication cycle (Gubler, 1999). NS4A and NS4B may be involved in 
membrane localization of NS3 and NS5 replication complexes via protein-protein interaction, 
since the NS3-NS5 complex is weakly associated with the membrane in spite of its 
hydrophilic characteristics (Chambers T.J., 1990). Unexpectedly, identified antigenic 
peptides were not associated with any recognized conserved structural motif (protein C, E, 
prM/M).
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The mechanisms underlying the increased vascular permeability that occurs in some 
individuals following secondary infection with a dengue virus remains poorly understood. In 
this study, no significant differences were observed in either the breadth or magnitude of the 
total T cell response between patients with different clinical disease grades. We did, however, 
observe that the sum of peptide-specific responses measured in ELISPOT assays correlated, 
albeit weakly, with the extent of hemoconcentration recorded in each patient. These data fit 
with the general observation of relatively greater immune activation in patients with severe 
dengue disease. For example, relatively higher frequencies of activated, crossreactive CD8+ T 
cells (Mongkolsapaya, 2003) (Zivna, 2002) and a range of direct and indirect markers of 
CD4+ and CD8+ T cell activation have been associated with increasing disease severity 
during secondary infection (Gagnon, 2002) (Green, 1999) (Green, 1999) (Green, 1999) 
(Jufffie, 2001) (Kurane, 1991). An important distinction of this study is that we performed a 
comprehensive analysis of the functional T cell response in adult patients to 260 peptides 
spanning five viral antigens as opposed to an analysis of responses in children to a single 
CD8+ T cell epitope in other studies (Mongkolsapaya, 2003) (Zivna, 2002). Other 
confounding influences, such as ethnicity, HLA background, and viral factors, may also 
explain differences between this study and those that have been reported previously.
Two novel CD8+ T cell epitopes were identified in this study. The peptide Env4 i 1-425 was 
among peptides evoked the highest responses of T cells in ELISPOT assays from dengue 
patients. Responses to the HLA-B*07-restricted epitopes Env4n ^ 2 5  were detected in all 
prospectively identified HLA-B*07-positive patients, suggesting this is a dominant epitope. 
The rationale for studying the NS3s5o_564 peptide was threefold. First, previous studies had 
suggested this peptide might contain an HLA-A*24 epitope (Loke, 2001). Second, A*24 is 
one of the more common alleles present in the Vietnamese population (33%) and hence an
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A*24 epitope might be widely recognized. Third, A*24 has been associated with 
susceptibility to DHF in Vietnamese children (Loke, 2001), suggesting immune responses 
restricted through this allele might be poorly protective and/or pathogenic. Responses to the 
A*24-restricted NS3556-564 epitope were detected in a minority of HLA-A*24- positive 
patients, suggesting that it is not a dominant epitope. Consistent with other studies on 
unrelated epitopes (Mongkolsapaya, 2003) (Zivna, 2002), responses to the CD8+ T cell 
epitopes defined in this study were generally strongest after the patient had been discharged 
from hospital (Study day 14), suggesting that the antigen may continue to persist, possibly in 
the form of immune complexes, well after the resolution of viremia. Other explanation for 
this that there might be higher levels of apoptosis in PBMC of patients with DHF, indicating 
that T cell expansion during acute DV infection may be balanced by apoptosis so the peak 
response to the CD8+ T cell epitopes was not recorded at discharged day (study day 3). The 
establishment of a library of defined T cell epitopes from dengue viruses will help to define 
the role of T cells in immunity and disease pathogenesis. They should also prove useful in 
measuring the immunogenicity of live dengue virus vaccine candidates (Edelman, 2003) 
(Gwinn, Sun et al. 2003) (Sabchareon, 2004).
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Chapter 5: Timing of CD8+ T cell responses in acute dengue infection
5.1 Rationale
Results from the genetic susceptibility study (see chapter 3) suggest that HLA class I and II 
restricted cellular immune responses influence susceptibility to DHF. However, this genetic 
study does not provide any functional evidence for the mechanism by which HLA-restricted 
responses might take effect. In order to understand the role of T cells in natural dengue 
infection, be it recovery or pathogenesis, we would need to study cellular immune responses 
resulting from natural dengue infection.
Data on DENV-epitope specific responses during the febrile phase is sparse. We previously 
showed that DENV-epitope specific responses are difficult to detect in the acute febrile phase 
by ELISPOT assay and that the magnitude or breadth of early convalescent responses was not 
associated with the clinical phenotype (chapter 4). Similarly, Mongkolsapaya et al showed 
CD8 + T cells specific for the dominant HLA-A* 11-restricted epitope NS3133-142 were present 
only at very low frequency during the febrile phase of dengue in Thai children, but were 
readily detected in early convalescence (Mongkolsapaya, Dejnirattisai et al. 2003). Other 
studies to characterise DENV-epitope specific T cell responses have used PBMC collected in 
late convalescence and so it is difficult to know whether these findings can be extrapolated to 
the febrile phase (Zivna, Green et al. 2002; Bashyam, Green et al. 2006). A thorough 
characterization of DENV-epitope specific immune response in people experiencing natural 
dengue infections, especially those who live in dengue-endemic regions, may contribute 
towards the understanding of DHF pathogenesis and the role of cellular immune responses in 
dengue infections.
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A systematic description of the kinetics of CD8 + T cell activation, and particularly DENV- 
specific CD8 + T cells, in the context of dynamic changes in viraemia and haemoconcentration 
would provide further insights into the role of these cells in immunity and pathogenesis. To 
this end, the aim of the current study was to measure the timing of specific and non-specific 
CD8 + T cell responses and virological and clinically important haematological events during 
the febrile phase of dengue.
5.2 Patient recruitment
Two prospective studies are described. In the first study, consecutive children (<15 yrs) with 
suspected dengue and less than 72hrs of illness were enrolled at a private clinic in HCMC, 
Viet Nam between October 2007 and March 2008. All patients were examined by the same 
physician (TVN). Blood samples were collected daily during the febrile period for 
measurement of viraemia and routine haematological investigations. Convalescent blood 
samples were obtained 2-3 weeks after first presentation.
The 2nd study was a prospective study of children with dengue at Paediatric Hospital #1 and 
#2 between August 2006 . and March 2007. Inpatients above 6  months of age with suspected 
dengue and fever for less than 7 days were enrolled in the study. All patients were assessed 
daily by a study physician and had daily serial haematological measurements and an 
ultrasound within 24hrs of defervescence.
For both studies, if patients received laboratory confirmation of dengue then World Health 
Organization clinical classification criteria (Organisation 1997) were applied to each case. 
Written informed consent was obtained from a parent or guardian of each study participant. 
The study protocols were approved by the Scientific and Ethical committees at each 
participating hospital.
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5.3 Summary of study method
In study #1, T cell phenotyping staining was routinely performed on fresh whole blood. 
Staining for intracellular markers of cellular proliferation (nuclear antigen Ki-67) and surface 
markers of activation (CD38+ and HLA-DR+), were performed at enrolment and every 2nd 
day on fresh whole blood samples. To examine DENV-specific responses, whole blood 
samples from each study participant was stained at enrolment and then every second day with 
a pool of HLA-class I tetramers carrying the HLA-A*1101-restricted NS3i33-i42 peptide from 
DENV-1, DENV-2 and DENV-3/4. The limit of detection was set at 3 times the standard 
deviation of the mean percentage Of tetramer positive events in 23 patients with no 
virological or serological evidence of acute dengue.
In study #2, T cell tetramer staining was performed to paired (study enrolment and early 
convalescent) peripheral blood samples by using same pooled tetramers as study #1. Patients 
with blood samples were ever positive with the pooled NS3133-142- specific tetramers were 
confirmed as being HLA-A* 11-positive by SSP-PCR.
5.4 Definition
In study #1, the extent of haemoconcentration in dengue cases was determined by comparing 
the maximum haematocrit recorded during the acute phase with the baseline haematocrit. 
Baseline haematocrit was defined as the lowest of either the value recorded before day 2 of 
illness if platelet count was >= 2 0 0 , 0 0 0  (available for 6 % of patients), or the value recorded 
at follow-up 2-3 weeks after illness onset (available for 82% of cases), or a mean of age- and 
sex-matched healthy population value (13% of cases).
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In study #2, the extent of haemoconcentration was determined by comparing the maximum 
haematocrit recorded during hospitalisation with a mean age- and sex-matched healthy 
population baseline haematocrit. These population values were determined from Hct values 
measured in healthy children attending the Hospital for Tropical Diseases for follow-up study 
visits. The reference Hct values for males were; age 1-4 yrs, 34.4 (n=5); age 5-9 yrs, 36.0 
(n=116); age 10-13 yrs* 37.7 (n=190); age 14-15 yrs, 40.2 (n=54). The reference Hct values 
for females were; age 1-4 yrs, 33.0 (n=4); age 5-9 yrs, 36.2 (n= lll); age 10-13 yrs, 37.8 
(n=l8 8 ); age 14-15 yrs, 37.0 (n=34).
The platelet nadir in study #1 and #2 studies was defined as the lowest platelet count recorded 
in patients with a minimum of 4 platelet counts. The day of defervescence was defined as the 
day the fever dropped below <37.5°C (axillary) and remained so for 48hrs. The day of illness 
was as self-reported by the patient’s parent or guardian.
5.5 Statistical analysis
The nonparametric Mann-Whitney test was used to evaluate differences in frequencies of 
HLA-A* 1101-restricted NS3 i33ri42-specific CD8 +T cells during the course of disease. P- 
values lower than 0.05 were considered statistically significant. The program Prism (version 
5.0) was employed for analyses (GraphPad Software, San Diego, CA, USA).
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5.6 Results
5.6.1 Characteristics of study population
Children with dengue are not usually hospitallised until the 3-4th day of illness so all clinical 
finding from dengue infected children have not been recorded in the very early phase of 
diseases. To focus on the early events of dengue patients, we performed a community based 
study. This allows us to follow a cohort of patients from first presentation through all the 
various stages of disease. This study was carried out at private clinic, district 8 , Ho Chi Minh 
City, Vietnam.
The characteristics of the 126 patients in whom CD8 +T cells were phenotyped are described 
in Table 5.1. These patients were a subset of 138 consecutively enrolled patients at an 
outpatient primary care clinic of whom there were 1 2  patients who were not investigated due 
to inadequate samples (clotted or insufficient sample). Amongst the 126 enrolled and 
investigated patients there were 103 patients with laboratory confirmed DENV infection and 
23 patients with other febrile illnesses (OFI) that were not dengue (Table 5.1). There were 92 
patients who returned for follow-up 15-30 days after enrolment.
After applying WHO criteria (Organisation 1997) to each dengue case, there were 17 DHF 
patients and 8 6  DF patients. During the period time of study, the mean nadir of the platelet 
count of the DHF patients was considerable lower than of the DF patients, 47,100 (range, 
11,600 to 88,300) vs. 116,000 (range, 35,200 to 270,000) respectively. And the average 
maximum percentage change in hematocrit attained of the DHF patients was significant 
higher than of the DF patients, 27% (range, 22 to 53%) vs. 8 % (range, -13 to 54%) 
respectively.
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Table 5.1 Characteristics of the patient population in whom serial blood samples were 
investigated for CD8+ T cell phenotype and frequency of NS3133.142- specific T cells.
Other febrile
DF (n = 86) 
Median (range)
DHF (n = 17) 
Median (range)
illness (n=23) 
Median (range)
P
value a
Variable or No. (%) or No. (%) or No. (%)
Male sex, no. (%) 40 (46.5) 12 (70.6) 14 (60.9)
Age (years) 11 (4-15) 13(8-15) 11 (5-14)
Day of illness6 2(1-4) 3 (1-4)
Fever day6,0 -3 (-5 to -1) -3 (-6 to -1)
Infecting serotype, no. (%)
DENV-1 39 (51.3) 10 (58.8)
DENV-2 10(13.2) 3(17.6)
DENV-3 26 (34.2) 4 (5.3)
DENV-4 1 (1.3)
Secondary infection, no. (%) 60 (69) 14 (76)
Log 10 of peak viremia, 
mean(range), cDNA copies/mL
7.37 (4.45-9.90) 7.81(5.88-9.63)
Platelet nadir, cells/pL
116,000
(35,200-270,000)
47,100
(11,600-88,300)
< 0.001
Maximum hemoconcentration, % 8(-13 to 54) 27 (22 to 53) < 0.001
NOTE. Data are median (range) values, unless otherwise indicated. 
a Mann-Whitney (7-test. 
b at time of study enrolment
0 the day of defervescence (axillary temperature) was regarded as fever day 0 .
5.6.2 The timing of overall activated CD8+ T cells during dengue infection
Cellular immune responses in children with dengue in the early events of dengue diseases 
have not been described elsewhere. To study the timing of overall CD8 + T cell activation in 
the relation to the course of disease and correlate response to viraemia and clinical outcomes. 
We therefore studied the phenotype of activated, proliferated CD8 + T cells in both acute and
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early convalescence dengue infection of paediatric patients with intracellular and surface 
marker such as Ki-67, CD38, HLA-DR. The study was primarily carried out directly on fresh 
whole blood, which provides a more sensitive staining than the use of purified peripheral 
blood mononuclear cells.
Our studies show that the frequency of double marker activated CD8 + T cells was higher in 
dengue infected patients as compared to control during the course of acute dengue infection. 
The population of activated CD8 + T cells appeared low level at febrile phase but increased in 
afebrile phase. As we expect, the frequencies of activation markers were reduced in the 
follow-up samples. We observed a significant increase in the activated CD8 + T cells in 
dengue patients after defervescent day, peak at fever day 0-3 (Figure 5.1A-C).
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Figure 5.0 Flow-cytometry plot showing an example o f double markers staining for CD8 + T 
cell phenotype (CD38/Ki67).
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Figure 5.1 Frequencies of activated CD8 + T cells during the course of acute dengue 
infection and follow-up. Shown in each box and whisker plot is the percentage o f CD8  T 
cells that were double positive for Ki-67 /HLA-DR (A), CD38/Ki-67 (B) or CD38/ HLA-DR 
(C) from 103 dengue patients by fever day. Fever day 0 was regarded as the defervescent 
day. Days prior to fever day 0 are designed fever day -1(1 day before defevescence), fever 
day -2, etc. Days after defervescence day are fever day 1, fever day 2, etc. The number o f 
patients that were evaluated on each day for T cell phenotype is shown below panel C.
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5.6.3 Circulation of surface-activated CD8+ T cells and their relationship to viraemia 
dynamics
There were 93 patients with a measurable viraemia at enrolment, with DENV-l the most 
prevalent serotype detected (49/93 (52%)) (Table 5.1). Staining for intracellular markers of 
cellular proliferation (nuclear antigen Ki-67) and surface markers of activation (CD38+ and 
HLA-DR+), were performed at enrolment and every 2nd day on fresh whole blood samples. 
Results are shown for DENV-1 and DENV-3 only as the sample size for other serotypes was 
small. Double-positive CD8 + T cells (CD38+HLA-DR+, CD38+Ki-67+ or HLA-DR+Ki 67+ 
were increased in blood only when the DENV-1 (Figure 5.2A, C, E) or DENV-3 (Figure 
5.2B, D, F) viraemia had already begun to decline. Indeed, phenotypically activated CD8 + T 
cells were most prominent after defervescence, a time when most patients were aviraemic. 
Collectively, these data suggests the commencement of clearance of viraemia, and a sizable 
fraction of the resolved viraemia, occurs in the absence of measurable peripheral blood T cell 
activation as defined by the activation markers used here.
114
Chapter 5: Timing o f  CD8+ T cell responses in acute dengue infection
A
>zIUo
E
*35
©aoo
o
©
o>o
- 5 - 4 - 3 - 2 - 1 0  1 2 3 C
Fever day
D
s . 8-
'10
-5 -4 -3 -2 -1 0 1 2 3 C
Fever day
10i
>z
IUo
E
o
e
03O
Fever day
- 4 - 3 - 2 - 1 0  1
Fever day
>zUlQ
O©
03o_J
Fever day
N= 4 15 22 33 43 43 38‘ 19
T cefl phenotype N= 3 
Viraemia N= 4
Fever day
8 11 16 13 17 14
12 20 27 30 29 26
r 30rt
>
Z
UJo
E
*35
£Cloa
oo
03
o
- 5 - 4 - 3 - 2 - 1 0  1 2 EC
Figure 5.2 Relationship between kinetics of viraemia and the appearance of surface 
activated CD8+ T cells in peripheral blood. Showm in each panel are the mean (±95% Cl) 
o f DENV-1 (panel A, C and E) or DENV-3 (panel B, D and F) viraemia levels in serial 
plasma samples from children with DF (DENV-1, n=39 and DENV-3, n=26) or DHF 
(DENV-1, n=10 and DENV-3, n=4) by fever day. In each panel, the box and whisker plots 
represent the percentage o f CD8 + T cells that were double positive for CD38/ HLA-DR 
(panel A, B), CD38/Ki-67 (panel C, D) or HLA-DR /Ki-67 (panel E, F). The number o f 
patients that were evaluated on each day are shown below panels E and F.
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5.6.4 CD8+ T cell activation and their relationship to thrombocytopaenia and vascular 
leakage
Thrombocytopaenia and vascular leakage are two of the most prominent features of DHF. In 
DHF patients (n=17), haemoconcentration began during the febrile phase and on average 
peaked 1 day (fever day -1) before defervescence (Fig. 5.3A, B and C). Similarly, 
thrombocytopaenia was evident during the febrile phase and before increased CD8 + T cell 
activation in DHF patients (Fig. 5.4A, B and C). In contrast, an increase in the percentage of 
surface activated CD8 +T cells (CD38+HLA-DR+, CD38+Ki-67+ or HLA-DR+Ki-67+) did not 
occur in DF or DHF patients until the day of defervescence (Fig. 5.3 and Fig. 54), suggesting 
haemoconcentration and thrombocytopaenia in DHF patients commenced in the absence of 
any increase in the percentage of surface activated CD8 + T cells in peripheral blood.
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Figure 5.3 Relationship between haemoconcentration and the appearance of surface 
activated CD8 + T cells in peripheral blood. Shown in each panel are the mean (±95% Cl) 
percentage levels o f haemoconcentration in serial plasma samples from children with DF 
(n -8 6 ) or DHF (n=17) by fever day. Haemoconcentration was measured against autologous 
convalescent samples for 82% o f patients. In each panel, the bars represent the mean (±95% 
Cl) percentage o f CD8 + T cells that were double positive for Ki-67 /HLA-DR (panel A), 
CD38/Ki-67 (panel B) or CD38/ HLA-DR (panel C). The number o f patients that were 
evaluated on each day for either T cell phenotype or level o f haemoconcentration is shown 
below panel C.
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Figure 5.4 Relationship between thrombocytopaenia and the appearance of surface 
activated CD8 + T cells in peripheral blood. Shown in each panel are the mean (±95% Cl) 
platelet count in serial plasma samples from children with DF (n=8 6 ) or DHF (n=17) by 
fever day. In each panel, the bars represent the mean (±95% Cl) percentage o f CD8 + T cells 
that were double positive for Ki-67 /HLA-DR (panel A), CD38/Ki-67 (panel B) or CD38/ 
HLA-DR (panel C). The number ofpatients that were evaluated on each day for either T cell 
phenotype or platelet count is shown below panel C.
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5.6.5 DENV-specific CD8+ T cell responses and their relationship to vascular leakage
Previous studies have suggested the the envelope and NS3 proteins are frequent targets of 
immune responses in flavivirus infections, including dengue (Kurane and Ennis 1994), 
(Mathew, Kurane et al. 1996). Gur previous finding is consistent with these findings that 
have emphasized the importance of NS3 as important T-cell target (chapter 3). The result 
found a T-cell response to peptide FSPGTSGSPIIDKKG, which covers NS3 residues 130- 
144, in four of 39 patients. This result are in agreement with Mongkolsapaya et al shown 
peptide NS3133-142 as a dominant, DENV-specific HLA-A*1101-restricted T cell epitope 
(Mongkolsapaya, Dejnirattisai et al. 2003). HLA-A* 11 is one of the most frequent alleles in 
Vietnamese population (Loke et al, 2001). To examine DENV-specific responses, whole 
blood samples (median, 4, range, 2 to 6  samples investigated per patient) from each study 
participant was stained at enrolment and then every second day with a pool of HLA-class I 
tetramers carrying the HLA-A* 11-restricted NS3133-142 peptide from DENV-1, DENV-2 
and DENV-3/4. Of the 103 dengue patients, 33 patients (32%) had at least one sample with a 
measurable NS3133-142- specific tetramer staining population of CD8 + T cells, including 9 
dengue patients with DHF and 24 dengue patients with DF (Figure 5.5). The median fever 
day on which tetramer positive cells were first detected in the 9 DHF patients was +1 (range - 
3 to 12) and this was 2 days later than the mean peak in haemoconcentration described for 
these patients in Fig. 5.3.
Amongst the 33 patients who were ever tetramer positive, NS3133-142-specific T cells were 
detected during the febrile phase in less than half (13/33, (39%)) the cases. In the early 
convalescent afebrile phase, measurable NS3133-142-specific CD8 + T cells were present in a 
significantly greater proportion of patients who were ever positive (23733 (70%)) (P = 0.02). 
The percentage of circulating NS3133-142- specific CD8 + T cells during the early
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convalescence phase was significant higher than during the febrile phase (paired t test, P = 
0.037) (Fig. 5.6). These results suggest NS3133-142-specific CD8 + T cells reach measurable 
frequencies around the time of defervescence and after the commencement of 
haemoconcentration in DHF patients.
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Figure 5.5 DENV-specific CD8 + T cell responses. Whole blood samples were double­
stained with a pool o f PE-conjugated HLA-A* 11 tetramers carrying the HLA-A* 11-restricted 
NS3133.142 peptide from DENV1-4 (Tetramer A l 1 (GTS) PE) and APC conjugated monoclonal 
antibody to CD8  (CD8  APC). Panel A shows the specificity o f the A l l  tetramer. Flow- 
cytometry plot showing detection o f NS3133.142-specific CD8 + T cells in whole blood o f 
dengue confirmed patient (left) and non-dengue patient (right). Panel B and C show the 
frequency o f NS3133.142-specific CD8 + T cells in whole blood from dengue patients with DF 
(n=24) and DHF (n=9) by fever day.
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Figure 5.6 . Frequencies of NS3i33-i42-specfIc CD8+ T cells during the febrile and 
afebrile phase. Serial whole blood samples from 103 children with dengue were stained with 
a pool o f tetramers (DENV-1, DENV-2 and DENV-3/4) specific for NS3 j3  3-i4 2 -specfic CD8 + T 
cells. The scatterplot shows the frequency o f tetramer staining NS31 3 3 .1 4 2-specfic CD8 + T 
cells in individual patient samples according to whether they were detected during the febrile 
phase (fever day, FD, - 6  to -1), afebrile phase (FD, 0 to 3) or convalescence (FD, 10-24). 
The frequency o f circulating DENV-specific CD8 + T cells at early convalescence phase were 
significant higher than at febrile phase (P = 0.037, by Mann-Whitney test). The lower limit of 
detection (solid horizontal line) was defined as the mean plus 3 standard deviations o f the 
frequency of tetramer-positive staining events in blood samples from patients with no 
evidence o f dengue (62 measurements in 23 non-dengue patients).
5.6.6 Timing of DENV-specific CD8+T cell responses in relationship to haematological 
markers
To explore more fully the relationship between the appearance of measurable NS3133-142- 
specific T cells in blood and haemoconcentration and thrombocytopaenia in a larger patient
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population, pooled tetramers were used to stain paired (study enrolment and early 
convalescent) peripheral blood samples from 422 children hospitalised with suspected 
dengue, of whom 390 were laboratory confirmed. The characteristics of this patient 
population are described in Table 5.2. At enrolment, the median illness day was 4 days (range 
1-6) and the median number of days prior to defervescence 2 days (range - 6  to 0). Amongst 
the 390 patients with laboratory confirmed dengue, there were 62 (16%) patients (41 with 
DHF and 21 with DF) with blood samples that were ever positive with the pooled NS3133- 
142- specific tetramers. All 62 patients were confirmed as being HLA-A* 11-positive by SSP- 
PCR.
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Table 5.2 Characteristic of the patient population in whom tetramer staining was
performed for NS3133-142- specific T cells
Tetramer positive Tetramer negative
DF (n = 21) 
median (range)/ No. (%)
DHF (n = 41) Dengue (n=328)
Variable median (range)/ No. 
(%)
median (range)/ No. 
(%)
Male sex, no. (%) 13(61.9) 25(60.9) 176
Age (years) 10(3-14) 10(2-15) 10(1-15)
Day of illness at enrolment 3(1-4) 3(1-6) 4(2-7)
Fever day at enrolmenta -2(-3 to 0) -2(-5 to 0) -2(-6 to 0)
Infecting serotype,.
DENV-1 4(22.2%) 12(31.6%) 186(63.9%)
DENV-2 10(55.6%) 19(50%) 83(28.5%)
DENV-3 4 (22.2%) 7(18.4%) 21(7.2%)
DENV-4 0(0%) . 0(0%) 1(0.3%)
Secondary infection, no. (%) 18(85.7) 34(82.9) 247
Log 10 of viremia, mean (range), 
cDNA copies/mLb
6.82(3.98-9.77) 7.49(3.78-12.21) 6.80(3.03-11.83)
Platelet nadir, cells/pL
61,000(33,000-
124,000)
36,000 (10,GOO- 
96, 000)
50,000(1,000-
270,000)
Maximum hemoconcentration, % 13.9(2.2-19.4) 28(10.5-54.1)° 22(-22.6-52.78)
NOTE. Data are median (range) values, unless otherwise indicated. 
a The day of defervescence was regarded as fever day 0. 
b DENV viraemia measured at enrollment.
c one patient without haemoconcentration but with pleural effusion by ultrasound finding
Daily haematocrit measurements indicated haemoconcentration (>20%) was first present a 
median of 1 day (fever day range: -5 to 2 days) prior to defervescence in the 41 patients with 
DHF that were ever positive with the pooled NS3133-142-specific tetramers (Fig. 5.7A). 
Thrombocytopaenia of <100,000 cells/mm3 was also first detected a median of 1 day (fever 
day range: -5 to 2 days) prior to defervescence in the same patients (Fig. 5.7B). In contrast, 
NS3133-142-specific CD8 + T cells first became detectable in DHF patients on fever day +1
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(fever day range: -3 to 4 days) (Fig. 5.8A), a median of 2 days (fever day range, 0 to 5 days) 
after thrombocytopaenia (<100,000 cells/mm3) was first detected (comparison of median 
fever day, P0.0001) (Fig. 5.8B) and a median of 2 days (fever day range, 0 to 5 days) after 
haemoconcentration (>2 0 %) was first detected in each patient (comparison of median fever 
day, P<0.0001) (Fig. 5.8C). The timing of these events is summarised in Table 5.3. 
Collectively, these data indicate NS3133-142- specific CD8 + T cells generally become 
measurable in the peripheral blood only after the commencement of vascular leakage or 
thrombocytopaenia in patients with DHF.
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Figure 5.7 Timing of haemoconcentration in children with DHF. The box and whisker 
plots represent percentage haemoconcentration (panel A) and platelet counts (panel B) in 
children with DHF (n=41) by fever day. Levels o f haemoconcentration were determined by 
comparison o f daily Hct values in patients against healthy population age and sex stratified 
mean Hct values (see Table 1). Haemoconcentration o f >20% was first detected a median of 
1 day before defervesence in these children. The number o f children with haematocrit or 
platelet measurements on each fever day is shown beneath the X-axis.
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Figure 5.8 Temporal relationship between detection and frequency of HLA-A*1101- 
restricted NS3i33-i42-specfic CD8+ T cell responses and haemoconcentration, 
thrombocytopaenia and defervescence in children with dengue. Shown in each scatterplot 
is the percentage o f NS3;ss-i42-specficCD8 + T cell detected by tetramer staining in individual 
patient blood samples against a reference timepoint o f day o f defervescence (day 0  in panel 
A), day when platelet count o f <100,000 cells/pi was first detected in each patient (day 0 in 
panel B) and day when haemoconcenti-ation o f >20% was first detected in each patient (day 
0 in panel C). The values below the X-axis are the number o f patients evaluated on each day.
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Table 5.3 Timing of haematological events in relation to appearance of NS3m-i42- 
specific T cells
Event in DHF patients (n=41) Median fever day 
(range)
P value
First haemoconconcentration (>20%) -1( -5 to 2)
First thrombocytopaenia (<100,000 
cells/mm3)
-1  (-5 to 2)
First detection of NS3133.142-specific T cells +1 (-3 to 4) P<0 .0 0 0 1 ab
a Compared to first haemoconcentration (>20%) 
b Compared to first thrombocytopaenia (<100,000 cells/mm3)
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5.7 Discussion
Secondary heterotypic DENV infections are a risk factor for DHF in children and adults. 
Anaemestic, cross-reactive T cells responses are a part of the host response to secondary 
infection and have been suggested to contribute to immunopathogenesis. The major findings 
in the current study are that surface activated CD8 + T cells and NS3133-142 specific CD8 + T 
cells are generally not measurable in peripheral blood prior to the commencement of 
haemoconcentration, thrombocytopaenia or resolution of viraemia artd therefore it seems 
unlikely they are critical triggers of these events.
Significant immune activation undoubtedly occurs in patients with DHF and secondary 
infections. Relatively higher levels of various pro-inflammatory cytokines and their receptors 
and soluble CD4/8 are found in acute sera of children with DHF compared with children with 
DF (Kurahe, Innis et al. 1991; Green, Vaughn et al. 1999; Libraty, Endy et al. 2002). DHF 
patients also have a greater percentage of CD8 + T cells bearing the early activation marker 
CD69+ than DF patients during the febrile phase (Green, Pichyangkul et al. 1999). In the 
context of virus- specific responses, Mongkolsapaya et al detected very low frequencies of 
NS3133-142-specific T cells in the late febrile phase with a subsequent peak in frequency a few 
weeks after illness onset (Mongkolsapaya, Dejnirattisai et al. 2003). The very low frequency 
of NS3133-142-specific T cells during the febrile phase was suggested to be a consequence of 
huge proliferation balanced by massive apoptosis (Mongkolsapaya, Dejnirattisai et al. 2003). 
However these findings were not analysed in relation to the commencement of capillary 
leakage. Our own previous studies have indicated DENV-epitope specific T cells are difficult 
to detect during the febrile phase by ELISPOT assay, but that responses are readily measured 
in early convalescence (Simmons, Dong et al. 2005). Other studies of virus-specific 
responses demonstrated ELISPOT frequencies of T cells specific for the HLA-B*7 restricted
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epitope NS3222-230 were higher in the late convalescent phase in patients who had DHF 
compared to DF; assessments during the febrile phase were hot performed (Zivna, Green et 
al. 2002). Collectively, a limitation of previous studies of X cell responses in dengue is that 
the temporal relationship (or lack thereof) between measurable T cell immune activation and 
the commencement of vascular leakage (as opposed to when vascular leakage is at its most 
severe) has not been directly addressed. This is important for understanding the triggers for 
capillary leakage.
In two populations of children with DHF we found that haemoconcentration and 
thrombocytopaenia first occurred prior to the appearance in peripheral blood of CD8+ T cells 
bearing markers of activation (CD38, HLA-DR) or proliferation (Ki-67). Frequencies of 
proliferating CD8+ T cells (Ki-67+) were high in early convalescence and this was consistent 
with previous studies that have used this marker (Mongkolsapaya, Dejnirattisai et al; 2003). 
NS3133-142-specific CD8 + T cells were also rarely detected during the febrile phase, and 
significantly, were generally not measurable prior to the detection of haemoconcentration 
(>20%) or thrombocytopaenia in children with DHF. The temporal mismatch between the 
first detection of haemoconcentration in particular and measurable CD8 + T cells or NS3133- 
142-specific CD8 + T cells suggests these cells have a negligible role in triggering capillary 
leakage. Our finding differ from studies on acute viral infection that activated HCMV and 
EBV specific CD8  was detected during pathological human viral infection (Doisne et al, 
2004) (Tuuminen et al, 2007) (Papagno et al, 2004) (Sandalova et al, 2010). In contrast to 
HCMV and EBV-speeific CD8  cells, they observed that CD8  T cells specific for influenza 
were not activated during the acute phase of heterologous acute viral infection (Sandalova et 
al, 2010). It is possible that T cells responding to altered peptide ligands in vivo may not 
express these surface markers or enter cell cycle. An alternative explanation for the very low
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frequency of NS3133-142-specific T cells during the febrile phase (this study and 
(Mongkolsapaya, Dejnirattisai et al. 2003), is that they are sequestered in sites of infection or 
have down-regulated T cell receptors (Dong, Moran et al. 2007). This would imply a massive 
expansion and distribution of central and/or effector memory NS3133-142-specific CD8 + T cells 
after just a few days of infection and negligible ongoing circulation of CD8 + T cells 
expressing the relevant, specific T cell receptor. Here, the resurrection from memory of 
response has rapid mobilized right after viral load falls abruptly. Memory cells have a much 
lower threshold for activation compared with naive cells (Veiga-Femandes et al, 2000), 
however, so there is a risk that clones activated by original antigenic sin may have lower 
affinity and be less effective at clearing the secondary challenge (Alexander-Miller, et al, 
1996) and indeed may promote immunopathology. Original antigenic sin has been shown in 
T cell response that expansion of T cells with relatively lower affinity for the currently 
infecting virus and higher affinity for serotypes presumed to be previously encountered 
(Mongkolsapaya et al, 2003). A second alternative explanation is that they are sequestered 
and proliferating in lymphoid tissue during the febrile phase but have yet to enter the 
peripheral circulation. Studies (e.g. fine biopsy collections) to address these issues will assist 
our understanding of pathogenesis but are of course ethically and practically problematic in 
children with dengue.
A plausible role for T cells in the immunopathogensis of secondary dengue is that they act to 
amplify an already established pro-inflammatory cascade mediated by innate responses to a 
large viral burden. In this two stage model, a large viral antigen mass (plausibly mediated by 
ADE) might be necessary and sufficient to trigger capillary leakage through innate 
mechanisms such as complement activation, cytokine secretion by activated 
macrophages/dendritic cells and/or NS1 mediated pertubations of the vascular endothelium.
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Exacerbation of capillary leakage that has already commenced might occur when effector T 
cells accumulate at sites of infection. Such a model could also explain DHF in infants with 
primary infections and no DENV-specific memory T cells; the innate response (complement 
activation, cytokine secretion) may be necessary and sufficient to trigger clinically significant 
capillary leakage in infants because of their intrinsically poor capacity to compensate for 
microvascular leakage compared to older children or adults (Bethell, Gamble et al. 2001). 
Consistent with this, many of the cytokines found to be elevated in children with DHF and 
secondary infection are also elevated in infants with primary infection (Nguyen, Lei et al. 
2004; Tran Nguyen Bich Chau 2008).
There are several limitations to our study. First, our investigations of surface markers on 
CD8+ T cells was not exhaustive but focused on two well-described markers of activation 
(HLA-DR and CD38) and one intracellular marker of cellular proliferation (Ki-67). A 
plausible explanation for the surface activated CD8+T cells (CD38+HLA-DR+, CD38+Ki-67+ 
or HLA-DR+Ki-67+) were not measurable in peripheral blood during febrile phase is that, 
dengue-specific activated CD8 T cells are true memory CD8 cells without any recent 
encounter to their specific ligand. Memory CD8 cells specific for persistent and non- 
persistent viruses not only differs in term of phenotypic profile in healthy individuals, but 
respond differently to the pathological condition triggered by a heterologous acute viral 
infection (Sandalova et al, 2010). It is possible that T cells responding to altered peptide 
ligands in vivo may not express these surface markers or enter cell cycle and this should be a 
focus for future research. Secondly, we investigated CD8+ T cells only when T regulatory and 
conventional CD4+ T cells could also be important (Mangada, Ennis et al. 2004; Luhn, 
Simmons et al. 2007; Moran, Simmons et al. 2008). Luhn et al show that the T reg cell 
population expands in acute dengue infection has the conventional phenotype and
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suppressive capacity. Their demonstration that T reg cells suppress the dengue-specific 
secretion of vasoactive cytokines of effector T cells leads us to suggest that this population 
plays an active role in dengue infection (Luhn et al, 2007). Third, our analysis of DENV- 
specific CD8+ T cells was limited to one dominant epitope (NS3133-142)restricted through the 
most common class I HLA allele in the Vietnamese population, HLA-A*11. Reponses to 
other DENV CD8+ T epitopes might occur with greater rapidity than that described in this 
study. Fourth, all of the results are presented as percentage of CD8 expressing markers or 
binding tetramers rather than as absolute counts. Here, CD8 percentage takes in consideration 
factors which could cause a false high or false low CD8 count. The absolute count can reflect 
exact number of CD8 cells which contribute to disease progression. The absolute count is the 
more important measure of immune status and is preferred over the percentage for making 
treatment decision in infectious diseases (Kelly et al, 2004). Finally, pur study was biased 
toward patients with DENV-1 as this was the most prevalent serotype in circulation at the 
time.
Nevertheless* this study provides the first description of the temporal mismatch between the 
CD8+ T cell response to a dominant epitope and commencement of vascular leakage. Future 
studies of T cell responses in dengue need to consider the timing of responses relative to the 
commencement of capillary leakage, arguably the most important clinical manifestation of 
DHF.
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Cellular immune responses, and particularly responses elicited by altered peptide ligands, 
have been nominated as being very important to the pathogenesis of severe dengue. This 
premise stemmed in part from the epidemiological association between secondary dengue 
and severe disease, and the finding of robust humoral and cellular immune responses in these 
patients, characteristic of a memory response. Advances to our understanding of T cell 
responses in the pathogenesis of dengue that are described in this thesis include the 
importance of NS3 and cross-reactive T cells during acute secondary infection and also the 
paradoxical finding that the overall breadth and magnitude of the T cell response was not 
significantly related to clinical parameters! Furthermore, the temporal mismatch between the 
appearance of surface activated and DENV-specific CD8+T cell suggests other mechanisms 
are responsible for triggering of vascular leakage.
Mapping and characterization of T cell epitopes in DENV is important for understanding the 
host response and in the development of dengue vaccines. There are variants of most CD8 T 
cell epitopes in different DENV serotypes, but the amount of intraserotype diversity in the 
epitope sequences is small, with most serotypes being represented by one or two sequences. 
The interaction between TCR and altered peptide ligands can reportedly result in dramatically 
different phenotypes of the T cells, ranging from inducing selective stimulatory functions to 
completely turning off their functional capacity (Pfeiffer et al, 1995) (Sloan-Lancaster et al, 
1993).
Our study on T-cell responses in patients with secondary dengue identified forty-seven 
different peptides that evoked significant IFN-y ELISPOT responses in 39 patients, and of 
these, 34 peptides contained potentially novel T cell epitopes. NS3, and particularly N S 2 0 0 - 3 2 4 ,
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were important T cell targets. The breadth and magnitude of ELISPOT responses to DENV-2 
peptides was independent of the infecting dengue serotype, suggesting cross-reactive T cells 
dominate the acute response during secondary infection. Acute ELISPOT responses were 
weakly correlated with the extent of haemoconcentration in individual patients, but not with 
the nadir of thrombocytopaenia or the overall clinical disease grade. NS3s56-564 and Env4i4.422 
were identified as novel HLA-A*24 and B *07-res trie ted CD8+ T cell epitopes, respectively. 
Acute T cell responses to natural variants of Env4i4_422 and NS3s56-564 were largely cross­
reactive and peaked during disease convalescence. Duangchida et al have reported that a 
number of T-cell epitopes in dengue infection where NS3 responses were the most frequently 
seen and there was a very strong association between the magnitude of the response and 
disease severity.
By phenotyping CD8+ T cells (CD38+/HLA-DR+, CD38+/Ki-67+ or HLA-DR+/Ki-67+) in 
serial blood samples from children with dengue, we found no evidence of increased CD8+ T 
cell activation prior to the commencement of resolution of viraemia or haemoconcentration. 
Investigations with MHC class I tetramers to detect NS3i33-i42- specific CD8+ T cells in two 
independent cohorts of children suggested the commencement of haemoconcentration and 
thrombocytopaenia in DHF patients generally begins before the appearance of measurable 
frequencies of NS31 3 3 - 1 4 2 -  specific CD8+ T cells. The temporal mismatch between the 
appearance of surface activated and DENV-specific CD8+ T cells suggests other mechanisms 
are responsible for triggering capillary leakage in children with DHF. The absence or very 
low frequency of NS3i33-i42-specific T cells during the febrile period can be explained that 
they are sequestered in sites of infection or have down-regulated T cell receptors (Dong, 
Moran et al. 2007). This would imply a massive expansion and distribution of central and/or 
effector memory NS3i33.i42-specific CD8+ T cells after a few days of infection and negligible
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ongoing circulation of CD8+ T cells expressing the relevant, specific T cell receptor. A 
second explanation is that they are sequestered and proliferating in lymphoid tissue during 
the febrile phase but have yet to enter the peripheral circulation. Studies to address these 
issues, in either primate animal models or more directly in patients (e.g. fine biopsy 
collections), will be needed to resolve these questions.
It would be very informative to compare acute CD 8+ T cell responses between adults and 
children with asymptomatic, mild and severe dengue disease, throughout the infection, 
disease and recovery phases. Results from such study may provide more direct evidence on 
the exact role of CD8+ T cells in DHF diseases pathogenesis, be it significant or negligible. 
Further studies, both children and adults, will help determine whether there are differences in 
the kinetic of responses between children and adults.
Our investigations of surface markers on CD8+ T cells was focused on two well-described 
markers of activation (HLA-DR and CD38) and one intracellular marker of cellular 
proliferation (Ki-67). This is one of our limitations because T cells responding to altered 
peptides ligands in vivo may not express these surface markers or enter cell cycle and this 
should be a focus for future studies. There are other well-described surface markers such as 
CD69, CD27, CD28, CD45RO, CD44 and Perforin and these have been described on CD8+ 
T cells from dengue patients previously (Mongkolsapaya, 2003) (Green, 1999) (Azeredo, 
2006). The antigenic peptide-specific T cells showed an activated effector phenotype, with 
almost all of them expressing CD45RO, CD27, CD38 and HLA-DR during acute phase but 
CD28 activated marker reducted in the follow-up samples (Mongkolsapaya, 2003). The 
majority of NK cells from dengue patients display early markers for activation (CD69, HLA- 
DR, and CD38) and cell adhesion molecules (CD44, CD 11 a) during the acute phase of 
disease (Azeredo, 2006). The percent of cells expressing CD69 was also increased on CD8 T
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cells and NK cells in children who developed DHF more than in those with DF (Green,
1999).
In this study, we investigated CD8+ T cells only when T regulatory and conventional CD4+ 
T cells could also be important. Luhn et al previously reported that T regulatory cells of 
patients with acute dengue had a conventional phenotype with suppressive capacity. T 
regulatory cells in acute dengue could also suppress secretion of vasoactive cytokines from 
effector T cells, leading to the suggestion that this population plays an active role regulating 
the host T cell response in secondary dengue (Luhn, 2007).
This study has found that HLA Class I and II polymorphisms are associated with 
susceptibility to DSS. In particular, secondary DENV-2 infected children with HLA-B*44 
were likely to have DSS, whereas secondary DENV-2 infected children with HLA-Cw*12 
and HLA-DQB1 *03 were at increased risk of DHF when compared with the controls. HLA- 
A and HLA-DRB1 polymorphisms were not associated to DSS. So far, HLA class I and II 
associations with disease severity were detected in Vietnamese patients undergoing 
secondary infection would imply that HLA class I and Il-restricted cross-reactive T cell drive 
immune responses are contributing to the pathology of DENV.
The significance of HLA class I and II polymorphisms on susceptibility to severe dengue has 
been suggested by some previous studies (Table 3.1), even though the allelic associations in 
each study differ. Those studies were carried out at different geographic locations. Therefore, 
differences in association could be due to naturally occurring differences in HLA frequencies 
between ethnic groups, or possibly because of differences in circulating viral serotype and 
epidemiological setting, e.g. primary vs secondary dengue, children vs adults. The resolution 
of the HLA typing technique could also be important. Studies to confirm the associations
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found in this thesis (HLA-B*44, HLA-Cw*12, and HLA-DQB1*03) should be carried o u t, 
in a second Vietnamese population of severe dengue cases. This approach of discovery and 
validation has become the norm for large genetic association studies (but was not the norm 
when this study was conducted in 2006). However, studies in other populations may provide 
additional information on the overall influence of HLA on DHF disease susceptibility.
During secondary infections, both the humoral and cellular flavivirus-specific responses can 
confer protection or be involved in the pathogenic event. In genetically “more resistant” 
individuals such as those who have an HLA type associated with protection, the interaction 
with the specific dengue protein epitopes could induce an immune response that would help 
to clear the infection before disease symptoms appear. The presence of the susceptibility- 
associated allotypes could, in turn, induce an overly vigorous immune response responsible 
for the most severe clinical pictures. Many factors, including differences in viral load, 
intrinsic viral virulence, host immune response, immune enhancement, are also likely to 
contribute to the final disease expression. Research to try to understand the pathophysiologic 
mechanisms underlying the various clinical manifestations seen in dengue infections is 
needed if we are to develop new treatments or vaccines against this disease.
The potential involvement of multiple serotypes of dengue virus, DENV-specific antibodies 
and T cells in the pathogenesis of severe dengue and the lack of animal models to assess 
these interactions are important challenges in furthering our knowledge of dengue. 
Management of dengue currently relies on symptomatic treatment with fluid replacement 
when necessary that aims to compensate for plasma leakage and swift fluid resuscitation if 
circulatory failure occurs. The only method currently available to prevent dengue is the 
control of Aedes aegypti, the mosquito vector. This approach has proved unable to reduce the 
burden of dengue in most endemic settings because it requires substantial and ongoing
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community commitment. Vaccination is the most promising strategy to control the spread of 
dengue. Dengue vaccines must provide solid and long lasting protection against all four 
serotypes of dengue viruses. Vaccine-induced DENV-specific antibodies/T cells may 
decrease or protect against disease severity through their effects to decrease viremia burden. 
Conversely, it is also feasible that dengue vaccines will increase the risk severe disease when 
vaccinees are exposed to natural infection.
In recent years there has been considerable progress in the production of a vaccine against 
dengue with advanced candidates undergoing Phase II testing and positioned to initiate large 
scale efficacy trials within 1-3 years (Bhamarapravati, 2000) (van Der Most, 2000) (Kochel,
2000) (Guirahkoo, 2002) (Monath, 2007). The aetiology of DHF appears to be multifactor. 
Cross-reactive immune responses between dengue serotypes and ADE have been proposed to 
constitute mechanism leading to severe dengue disease. An ideal vaccine should induce both 
humoral and cellular immunity. There is still a big gap in our knowledge of immune 
responses in dengue infections, especially cellular immune responses. With the available 
information, it is not possible to tell whether a T cell-based vaccine, or in fact any of the other 
dengue candidate vaccine strategies, will actually be beneficial in the long run. For basic 
research on the immune responses to DENV to advance the development of new treatments 
and preventive measures (such as vaccines), priorities for future immunologic research on 
dengue are- (i) more detailed clinical studies of natural DENV infection are needed to 
confirm the disease associations of different measures of the innate and adaptive immune 
responses in vivo. These studies should optimally involve longitudinal evaluations to evaluate 
the kinetics of each component of the immune response and should encompass the broadest 
representation of viral and human genotypes, (ii) further refinement of animal models of 
DENV infection (including both humanized and non-humanized mice) is needed to capture
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the key features of DHF in humans. In addition to the vascular leakage phenomenon, a valid 
animal model must recapitulate the temporal dissociation between viral burden and vascular 
permeability as well as the contribution of DENV-specific antibody and T-cell responses, (iii) 
the anticipated initiation of large-scale (phase Ilb/III) vaccine efficacy trials in DENV- 
endemic populations will present a singular opportunity to conduct the critical studies to 
identify immunologic correlates of protective and/or pathologic immune responses. Efforts to 
maximize our understanding of DHF pathogenesis should be given priority, as it should assist 
in rational vaccine development. With this knowledge in hand, we will be on much better 
ground to develop a truly effective vaccine against dengue.
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Appendix 2: Sense and antisense primer sequences for SSP-PCR
Sense
Primer Sequences
Sense
Primer Sequences
625 qgCCqgAqTATTggqACCA 400 C l I gCCgTCgTAggCgTC
292 gqCCggAgT ATT gggACgA 431 AgCCCgT CCACgCACCg
286 CgACgCCgCgAgCCAgAA 249 CCT CC AqgTAggCT CT C AA
753 Agg ATTACAT CgCCCT g AAA 302 CCAAqAgCgCAggTCCTCT
3421 CCCACTCCAT gAgqTATTT CTT 299 CACTCCACgCACgTgCCA
296 gTgqATAgAgCAggAggqT 299 CACTCCACqCACgTgCCA
1173 ATggCT qCgACgT ggggT 249 CCT CCAggT AggCT CT C AA
291 AgCgACgCCgCgAgCCA 168 gAgCCACTCCACgCACgT
290 ACggAAT gT gAAggCCC Ag 302 CCAAqAgCgCAggTCCTCT
286 CgACgCCgCgAgCCAgAA 244 CAggTATCTgCggAgCCC
284 TATT ggg ACg AggAq ACAg 249 CCTCCAggTAggCTCTCAA
284 TATT ggg ACgAqgAq ACAg 170 CCT CCAggT AggCT CT CT g
292 ggCCqgAqT ATT gggACgA 146 CCCTCCAggT AggCT CT CT
292 gqCCggAgT ATT gggACgA 145 gAgCCACTCCACqCACTC
208 ACCgAgAgAACCT gCggAT 167 gAgCCACTCCACqCACCq
292 ggCCggAgTATT gggACgA 298 ATgTAATCCTTgCCgTCgTAA
239 gggTACCAgCAgg ACgCT 298 AT gT AAT CCTT gCCgT CgT AA
193 gg AgT ATT ggg ACCgg AAC 298 ATgTAATCCTTgCCgTCgTAA
294 TCACAgACTgACCgAgAgAg 298 ATgTAATCCTTgCCgTCgTAA
288 T CACAgACT g ACCgAgCg AA 168 gAgCCACTCCACgCACgT
174 CCggAgTATT gggACCT gC 298 ATgTAATCCTTgCCgTCgTAA
451 gggTACCggCAggACgCT 303 CT CT CT gCT gCTCCgCCq
239 gggTACCAgCAggACgCT 167 gAgCCACTCCACqCACCq
475 ACqgAAAgTgAAggCCCAg 300 AgCgC AqgT CCT CgTT CAA
290 ACqqAATgTg AAggCCCAg 301 CCqT CqTAggCgT gCT gT
290 ACggAAT gT g AAggCCCAg 249 CCTCCAggTAggCTCTCAA
174 CCqgAqTATTgggACCTgC 486 CTT CACATTCCgT gTCTCCT
295 CCCggCCCggCAgT ggA 414 ACqT CgCAqCCATACAT CA
754 gATAgAgCAggAgAqgCCT 429 qCCTT CACATTCCgT gT qTT
434 CCACT CCAT q AggTATTT CAC 399 . CCTT CCCgTT CT CCAggT q
3421 CCC ACT CC AT gAgqTATTT CTT 494 gCAgggT CCCCAggT CCA
3421 CCCACT CCAT q AqgTATTT CTT 302 CCAAg AgCgC AggT CCT CT
434 CCACT CCAT gAgqT ATTT CAC 171 CCgCqgAgqAAgCgCCA
1 CACggAAT gT gAAggCCCAC 287 gAgCCCgT CCACqCACT C
493 CACgCAqTT CgT gCggTTT 221 TACCAqCgCgCTCCAgCT
193 gg AgTATT ggg ACCgg AAC 285 CgT CqTAggCgT ACT ggTC
290 ACggAAT gT g AAggCCCAg 517 ACgTCgCAgCCgTACATg
367 TACTACAACCAgAgCgAggA 425 CgTCqTAggCgTACTggTT
193 gg AgTATT ggg ACCgg AAC 220 CCgCgCgCTCCAgCgTg
203 CAgATCTACAAggCCCAgg 212 CCT CCAggT AggCT CT gT C
271 CCqCqqAggAAgCgCCA 220 CCgCgCgCTCCAgCgTg
203 CAgATCTACAAggCCCAgg 225 CT CT CAgCTgCT CCgCCT
242 CgAgAgAgCCT gCgqAAC 215 AT CCTT gCCgT CgTAggCT
195 gACCggAACACACAgAT CTT 215 ATCCTTgCCqTCgTAggCT
Appendix 2: Sense and antisense primer sequences for SSP-PCR (continue)
Sense
Primer Sequences
Sense
Primer Sequences
195 qACCgq AACACACAg AT CTT 219 CCAggT AT CT gCggAgCg
280 gCTACgTgg ACgACACgCT 212 CCT CCAggT AggCT CT gT C
208 ACCg AgAgAACCTgCggAT 393 gT CgT AqgCgT CCTggTC
246 CCACTCCAT gAgqTATTT CC 285 CgTCgTAggCgTACTggTC
207 CCgAgAgAgCCTgCgqAA 212 CCT CCAggT AggCT CT gT C
192 ACCggg Ag ACACAg AT CT C 393 gTCgTAggCgTCCTggTC
202 gggg AgCCCCgCTT CATT 382 CCT CCAggTAggCT CT CAg
272 CgCCACgAgTCCgAggAA 227 gCCCCACgT CgCAgCCg
435 CCT gCgCACCgCgCT CC 220 CCgCgCgCTCCAgCgTg
435 CCTgCgCACCqCgCTCC 276 T CCCACTTgCgCT gggT
435 CCT gCgCACCgCgCT CC 247 qCggCggTCCAggAgCq
196 TACCgAgAgAACCT gCgC 218 qAgCCACT CCACgCACTC
192 ACCggg Ag AC ACAg AT CT C 229 CT CCAACTT gCgCT ggg A
272 CgCCACgAgTCCgAggAA 215 AT CCTT gCCgT CgT AggCT
192 ACCggg AgACACAgATCTC 127 qgTCqCAgCCATACATCCA
272 CgCCACgAgT CCgAggAA 217 CgT gCCCT CCAggT AggT
280 gCTACgTggACgACACgCT 217 CgT gCCCT CCAggTAggT
243 CgCgAqTCCgAqqATggC 217 CgTgCCCTCCAggTAggT
197 AgCAggAggggCCggAA 217 CgT gCCCT CCAggT AggT
207 CCgAgAgAgCCT gCggAA 217 CgT gCCCT CCAggT AggT
581 CAAgACCAACACACAqACTT 213 qAgqAgqCqCCCqT Cq
206 gACCgg AACACACAg AT CT A 224 CgT CgCAgCCATACAT CAC
435 CCTgCgCACCqCgCTCC 214 CTT gCCgT CgT AqqCqq
208 ACCgAgAgAACCT gCggAT 236 CCATACAT CgT CT gCCAA
209 CgCCgCgAgT CCqAgAgA 215 ATCCTTgCCgTCqTAgqCT
194 AACAT gAAggCCT CCgCg 238 qAgCCACT CCACgCACAg
194 AACAT gAAggCCT CCgCg 236 CCATACATCgT CT gCCAA
187 gCgCCgTggATAgAgCAA 281 CT CggT CAgT CT gT gCCTT
209 CgCCgCgAgT CCqAgAgA 282 TCTCggTAAgTCTgTgCCTT
242 CgAgAqAgCCTgCggAAC 228 T CqTAggCgT CCT ggT gg
203 CAgATCTACAAggCCCAgg 212 CCT CCAggT AqgCTCTgTC
395 gCCgCgAgTT Cg Ag Agg 392 CCTTgCCgT CgTAggCg A
280 gCT ACgT ggACgACACgCT 228 T CgTAggCgT CCT ggT gg
575 qCAggAggqgCCggAgT 236 CCAT ACAT CgT CT gCCAA
188 gCCgCgAgT CCgAggAC 220 CCgCgCgCTCCAgCgTg
192 ACCggg AgACACAgATCTC 229 CT CCAACTT gCgCT gggA
192 ACCggg AgACACAg AT CT C 225 CTCTCAgCTgCTCCqCCT
367 TACTACAACCAgAgCgAggA 241 qCCgCgqT CCAgg AgCT
203 CAgATCTACAAggCCCAgg 226 gT CgTAqgCgg ACT ggTC
209 CgCCgCgAgT CCqAgAgA 250 gCAggTT CCgCAggCT CT
194 AACATgAAggCCT CCgCg 214 CTTgCCgTCgTAggCgg
240 g AgACACAg AAgT AC AAgCg 223 qCCAT ACAT CCT CT gg AT gA
243 CqCgAqT CCgAggAT ggC 223 qCCATACAT CCT CTgg ATgA
243 CgCg AgT CCgAggAT ggC 214 CTTgCCgTCgTAggCgg
192 ACCggg AgACACAgATCTC 238 qAgCCACT CC ACgCACAg
Appendix 2: Sense and antisense primer sequences for SSP-PCR (continue)
Sense
Primer Sequences
Sense
Primer Sequences
243 CgCq AgT CCgAggAT ggC 226 gT CgT AqgCgg ACT ggTC
271 CCgCggAggAAgCgCCA 219 CCAggTATCTgCggAgCg
209 CgCCgCgAgT CCqAgAgA 244 CAggTATCTgCgg AgCCC
271 CCgCggAggAAgCgCCA 377 CCT CCAggT AggCT CT CCA
189 gCgCCgT gg ATAg AgCAA 223 gCCATACAT CCTCTgg ATgA
243 CgCgAgTCCgAgqATqgC 237 gCgCAggTT CCqCAggC
193 gg AgTATT ggg ACCgg AAC 213 gAgqAggCgCCCgTCg
193 ggAgTATT gggACCggAAC 277 ggAggAAgCgCCCgTCg
188 gCCgCgAgT CCgAggAC 226 gT CgTAggCgq ACT ggT C
195 gACCgg AAC AC ACAg AT CTT 392 CCTTgCCgTCgTAggCgA
195 g AC Cgg AAC AC AC Ag AT CTT 216 CgTT C AgggCgAT gTAAT CT
195. gACCgg AACACACAg AT CTT 216 CgTT C Aggg Cg ATgTAAT CT
207 CCqAgAqAgCCTgCggAA 236 CCATACAT CgT CT gCCAA
208 ACCgAgAgAACCT gCggAT 216 CgTTC AgggCgATgTAATCT
202 ggggAgCCCCgCTTCATT 399 CCTTCCCgTT CT CCAggTg
193 qgAgTATTggg ACCgg AAC 216 CgTT CAgggCg AT gT AAT CT
195 gACCgg AACACACAg AT CTT 237 gCgCAggTTCCqCAgqC
192 ACCgggAgACACAgATCTC 315 CCCCAggTCgCAgCCAC
1719 qCqAqqqqACCgCAgqC 145 gAqCCACTCCACgCACTC
1719 qCgAggqqACCgCAggC 389 AqCqT CT CCTT CCCATT CTT
368 CACAgACTgACCgAgTgAg 143 gCCCCAggT CgCAgCCAA
366 CCgAgTgAACCTgCggAAA 143 gCCCCAggTCgCAgCCAA
368 CACAg ACT g ACCgAgT g Ag 379 CgCgCgCTgCAgCgTCTT
366 CCg AgT gAACCT gCgg AAA 818 gggT gAT CT gAgCCgCCT
271 CCgCggAggAAgCgCCA 127 ggT CqCAgCCATACAT CCA
366 CCgAgT gAACCTgCgg AAA 184 CgCACgggCCgCCTCCA
240 g AgACACAg AAgTACAAgCg 184 CgCACgggCCgCCTCCA
367 TACTAC AACCAg AgCgAgg A 247 gCggCggTCCAggAgCg
4 CACAggCTqACCqAgT g Ag 379 CgCqCgCTgCAgCgT CTT
313 ggACCgggAgACACAgAAC 166 gCgCAggTTCCgCAggC
367 TACTAC AACCAg AgCgAgg A 317 T CT CAgCTqCT CCqCCqT
165 ACgACACgCAgTT CgT gCA 389 AgCqT CT CCTT CCCATT CTT
159 TACAACCAgAgCgAggCCA 389 AgCgT CTCCTT CCCATT CTT
. 130 CCgCgggT AT gACCAgT C 126 T g AgCCgCCgT gTCCgC A
160 ACAACCAgAgCgAggCCg 157 CCgCCgTgTCCqCggCA
369 AgTCCAAgAggggAgCCg 388 ggT CqCAgCCAAACAT CCA
368 CACAgACT gACCgAgT gAg 223 gCCATACAT CCTCTgg AT g A
371 CCACT CCAT g AggT ATTT CT C 382 CCT CCAggTAggCTCT CAg
366 CCgAgT gAACCTgCggAAA 146 CCCT CCAggT AggCT CT CT
366 CCgAgT gAACCTgCggAAA 146 CCCT CCAggTAggCT CT CT
368 CACAgACT gACCgAgT gAg 377 CCT CCAggT AggCT CT CCA
366 CCgAgTgAACCTgCggAAA 127 ggTCgCAgCCATACATCCA
368 CACAgACT gACCgAgT gAg 377 CCTCCAggTAgqCTCTCCA
366 CCgAgT qAACCTgCggAAA 157 CCgCCgTgTCCqCggCA
366 CCgAgTgAACCTgCggAAA 39 CCgCCT CTgCT CCAggAg
36 TT gT ggC AgCTT AAgl I I gAAT 38 CT gCACT gT q AAgCT CT CCA
Appendix 2: Sense and antisense primer sequences for SSP-PCR (continue)
Sense
Primer Sequences
Sense
Primer Sequences
36 TTqT ggCAgCTT AAqTTTg AAT 252 CCACCgCggCCCgCgC
41 TCCTgTggCAgCQTAAgAg 38 CTgCACT gT q AAgCT CT CCA
41 TCCT gTggCAgCCTAAgAg 491 CT CCgT CACCgCCCggT
41 TCCTgTggCAgCCTAAgAg 255 gTCCACCCggCCCCgCT
68 qTTT CTT gg AgTACT CTACgT C 38 CT gCACT gT g AAgCT CT CCA
46 qACggAgCqgqTgCgqTA 37 CT qCACT gT g AAgCT CT CAC
44 TACTT CCAT AACCAggAgg Ag A 491 CT CCgT CACCgCCCggT
68 gTTT CTT ggAgT ACT CTACgT C 2510 g g CT gTTCC AgTACT Cgg CAT C
3291 CggTTCCT gg AC Ag ATACTT CT AT C 256 CT gTT CCAgg ACT CggCgA
47 gTTT CTT gg AgC AggTT AAACA 49 CCCqTAgTTgTgTCTgCACAC
47 qTTT CTT gg AgCAggTT AAACA 51 CT gCAgTAggTgT CC ACCAg
47 gTTT CTTggAgCAggTTAAACA 102 T gTT CCAgT ACT CggCgCT
48 CCT gT ggCAgggTAAqTATA 491 CT CCgT CACCgCCCggT
1737 ggT gCAgTTgCT ggAAAgACT 1635 CCCgCCT gT CTT CCAggAT
50 AgT ACT CTACgggT gAgT gTT 58 TCT qCAATAggT gT CC ACCT
50 AqTACT CTACgggT gAgT gTT 51 CT gCAgTAggT gT CCACC Ag
2518 CT gg ACAg AT ACTT CT AT AACC AA 49 CCCqTAgTTgTgTCTgCACAC
263 gTT CCT ggACAq ATACTT CC 37 CT qCACT gT g AAgCT CT CAC
46 gACgg AgCgggT gCggT A 54 CTqgCT gTT CCAgT ACT CCT
53 CqqTTqCTgqAAAgACqCq 37 CTgCACT gT q AAgCT CT CAC
273 TT CTT ggAgT ACT CT ACggg 54 CT qqCT gTT CCAgT ACT CCT
1630 TggggCggCCT gAT gAg 256 CT gTT CCAgg ACT CggCgA
44 T ACTT CCATAACCAggAgg Ag A 55 CACT qT g AAgCT CT CCACAg
50 AgT ACT CTACgggT gAgT gTT 259 TCCACCgCggCCCgCTC
50 AgT ACT CTACgggT gAgTgTT 259 TCCACCgCggCCCgCTC
68 qTTT CTT ggAgTACT CTACgT C 252 CCACCgCggCCCgCgC
273 TTCTTgg AgT ACT CT ACggg 40 CCCqCT CgT CTTCCAgg AT
263 qTTCCTggACAg ATACTTCC 485 TCCACCgCggCCCgCTT
44 TACTTCC ATAACCAggAgg Ag A 258 ACCgCggCCCgCCT gT C
44 TACTT CCATAACC Agg Agg Ag A 485 TCCACCgCggCCCgCTT
68 qTTTCTTgg AgTACTCTACgTC 485 TCCACCgCggCCCgCTT
68 gTTT CTT ggAgT ACT CTACgT C 102 T gTT CCAgT ACT CggCgCT
68 qTTT CTT ggAgT ACT CT ACgT C 104 CCCgCCT gT CTT CCAggAA
68 qTTT CTT ggAgT ACT CT ACgT C 2510 ggCT gTT CCAgTACT CggCAT C
68 qTTT CTT ggAgT ACT CT ACgT C 58 T CT gCAAT AqgT gT CC ACCT
1631 qAgCT ggggCggCCT gC 38 CT qCACT gT gAAgCT CT CCA
68 qTTT CTT ggAgT ACT CT ACgT C 38 CT gCACT gT g AAgCT CT CCA
2489 ATACTTCCATAACCAggAggAgA 492 gCT gTT CCAgTACT CAgCg
61 gTTT CTT gCAgCAggAT AAgTA 268 CT gCAgT AATT gT CCACCCg
69 TTT CTT ggAgCTgCgT AAgT C 255 gTCCACCCggCCCCgCT
1674 CACqTTT CTT gg AgCT gT g 76 ggAgT ACCgggCggT gAg
151 CCgTAgTT gT gT CTgCAgT AA 2510 ggCT gTT CCAgTACT CggCAT C
70 qTTT CTT gg AgCT gCTTAAgT C 256 CT gTT CCAgg ACT CggCgA
70 qTTTCTTgg AgCTgCTTAAgTC 38 CTgCACTgT g AAgCT CT CCA
60 g AgCg AgT gT gg AACCT gA 350 T gCAC ACCgT gTCCAACT C
Appendix 2: Sense and antisense primer sequences for SSP-PCR (continue)
Sense
Primer Sequences
Sense
Primer Sequences
77 qCTACTTCACCAACgggACC 112 CgTgCgg AgCTCCAACTg
82 gT gCgT CTT qT q AgCAq AAg 78 T ggTAqTT gTgT CTgC AT ACg
77 qCTACTTCACCAACgggACC 152 CCCqCqqTACgCCACCTC
79 ACggAgCgCqTqCgggg 111 CCqCqgAACgCCACCTC
347 TTT CgT gCT CCAg I I IAAggC 350 T gCACACCqT gT CCAACT C
348 g ACgT gggqgT gT ACCgC 619 CCTgCggCgTCACCgCC
349 qq AqCgCqT gCgT CTT gTA 112 CgT gCggAgCT CCAACT g
181 gACggAgCqCqTgCgTTA 350 T gCACACCqT gT CCAACT C
88 gACgg AgCgCqT gCgT CT 831 TggCT gTT CCAgT ACT CgqCgq
353 qTq CgT CTT gT g ACC Ag ATA 1466 gCTgTTCC AgTACTCggCgT
1465 gqACggAgCqCgT gCgT CT
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Appendix 3: Overlapping peptides span on DENV serotype 2 isolate (strain 16681) 
Capsid
MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPTAGILKRWGTIK 
NNQRKKAKNTPFNMLKRERN # 2 2 1
PFNMLKRERNRVSTVQQLTK # 2 2 6
RVSTVQQLTKRFSLGMLQGR # 2 2 2
RFSLGMLQGRGPLKLFMALV # 2 2 7
GPLKLFMALVAFLRFLTIPP # 2 2 3
AFLRFLTIPPTAGILKRWGT # 2 2  8 
TAGILKRWGTIK 
IK
prM
KSKAINVLRGFRKEIGRMLNILNRRRRSAGMIIMLIPTVMAFHLTTRNGEPHMIVSRQEKGKSLLFKTEDGVN 
KSKAINVLR # 2 2 4  
KSKAINVLRGFRKEIGRM # 2 2  9
RGFRKEIGRMLNILNRRRRS # 2 2 5
LNILNRRRRSAGMIIMLIFIVMA # 2 3 0
FHLTTRNGEPHMIVSRQEKG # 2 3 1
HMIVSRQEKGKSLLFKTEDG # 2 3  9
KSLLFKTEDGVN
VN
M
MCTLMAMDLGELCEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGEHRREKRSVALVPHV(3MGLET
MCTLMAMD # 2 3 2  
MCTLMAMDLGELCEDTIT # 2 4  0
LGELCEDTITYKCPLLRQNE # 2 3 3
YKCPLLRQNEPEDIDCWCNS # 2 4 1
PEDIDCWCNSTSTWVTYGTC #2 34
TSTWVTYGTCTTMGEHRREK # 2 4 2
TTMGEHRREKRSVALVPHVG # 2 3 5  
RSVALVPHVGMGLET 
MGLET
E
RTETWMSSEGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFV 
RTETW #2 4 3
RTETWMSSEGAWKHV # 2 3 6
MSSEGAWKHVQRIETWILRH #2 4 4
QRIETWILRHPGFTMMAAIL # 2 3 7
PGFTMMAAILAYTIGTTHFQ # 2 4  5
AYTIGTTHFQRALIFILLTA # 2 3 8
RALIFILLTAVTPSMT # 2 4 6
MRCIGMSNRDFV
MSNRDFV
Appendies
FV
EGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEE 
EGV #1
EGVSGGSW # 3 4
EGVSGGSWVDIVL # 6 6
SGGSWVDIVLEHGSC #2
VDIVLEHGSCVTTMA # 3 5
EHGSCVTTMAKNKPT # 67
VTTMAKNKPTLDFEL #3
KNKPTLDFELIKTEA # 3 6
LDFELIKTEAKQPAT # 6 8
IKTEAKQPATLRKYC #4
KQPATLRKYCIEAKL # 3 7
LRKYCIEAKLTNTTT # 6 9
IEAKLTNTTTESRCP #5
TNTTTESRCPTQGEP # 3 8
ESRCPTQGEPSLNEE # 7 0  
TQGEPSLNEE
SLNEE
QDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH
QDKRF #6  
QDKRFVCKHS # 3 9  
QDKRFVCKHSMVDRG # 7 1
VCKHSMVDRGWGNGC #7
MVDRGWGNGCGLFGK # 4 0
WGNGCGLFGKGGIVT #72
GLFGKGGIVTCAMFR #8
GGIVTCAMFRCKKNM # 4 1
CAMFRCKKNMEGKW # 7 3
CKKNMEGKWQPENL #9
EGKVVQPENLEYTIV # 4 2
QPENLEYTIVITPHS #7 4
EYTIVITPHSGEEHA # 1 0
ITPHSGEEHAVGNDT # 4 3  
GEEHAVGNDTGKH 
VGNDTGKH 
GKH
GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSN 
GK #7 5  
GKEIKIT # 1 1  
GKEIKITPQSST # 4 4
EIKITPQSSTTEAEL # 7 6
PQSSTTEAELTGYGT # 1 2
TEAELTGYGTVTMEC #4 5
TGYGTVTMECSPRTG # 7 7
VTMECSPRTGLDFNE # 1 3
SPRTGLDFNEMVLLQ #4 6
LDFNEMVLLQMENKA # 7 8
MVLLQMENKAWLVHR # 1 4
MENKAWLVHRQWFLD # 4 7
WLVHRQWFLDLPLPW # 7 9
QWFLDLPLPWLPGAD # 1 5
LPLPWLPGADTQGSN #4 8 
LPGADTQGSN
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TQGSN
WIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTG 
WIQKE # 8 0  
WIQKETLVTF # 1 6  
WIQKETLVTFKNPHA #4 9
TLVTFKNPHAKKQDV # 8 1
KNPHAKKQDVWLGS # 1 7
KKQDVWLGSQEGAM # 5 0
WLGSQEGAMHTALT # 8 2
QEGAMHTALTGATEI #1 8
HTALTGATEIQMSSG # 5 1
GATEIQMSSGNLLFT # 8 3
QMSSGNLLFTGHLKC # 1 9
NLLFTGHLKCRLRMD # 5 2
GHLKCRLRMDKLQLK #8 4
RLRMDKLQLKGMSYS #2 0  
KLQLKGMSYSMCTG 
GMSYSMCTG 
MCTG
KFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYK
# 5 3
KFKWK # 8 5  
KFKWKEIAET # 2 1  
FKWKEIAETQHGTI #5 4
EIAETQHGTIVIRVQ # 8 6
QHGTIVIRVQYEGDG # 2 2
VIRVQYEGDGSPCKI # 5 5
YEGDGSPCKIPFEIM #8 7
SPCKIPFEIMDLEKR # 2 3
PFEIMDLEKRHVLGR #5  6
DLEKRHVLGRLITVN #8  8
HVLGRLITVNPIVTE # 2 4
LITVNPIVTEKDSPV # 5 7
PIVTEKDSPVNIEAE #8  9
KDSPVNIEAEPPFGD # 2 5  
NIEAEPPFGDSY 
PPFGDSY 
SY
IIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSG
I I I # 5 8
IIIG V EPG  # 9 0  
IIIGVEPGQLKLN #2 6
GVEPGQLKLNWFKKG # 5 9
QLKLNWFKKGSSIGQ # 9 1
WFKKGSSIGQMFETT # 2 7
SSIGQMFE TTMRGAK # 60
MFETTMRGAKRMAIL #9 2
MRGAKRMAILGDTAW # 2 8
RMAILGDTAWDFGSL #6 1
GDTAWDFGSLGGVFT # 9 3
DFGSLGGVFTSIGKA #2 9
GGVFTSIGKALHQVFGA # 6 2
SIGKALHQVFGAIYG #9 4
LHQVFGAIYGAAFSG # 3 0  
IYGAAFSG 
AAFSG
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NS1
VSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQADSGCWSWKNKELKCGSGIFITDNVHTW 
VSWTMKILI # 6 3  
VSWTMKILIG # 9 5  
VSWTMKILIGVIITW #3 1
GVIITWIGMNSRSTSLS # 6 4  
VIITWGMNSRSTSLS # 9 6
IGMNSRSTSLSVTLV # 3 2
VTLVLVGIVTLVLGVMV # 6 5  
VTLVLVGIVTLYLGVMV # 9 7  
LVGIVTLYLGVMV # 3 3
TEQYKFQPESPSKLASAIQKAHEEGICGIRSVTRLENLMWKQITPELNHILSENEVKLTIMTGDIKGIMQAGKRS
LRPQPTELKYSWKTWGKAKMLSTESHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLKLKEKQDVF
CDSKLMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKNCHWPKSHTLWSNGVLESEMIIPKNLAGPVSQ
HNYRPGYHTQITGPWHLGKLEMDFDFCDGTTWVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPP
NS2A
LRYRGEDGCWYGMEIRPLKEKEENLVNSLVTAGHGQVDNFSLGVLGMALFLEEMLRTRVGTKHAILLVAVSFV
TLITGNMSFRDLGRVMVMVGATMTDDIGMGVTYLALLAAFKVRPTFAAGLLLRKLTSKELMMTTIGIVLLSQSTI
PETILELTDALALGMMVLKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILAWSVSPLLLTSSQQ
NS2B
KTDWIPLALTIKGLNPTAIFLTTLSRTSKKRSWPLNEAIMAVGMVSILASSLLKNDIPMTGPLVAGGLLTVCYVL
TGRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLTILIRTGLLVISGLFPVSIP
NS3
ITAAAWYLWEVKKQRAGVLWDVPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLM
RAGVLWDVPSPPPMG # 9 8
WDVPSPPPMGKAELE # 1 3 9
PPPMGKAELEDGAYR # 1 8 0
KAELEDGAYRIKQKG # 9 9
DGAYRIKQKGILGYS # 1 4 0
IKQKGILGYSQIGAG # 1 8 1
ILGYSQIGAGVYKEG # 1 0 0
QIGAGVYKEGTFHTM # 1 4 1
VYKEGTFHTMWHVTR # 1 8 2
TFHTMWHVTRGAVLM # 1 0 1  
WHVTRGAVLM 
GAVLM
HKGKRIEPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFS
HKGKR # 1 4 2  
HKGKRIEPSW # 1 8 3  
HKGKRIEPSWADVKK # 1 0 2
IEPSWADVKKDLISY # 1 4 3
ADVKKDLISYGGGWK # 1 8 4
DLISYGGGWKLEGEW # 1 0 3
GGGWKLEGEWKEGEE # 1 4  4
LEGEWKEGEEVQVLA # 1 8 5
KEGEEVQVLALEPGK # 1 0 4
VQVLALEPGKNPRAV # 1 4 5
LEPGKNPRAVQTKPG # 1 8  6
NPRAVQTKPGLFKTN#1 0 5
QTKPGLFKTNAGTIG # 1 4  6
LFKTNAGTIGAVSLD # 1 8 7  
AGTIGAVSLDFS
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AVSLDFS
FS
PGTSGSPIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHPGAGKTKRYL 
PGT # 1 0 6  
PGTSGSPI # 1 4 7  
PGTSGSPIIDKKG # 1 8 8
SGSPIIDKKGKWGL # 1 0 7
IDKKGKWGLYGNGV #1 4  8
KWGLYGNGWTRSG # 1 8  9
YGNGWTRSGAYVSA # 1 0 8
VTRSGAYVSAIAQTE # 1 4  9
AYVSAIAQTEKSIED # 1 9 0
IAQTEKSIEDNPEIE # 1 0 9
KSIEDNPEIEDDIFR # 1 5 0
NPEIEDDIFRKRRLT # 1 9 1
DDIFRKRRLTIMDLH # 1 1 0
KRRLTIMDLHPGAGK # 1 5 1
IMDLHPGAGKTKRYL # 1 9 2  
PGAGKTKRYL 
TKRYL
PAIVREAIKRGLRTLILAPTRWAAEMEEALRGLPIRYQTPAIRAEHTGREIVDLMCHATFTMRLLSPVRVPN 
PAIVR # 1 1 1  
PAIVREAIKR # 1 5 2  
PAIVREAIKRGLRTL # 1 9 3
EAIKRGLRTLILAPT # 1 1 2
GLRTLIAPTRWAA # 1 5 3
ILAPTRWAAEMEEA # 1 9 4
RWAAEMEEALRGLP # 1 1 3
EMEEALRGLPIRYQT # 1 5 4
LRGLPIRYQTPAIRA # 1 9 5
IRYQTPAIRAEHTGR # 1 1 4
PAIRAEHTGREIVDL # 1 5 5
EHTGREIVDLMCHAT # 1 9 6
EIVDLMCHATFTMRL # 1 1 5
MCHATFTMRLLSPVR # 1 5 6  
FTMRLLSPVRVPN 
LSPVRVPN 
VPN
YNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMTATPPGSRDPFPQSNAPIIDEEREIPERSWNSGHE 
YN # 1 9 7  
YNLIIMD # 1 1 6  
YNLIIMDEAHFT # 1 5 7
LIIMDEAHFTDPASI # 1 9 8
EAHFTDPASIAARGY # 1 1 7
DPASIAARGYISTRV # 1 5 8  
AARGYISTRVEMGEA # 1 9 9
IS  TRVEMGEAAGIFM # 1 1 8
EMGEAAGIFMTAT P P # 1 5 9
AGIFMTATPPGSRDP # 2 0 0
TATPPGSRDPFPQSN # 1 1 9
GSRDPFPQSNAPIID # 1 6 0
FPQSNAPIIDEEREI # 2 0 1
APIIDEEREIPERSW # 1 2 0
EEREIPERSWNSGHE # 1 6 1  
PERSWNSGHE 
NSGHE
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WVTDFKGKTVWFVPSIKAGNDIAACLRKNGKKVIQLSRKTFDSEYVKTRTNDWDFWTTDISEMGANFKAERVID 
WVTDF #2  02  
WVTDFKGKTV # 1 2 1  
WVTDFKGKTVWFVPS # 1 6 2
KGKTVWFVPSIKAGN # 2 0 3
WFVPSIKAGNDIAAC # 1 2 2
IKAGNDIAACLSKNG # 1 6 3
DIAACLSKNGKKVIQ # 2 0 4
LSKNGKKVIQLSRKT # 1 2 3
KKVIQLSRKTFDSEY # 1 6 4
SRKTFDSEYAKTRT # 2 0 5
FDSEYAKTRTNDWDF # 1 2 4
AKTRTNDWDFWTTD # 1 6 5
NDWDFWTTDISEMG # 2 0  6
WTTDISEMGANFKA # 1 2 5
ISEMGANFKAERVID#166  
ANFKAERVID 
ERVID
PRRCMKPVILTDGEERVILAGPMPVTHSSAAQRRGRIGRNPKNENDQYIYMGEPLENDEDCAHWKEAKMLLD 
PRRCM #2  07  
PRRCMKPVIL # 1 2  6 
PRRCMKPVILTDGEE # 1 6 7
KPVILTDGEERVILA # 2 0 8
TDGEERVILAGPMPV # 1 2 7
RVILAGPMPVTHSSA # 1 6 8
GPMPVTHSSAAQRRG # 2 0  9
THSSAAQRRGRIGRN # 1 2  8
AQRRGRIGRNPKNEN # 1 6 9
RIGRNPKNENDQYIY # 2 1 0
PKNENDQYIYMGEPL # 1 2  9
DQYIYMGEPLENDED # 1 7 0
MGEPLENDEDCAHWK # 2 1 1
ENDEDCAHWKEAKML # 1 3 0  
CAHWKEAKMLLD 
EAKMLLD 
LD
NINTPEGIIPSMFEPEREKVDAIDGEYRLRGEARKTFVDLMRRGDLPVWLAYRVAAEGINYADRRWCFDGVKN 
NIN # 1 7 1  
NINTPEGI # 2 1 2  
NINTPEGIIPSM F # 1 3 1
TPEGIIPSMFEPERE # 1 7 2
IPSMFEPEREKVDAI # 2 1 3
EPEREKVDAIDGEYR # 1 3 2
KVDAIDGEYRLRGEA # 1 7 3
DGEYRLRGEARTTFV # 2 1 4
LRGEARTTFVDLMRR # 1 3 3
RTTFVDLMRRGDLPV # 1 7 4
DLMRRGDLPVWLAYR # 2 1 5
GDLPVWLAYRVAAEG # 1 3 4
WLAYRVAAEGINYAD # 1 7 5
VAAEGINYADRRWCF # 2 1 6
INYADRRWCFDGVKN # 1 3 5  
RRWCFDGVKN 
DGVKN
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NS4A
NQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFKEFAAGRKSLTLNLITEMGRLPTFMTQKARD 
NQILE # 1 7 6  
NQILEENVEV # 2 1 7  
NQILEENVEVEIWTK # 1 3 6
ENVEVEIWTKEGERK # 1 7 7
EIWTKEGERKKLKPR # 2 1 8
EGERKKLKPRWLDAIY # 1 3 7
KLKPRWLDARIYSDP # 1 7  8
WLDARIYSDPLALKE # 2 1 9
SDPLALKEFKEFAAGRK # 1 3 8  
LALKEFKEFAAGRK # 1 7 9  
FKEFAAGRK # 2 2 0
SLTLNLITEMGRLPTFMTQK # 2 4 7  
GRLPTFMTQKARD 
ARD
ALDNLAVLHTAEAGGRAYNHALSELPETLETLLLLTLLATVTGGIFLFLMSGRGIGKMTLGMCCIITASILL
ALDNLAV # 2 5 4
ALDNLAVLHTAEAGGRA #2  4 8
LHTAEAGGRAYNHALSELPE # 2 5 5
YNHALSELPETLETLLLLTL # 2 4  9
TLETLLLLTLLATVTGGIFL # 2 5  6
LATVTGGIFLFLMSGRGIGK #2 50
FLMSGRGIGKMTLGMCCIIT # 2 5 7
MTLGMCCIITASILL
ASILL
WYAQIQPHWIAASIILEFFLIVLLIPEPEKQRTPQDNQLTYWIAILTWAATMA
WYAQI # 2 5 1
WYAQIQPHWIAASII # 2 5 8
QPHW IAASIILEFFLIVLLI # 2 5 2
LEFFLIVLLIPEPEKQRTPQ # 2 5 9
PEPEKQRTPQDNQLTYWIA # 2 5 3
DNQLTYWIAILTWAATMA #2  60
N S 4 B
NEMGFLEKTKKDLGLGSIATQQPESNILDIDLRPASAWTLYAVATTFVTPMLRHSIENSSVNVSLTAIANQATVL
MGLGKGWPLSKMDIGVPLLAIGCYSQVNPITLTAALFLLVAHYAIIGPGLQAKATREAQKRAAAGIMKNPTVDGI
TVIDLDPIPYDPKFEKQLGQVMLLVLCVTQVLMMRTTWALCEALTLATGPISTLWEGNPGRFWNTTIAVSMANIF
RGSYLAGAGLLF
NS5
SIMKNTTNTRRGTGNIGETLGEKWKSRLNALGKSEFQIYKKSGIQEVDRTLAKEGIKRGETDHHAVSRGSAKLRW 
FVERNMVTPEGKWDLGCGRGGWSYYCGGLKNVREVKGLTKGGPGHEEPIPMSTYGWNLVRLQSGVDVFFIPPEK 
CDTLLCDIGESSPNPTVEAGRTLRVLNLVENWLNNN'TQFCIKVLNPYMPSVIEKMEALQRKYGGALVRNPLSRNS 
THEMYWVSNASGNIVSSVNMISRMLINRFTMRYKKATYEPDVDLGSGTRNIGIESEIPNLDIIGKRIEKIKQEHE
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TSWHYDQDHPYKTWAYHGSYETKQTGSASSMVNGWRLLTKPWDWPMVTQMAMTDTTPFGQQRVFKEKVDTRTQ
EPKEGTKKLMKITAEWLWKELGKKKTPRMCTREEFTRKVRSNAALGAIFTDENKWKSAREAVEDSRFWELVDKER
NLHLEGKCETCVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGLHK
LGYILRDVSKKEGGAMYADDTAGWDTRITLEDLKNEEMVTNHMEGEHKKLAEAIFKLTYQNKWRVQRPTPRGTV
MDIISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVFKSIQHLTITEEIAVQNWLARVGRERLSRMAISGDD
CWKPLDDRFASALTALNDMGKIRKDIQQWEPSRGWNDWTQVPFCSHHFHELIMKBGRVLWPCRNQDELIGRAR
ISQGAGWSLRETACLGKSYAQMWSLMYFHRRDLRLAANAICSAVPSHWVPTSRTTWSIHAKHEWMTTEDMLTVWN
RVWIQENPWMEDKTPVESWEEIPYLGKREDQWCGSLIGLTSRATWAKNIQAAINQVRSLIGNEEYTDYMPSMKRF
RREEEEAGVLW
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Appendix 4: Matrix of peptide pools
Pool 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2 17 18 19 . 20 21 22 23 24 25 26 27 28 29 30 31 32
3 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
4 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
5 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
6 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96
7 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112
8 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128
9 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144
10 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160
11 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176
12 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192
13 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
14 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224
15 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
16 241 242 243 244 245 246 247 248 249 250 251
/
252 253
257
254
258
255
259
256
260
\  Peptide
Pool peptide
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Appendix 5: The breadth and magnitude of responses from all patients
Study number
Peptide(s)
recognised Sequence
SFU/million
PBMC
mean SFU/million 
per patients
BC 309 154 EMEEALRGLPIRYQT 260 260
BC 310 224 TAGILKRWGTIKKSKAINVL 100 100
BC 311 101 TFHTMWHVTRGAVLM 150 130
311 189 KW GLYGNGW TRSG 140
311 216 VAAEGINYADRRWCF 100
BC 313 117 E A H FTD PA SIA A R G Y . 160 162.5
313 143. IEPSW ADVKKDLISY 160
313 216 VAAEGINYADRRWCF 260
313 222 RVSTVQQLTKRFSLGMLQGR 70
BC 314 229 IKKSKAINVLRGFRKEIGRM 40 34
314 233 LGELCEDTITYKCPLLRQNE 28 j
BC 315 81 T LVT FKN P HAKKQ DV 66 177
315 194 ILAPTRW AAEM EEA 288
BC 316 61 RMAILGDTAWDFGSL 128 172!
316 216 VAAEGINYADRRWCF 216
BC 317 225 RGFRKEIGRMLNILNRRRRS 60 60
BC 318 101 TFHTMWHVTRGAVLM 60 120
318 153 G L R T L IA PT R W A A 100
318 154 EMEEALRGLPIRYQT 260
318 206 NDW DFW TTDISEMG 100
318 200 AGIFM TATPPGSRDP 80
BC 320 224 TAGILKRWGTIKKSKAINVL 130 130
BC 322 61 RMAILGDTAWDFGSL 60 58
322 134 GDLPVWLAYRVAAEG 60
322 159 EMGEAAGIFMTATPP 70
322 194 ILAPTRW AAEM EEA 40
322 224 TAGILKRWGTIKKSKAINVL 60
BC 323 188 F SPG T SG SPIID K K G 160 150
323 189 KW GLYGNGW TRSG 140
BC 324 2 SGGSWVDIVLEHGSC 60 110
324 61 RMAILGDTAWDFGSL 140
324 69 LRKYCIEAKLTNTTT 150
324 101 T FHTMWHVTRGAVLM 100
324 194 I  LAPTRW AAEM EEA 90
324 225 RG FRKEIGRMLNILNRRRRS 70
324 229 IKKSKAINVLRGFRKEIGRM 120
324 13 VTMECSPRTGLDFNE 120
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Study number
Peptide(s)
recognised Sequence
SFU/million
PBMC
mean SFU/million 
per patients
324 237 QRIETWILRHPGFTMMAAIL 120
324 244 MS S E GAWKHVQRIETWILRH 130
BC 325 147 A V SL D F SP G T SG SP I 140 125
325 157 VPNYNLIIM DEAHFT 190
325 195 LRG LPIRYQTPAIRA 45
BC 327 114 IRYQTPAIRAEHTGR 100 196.25
327 189 KW GLYGNGW TRSG 140
327 116 LSPVRVPNYNLIIM D 200
327 117 EA H FT D PA SIa a r g y 200
327 131 L D N IN T P E G IIP SM F 230
327 157 VPNYNLIIM DEAHFT 230
327 172 T PE G IIPSM FE PE R E 240
327 188 FSPG T SG SPIID K K G 230
BC 331 114 IRYQTPAIRAEHTGR 210 212.8571429
331 115 EIVDLMCHATFTMRL 200
331 116 LSPVRVPNYNLIIM D 230
331 117 EAHFTDPASIAARGY 200
331 157 VPNYNLIIM DEAHFT 220 .
331 172 TPE G IIPSM FE PE R E 190
331 188 FSPG T SG SPIID K K G 240
BC 332 198 L IIM D E A H FT D PA SI 120 120
BC 333 135 INYADRRWCFDGVKN 310 310.
333 198 L IIM D E A H FT D PA SI 310
333 216 VAAEGINYADRRWCF 310
BC 334 47 MENKAWLVHRQWFLD 80 80
BC 336 50 KKQDVWLGSQEGAM 117 87.5
336 250 LATVTGGIFLFLMSGRGIGK 58
BC 337 101 TFHTMWHVTRGAVLM 390 291.25
337 153 G LR TLIA PT R W A A 75
337 196 EHTGREIVDLMCHAT 200
337 233 LGELCEDTITYKCPLLRQNE 500
BC 338 50 KKQDVWLGSQEGAM 75 48.33333333
338 225 RG FRKEIGRMLNILNRRRRS 40
338 229 IKKSKAINVLRGFRKEIGRM 30
BC 343 61 RMAILGDTAWDFGSL 138 107.5
343 194 I  LAPTRW AAEMEEA 77
BC 347 178 KLKPRWLDARIYSDP 85 106.3333333
347 152 TKRYLPAIVREAIKR 85
347 184 ADVKKDLISYGGGWK 97
347 137 EGERKKLKPRWLDAIY 97
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Study number
Peptide(s)
recognised Sequence
SFU/million
PBMC
mean SFU/million 
per patients
347 233 LGELCE.DTITYKCPLLRQNE 80
347 143 IEPSW ADVKKDLISY 194
BC 348 114 IRYQTPAIRAEHTGR 27 49.33333333
348 137 EGERKKLKPRWLDAIY 38
348 200 AGIFM TATPPGSRDP 83
BC 349 225 RG FRKEIGRMLNILNRRRRS 80 63.33333333
349 229 IKKSKAINVLRGFRKEIGRM 30
349 69 LRKYCIEAKLTNTTT 80
BC 350 143 IEPSW ADVKKDLISY 100 100
BC 352 61 RMAILGDTAWDFGSL 300 152
352 194 I  LAPTRW AAEM EEA 116
352 225 RG FRKEIGRMLNILNRRRRS 40
BC 353 114 IRYQTPAIRAEHTGR 100 68
353 152 TKRYLPAIVREAIKR 64
353 244 MS S E GAWKHVQRIETWILRH 60 -
353 195 LRG LPIRYQTPAIRA 48
BC 354 164 KKVIQLSRKTFDSEY 118 117.6666667
354 188 F SPG T SG SPIID K K G 150
354 198 L IIM D E A H FT D PA SI 85
BC 500 101 TFHTMWHVTRGAVLM 55 55
BC 501 188 F SPG T SG SPIID K K G 53 53
BC 502 61 RMAILGDTAWDFGSL . 60 60
BC 503 61 RMAILGDTAWDFGSL 110 99
503 194 I  LAPTRW AAEM EEA 88
BC 504 61 RMAILGDTAWDFGSL 200 217.5
504 194 I  LAPTRW AAEM EEA 350
504 219 WLDARIYSDPLALKE 250
504 229 IKKSKAINVLRGFRKEIGRM 70
BC 507 154 EMEEALRGLPIRYQT 120 120
BC 508 152 TKRYLPAIVREAIKR 40 98.25
508 153 G L R T L IA PT R W A A 100
508 200 AGIFM TATPPGSRDP . 153
508 226 PFNMLKRERNRVSTVQQLTK 100
BC 509 115 EIVDLMCHATFTMRL 100 84
509 116 LSPVR VPNYN LIIM D 90
509 117 EAHFTDPASIAARGY 80
509 131 L D N IN T P E G IIP S M F 80
509 172 T PE G IIPSM FE PE R E 70
BC 510 2 SGGSWVDIVLEHGSC 400 450
510 66 FVEGVSGGSWVDIVL 500
